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ABSTRACT 
Intracellular and Extracellular biomarkers of drug-induced liver injury 
Drug-induced liver injury (DILI) is a common form of adverse drug reaction (ADR) seen within the 
clinic. Sensitive and specific circulating biomarkers would aid in the prediction of DILI early in its 
course. However, the current biomarkers of DILI, such as alanine transaminase (ALT) suffer from a 
lack of specificity and sensitivity. Because of this, we have examined both intracellular and extracellular 
biomarkers of DILI in order to validate and identify novel biomarkers of DILI. 
Protein tyrosine nitration (PTN), an intracellular marker of oxidative stress, has been shown to be 
present in paracetamol-DILI, and it is thought that the causative factor for its occurrence is 
mitochondrial damage. In order to test this, we used Furosemide (FS), a hepatotoxin not thought to 
cause mitochondrial injury or glutathione (GSH) depletion with the hypothesis that this compound 
would not generate PTN. First, we tested the role of GSH in protecting from PTN through depleting 
GSH in a mouse hepatoma cell line, followed by incubation with peroxynitrite. We found that GSH 
depletion was required in order to elicit PTN. Following this, we compared the ability of toxic doses of 
FS and paracetamol to cause PTN in mice. Interestingly, we found both compounds lead to PTN, 
suggesting that there is a pathway independent of GSH-depletion and mitochondrial injury which may 
lead to PTN.  
MicroRNA-122 (miR-122) a potential novel extracellular biomarker of DILI, has been demonstrated to 
be elevated in the circulation earlier in the course of injury than current DILI biomarkers. We examined 
the potential for miR-122 to be released actively in exosomes during paracetamol-DILI in rats and 
multiple forms of DILI in humans. Our findings suggested that in both human and rodent’s, miR-122 
is released in a similar profile throughout the course of DILI in exosomes, and in an exosome-free 
(protein-rich fraction) form. We also examined whether miR-122 is selectively released in exosomes 
during hepatocellular, mixed and cholestatic DILI in humans which had been prescribed a number of 
hepatotoxic compounds. Our study suggested that, similar to our rodent model, there is no specific 
pattern of exosomal release of miR-122 in any of these forms of injury. 
We then looked at new and relatively unexplored aspects of microRNAs, in order to evaluate how they 
may be used to look at damage to different zones of the liver, and damage to cells other than hepatocytes. 
Hepatocytes are heterogeneous, with their phenotype depending on their localisation along the porto-
central axis, which has resulted in certain drugs causing zone-specific hepatotoxicity. None of the 
current biomarkers is able to identify zone-specific injury. We examined zonal profiles of microRNA 
expression within the liver of rats under basal conditions and following paracetamol. Our analysis 
demonstrated that 45 miRNAs are significantly differentially expressed between zone I and zone III, 
with three species being expressed in only one zone. Of these differentially expressed miRNAs we 
found that 9 species were involved in regulating 109 members Wnt/β-Catenin pathway, the molecular 
driver of liver zonation. We also examined changes in zonal miRNA expression following a toxic dose 
of paracetamol in rats. Our study was able to demonstrate that paracetamol was able to cause significant 
changes in the profiles of 42 and 43 miRNAs in zone I and zone III respectively. Importantly, miRNAs 
were both up and down regulated in both zones, suggesting that not only a loss of miRNAs is occurring 
during liver injury in each zone.  
Biliary epithelial cells (BEC) can be damaged by a plethora of different compounds, leading to 
vanishing bile duct syndrome, or bile duct hyperplasia. Current biomarkers for the diagnosis of BEC-
injury lack in specificity, and are prone to false-positives. We developed a method to isolate BEC from 
the mouse liver and performed a global miRNA profile comparison of hepatocytes and BEC. As in 
previous studies we found miR-122-5p to be the most enriched miRNA in hepatocytes and miR-1224-
5p in BEC. On comparison of the profiles we found that 83 miRNAs were detectable in BEC but not in 
Hepatocytes, however further work will be required to validate any of these as markers of BEC injury.   
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1.1 ADVERSE DRUG REACTIONS AND DRUG-INDUCED LIVER INJURY 
Adverse drug reactions (ADR) account for between 2.4-12% of hospital admissions cases in 
the western world, and are defined as any undesirable effect cause by a xenobiotic or 
therapeutic. ADRs can be separated into two sub-categories, Type A and Type B. Type A 
reactions are common and occur as part of a dose-dependent relationship usually involving an 
exaggeration of the on-target pharmacology of a drug. Type B, ‘idiosyncratic’ reactions are 
less common, but are often more severe and are a product of unanticipated off-target 
pharmacological effects of a drug, and are therefore much less predictable (Hussaini and 
Farrington 2007). ADRs are a major impediment to both the National Health Service (NHS) 
and also to the drug development industry. Four in one hundred hospital bed days in the UK 
are dedicated to treating ADRs, costing near to £400m per annum. Similarly, in the 
pharmaceutical industry, 99% of lead compounds will have their development halted due to 
an ADR or undesirable pharmacological properties, which represents a significant cost when 
it is considered that it costs $1bn to take a drug from development through to market. Drug-
induced liver injury (DILI) is the most prominent form of ADR seen within the clinic in the 
UK and US, and is a major reason for the failure of new drugs in clinical trials (Ostapowicz 
et al. 2002). In the US, 50% of the cases of acute liver failure (ALF) are attributed to DILI 
when both cases of deliberate overdose and idiosyncratic reaction are considered, and 
therefore it is of no surprise that hepatotoxicity is the most cited reason for the withdrawal of 
a drug from the market during the post-marketing phase.   
Chapter 1 – General Introduction 
	  
3	  
	  
1.2 THE LIVER 
The liver is the main organ responsible for the metabolism of endogenous and exogenous 
chemical entities, including drugs. Under normal conditions the liver is responsible for the 
detoxification of the systematic and portal blood supplies, as well as the production of blood 
and bile components (Adams et al. 2003; Rodes et al. 2007). The liver also has a role in protein, 
fat and steroid metabolism, and macronutrient storage (Bioulac-­‐‑Sage et al. 1999). Structurally, 
the liver is made up of hexagonal groups of cells called liver lobules, which are each centred 
around a central vein. Each corner of the hexagonal lobule is formed by a portal triad, a 
grouping of vessels, which include the hepatic portal vein, the hepatic artery and a bile duct. 
The space between the central vein and portal triad is then filled by plates of non-parenchymal 
and parenchymal cells, making up a functional liver lobule. Plates of parenchymal cells are 
usually organised in cord like structures, which are separated from each other by the hepatic 
sinusoids, the capillaries of the liver, or intrahepatic bile ducts (Bioulac-­‐‑Sage et al. 1999). The 
lobule can be separated into three distinct zones, I, II and III. The blood enters the liver from 
zone I, the region containing the portal triad, and exits the liver through the central vein in 
zone III, moving along the porto-central axis through zone II in between (Gebhardt 1992; Ito 
et al. 2007; Rappaport 1977; Smith and Wills 1981; Ugele et al. 1991).  
At a cellular level, the liver is made up of parenchymal (hepatocytes) and non-parenchymal 
cells (liver sinusoidal endothelial cells; LSEC, biliary epithelial cells; BEC, kupffer cells; KC, 
hepatic stellate cells; HSC and natural killer t-cells) (Reviewed in (LeCluyse et al. 2012) (see 
table 1.1 for a description of cell types). Hepatocytes represent almost 80% of the liver mass, 
and 60% of the individual cells within the liver (Bioulac-­‐‑Sage et al. 1999; Kmiec 2001). The 
non-parenchymal cells make up the remainder, encompassing 40% of the individual cells, but 
only 6.5% of the liver volume. While the hepatocytes play a major function in the liver, the 
often overlooked non-parenchymal cells have an important role in supporting and regulating 
hepatic growth, and function (Kmiec 2001).    
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1.2.1 Hepatocytes 
Hepatocytes are responsible for the majority of the physiological functions associated with the 
liver. Their main function within the body is protein, fat and steroid metabolism, the 
production of serum albumin, and the storage of vital nutrients. Hepatocytes are also 
responsible for the detoxification of endogenous and exogenous compounds, including drugs 
and environmental toxins (Boyer et al. 2003). Hepatocytes are specified for this function 
through their expression of specific metabolism enzymes, which can be classified into Phase 
I and II (Berry and Edwards. 2001). Phase I enzymes, which mainly fall into the sub-class, 
Cytochrome P450 enzymes, are responsible for the bio-activation of compounds, either into 
their active form, or into a possibly toxic reactive metabolite. Phase II enzymes are responsible 
for the detoxification of either parent compounds or metabolites through altering their 
chemical nature to become more hydrophilic. This usually occurs through the conjugation of 
the drug to another chemical structure (Rautou et al. 2010; Singh 2010). Morphologically, 
hepatocytes are cuboidal in shape, and are polarised in their expression of transporters, 
depending on their proximity to a bile canaliculi or hepatic sinusoid, which is critical for their 
function in bile synthesis and secretion (Fu et al. 2011). In addition, hepatocytes are not a 
homogenous species, with their function and overall expression profile depending on their 
location within the liver lobule (Reviewed by (Jungermann and Keitzmann 1996).  
1.2.2 Liver sinusoidal endothelial cells 
Liver sinusoidal endothelial cells (LSEC) are vascular cells that line the walls of the hepatic 
sinusoid, the capillaries of the liver. Compared to other vascular endothelial cells they possess 
a relatively large number of pinocytotic vesicles, hinting at their role in endocytotic activity 
(Wisse 1970).  The adhesions between LSEC are much less prominent than those found 
between vascular endothelial cells, and their cell membranes are characterised by small pores 
or fenestrations (50-200nm diameter) which allow the passive movement of many substances 
between the blood and hepatocyte basolateral membrane (Cogger et al. 2010). This enables 
the hepatocyte to have a higher level of exposure to the bloods contents when compared to 
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cells within other organs, allowing for the efficient clearance of endogenous/exogenous 
substances. LSEC are part of the reticuloendothelial system and have three important roles in 
maintaining homeostasis within the liver. They are able to act as antigen presenting cells and 
are also to secrete a number of active substances, such as cytokines, eicosanoids, nitric oxide, 
endothelin-1, and extracellular matrix components (DeLeve 2007). This enables the liver to 
develop selective immunity to possible neo-antigens formed during hepatic metabolism. They 
also act as scavengers and act to clear the blood of macromolecular waste products using their 
high capacity for endocytosis (DeLeve 2007). Finally, they are able to act as a sieve for the 
bloods contents in order to control which substances are allowed to enter the hepatocytes 
(Wisse et al. 1985). Interestingly, they also contain a number of Cytochrome P450 (CYP450) 
enzymes, which have been demonstrated to produce reactive metabolites, demonstrating their 
role in hepatic metabolism and the clearance of xenobiotics. It was also demonstrated that 
paracetamol is able to cause toxicity in LSEC in the absence of hepatocytes, suggesting their 
capacity to produce N-acetyl-P-benzoquinoneimine (NAPQI), the reactive metabolite of 
paracetamol (Ito et al. 2003; Xie et al. 2010). LSEC have also been demonstrated to contain 
Phase II metabolism enzymes, however, it has been shown that their overall metabolism 
capacity is about 10% of that of a hepatocyte (Sacerdoti et al. 2003; Schrenk et al. 1991; Wu 
et al. 2008) 
1.2.3 Biliary epithelial cells 
Biliary epithelial cells or cholangiocytes (BEC) are the cells which line the biliary tract 
network. The biliary tract is made up of two separate components, the extrahepatic and 
intrahepatic biliary tract. The intrahepatic tract contains the canals of Hering, bile canaliculi, 
interlobular bile ducts, intrahepatic bile ducts, and the right and left hepatic bile ducts. The 
extrahepatic biliary tract contains the common hepatic duct, common bile duct, the cystic duct, 
and the gallbladder (Bogert and LaRusso 2007). Although BEC only account for 3-5% of the 
total liver cells, they are essential for the formation and effective transport of the bile 
components within the liver. Hepatocytes are able to secrete bile into the canalicular spaces 
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surround themselves, which is in turn transported through this network to the smallest of the 
bile duct structures, the cholangioles. The bile then passes through a series of increasingly 
large BEC-lined vessels, a process which allows the bile to become more alkaline and dilute 
through a series of absorptive and secretory processes.  Morphologically BEC are cuboidal, 
but become progressively more columnar and mucus-secreting as they approach the portal 
triad and the extrahepatic ducts, as the vessels become larger. BEC which line the small 
branching ducts are around 3µm in diameter, whereas the larger bile ducts in the portal regions 
can be up to 80µm in diameter (Alpini et al. 1996). BEC which line the large bile ducts 
participate in mucin secretion and hormone-regulated bile secretion, whereas BEC which line 
the smaller bile ducts play a role in proliferation and possess a plasticity which is thought to 
play a role in reparative activity in disease conditions (Bogert and LaRusso 2007; Glaser et al. 
2006; Marzioni et al. 2002).  
BEC have been shown to be implicated in liver injury caused by a number of liver toxins, 
including erythromycin, chlorpromazine, flucloxacillin, phenytoin, carbamazepine, and 
trimethoprim/sulfamethoxazole, to name only a few examples (Reviewed by Padda et al. 
2011; Read et al. 1961; Turner et al. 1988; Rodriguez et al. 1996; Zimmerman et al. 1999). 
However, small and large BEC are differentially susceptible to toxicity. Small BEC are most 
commonly affected by drug toxicities, which leads to vanishing bile duct syndrome. This 
aetiology often involves the permanent loss of the small branching intrahepatic bile ducts, 
which can ultimately lead to hepatic failure, requiring a liver transplant (Davies et al. 1994). 
In contrast the larger bile ducts are more commonly affected by bile duct hyperplasia, leading 
to a swelling of the large ducts and temporary, reversible jaundice. Unpublished data now 
suggests that patients suffering DILI involving bile duct damage have a much worse prognosis 
than those without, demonstrating the important of these cells in DILI (Fontana et al. 2015). 
Interestingly, large BEC express cyp2e1, the enzyme which forms NAPQI, the reactive 
metabolite of paracetamol, whereas small BEC do not (Lakehal et al. 1999).  
1.2.4 Other non-parenchymal cells 
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HSC (Ito cells, fat-storing cells, perisinusoidal cells) reside in the space between the sinusoidal 
endothelial cells and the basolateral surface of the hepatocytes, called the space of Disse 
(Asahina et al. 2009). Under normal conditions HSC are involved in the storage of vitamin A, 
the turnover and production of the ECM, and the contractility of the sinusoid (Parola and 
Pinzani 2009; Wang et al. 2010). Under disease conditions, HSC take on a myofibroblastic 
phenotype, causing them to secrete growth factors and cytokines which cause an inflammatory 
fibrotic response within the liver (Ramadori et al. 2008). KC are the resident macrophages of 
the liver which have endocytic and phagocytic functions. Under normal conditions they 
modulate the turnover of other hepatic cells through initiation of apoptosis, followed by the 
removal of cellular waste by phagocytosis. Under pathological conditions, KCs play an 
important role in modulating the inflammatory response, as well as scavenging foreign 
particles (Kolios et al. 2006). Pit cells are liver-specific natural killer cells located in the 
sinusoid, which proliferate locally when stimulated by interleukin-2 and possess a high level 
of cytotoxicity against a number of tumor cell lines (Wisse et al. 1996). 
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1.2.5.   Hepatocyte zonation 
In order to maximise the efficiency of the liver, hepatocytes are both homologous, and also 
specialised. All hepatocytes similarly hold the ability to produce a range of serum proteins, 
including the transferrin and transthyretin transporters, and albumin. Hepatocytes are also 
highly specialised for their function depending on their location along the porto-central axis 
of the liver lobule, causing the hepatocyte to either be defined as periportal (PP; zone I), mid-
zonal (Zone II), or pericentral (PV; Zone III) (Braeuning et al. 2006; Jungermann and 
Keitzmann 1996). Examples of well-defined specialised functions are, glucose metabolism 
which is largely based in zone I, and lipid metabolism, which is a zone III process (Berkowitz 
et al. 1995; Braeuning et al. 2006; Gebhardt 1992; Häussinger et al. 1991). Importantly, there 
is a large amount of evidence to suggest that the metabolism of xenobiotics and drugs is a 
zonated process. The cytochrome P450 system, responsible for the Phase I activation of many 
drugs is preferentially expressed within the zone III; whereas Phase II processes, such as 
sulfation occur within the Zone I region (Further examples of zonated processes can be seen 
in Figure 1.2). The zonated expression of CYP2E1 in the zone III, and GSH in the zone I 
causes the zone III region to be preferentially susceptible to paracetamol toxicity, due to 
increased bioactivation of the compound in this region, and decreased GSH conjugation 
(Anundi et al. 1993). In contrast, other compounds such as methapyrilene preferentially cause 
toxicity in the zone I region due to zonal expression profiles of detoxification proteins. 
Important also is the consideration of species differences in zonation, as much of the work 
investigating this area has been performed in rodents, with less information being available 
on zonation of the human liver. Studies to date have demonstrated that similar to rodent liver, 
human liver expresses gluconeogenic and glycolytic enzymes (Sokal et al. 1989; Morrison et 
al. 1965) in a zonal pattern whereas pyruvate kinase was found to be homogenously expressed 
throughout the liver in humans, dissimilarly to that of rodent liver (Wimmer et al. 1990).  
Several explanations have been developed for the source of the zonated phenotype. The 
‘developmental hypothesis’ suggests that zone III and zone I hepatocytes develop from 
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distinct origins, however there is limited evidence to support this, and the fact that the perinatal 
liver is not zonal in mice brings this into question (Häussinger et al. 1991; Notenboom et al. 
1997). The ‘streaming liver theory’ suggests that hepatocyte proliferation mainly occurs in the 
zone I region of the liver, where putative stem cells reside. Newly formed hepatocytes then 
move along the porto-central axis throughout their lifetime, changing phenotype depending 
on their environment/location. Similarly to the first hypothesis, the evidence to support this is 
limited. In fact, it has been demonstrated using cell-tracing that hepatocytes proliferate in both 
the zone III and zone I zones (Bralet et al. 1994). The ‘blood hypothesis’ suggests that zonation 
is based on the composition of the blood arriving at hepatocytes in the different regions of the 
liver. The blood arriving in the zone I region of the liver is highly oxygenated, whereas the 
oxygen content in the zone III region is much lower. This hypothesis suggests that the differing 
microenvironment surrounding these hepatocytes drives the zonal phenotype and zonal 
functionality. Studies in which the hormone and oxygen content of afferent vessels was altered 
demonstrated that some zonal functions are reversible, such as glycolysis and 
gluconeogenesis. However, processes such as zonal ammonia detoxification were not altered, 
which suggests there is another layer of zonal regulation involved (Tygstrup et al. 1962). 
Studies examining mRNA profiles from zone I and zone III hepatocytes were able to 
demonstrate that zonal processes were under the control of mRNA expression (Drug 
metabolism, glucose and ammonia metabolism), suggesting that there is a level of 
transcriptional control over zonation (Braeuning et al. 2007). Studies examining the effector 
pathways of these genes identified the Wnt/β-catenin pathway as a critical regulator of hepatic 
zonation (Cadoret et al. 2002). This pathway is negatively regulated in the zone I regions of 
the liver by adenomatous polyposis coli (APC), a tumour suppressor gene product, whereas 
APC is not present in the zone III regions of the liver (Benhamouche et al. 2006a; 
Benhamouche et al. 2006b).  
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Figure 1.2 Hepatocyte zonation in mice (Adapted from Jungermann and Kietzman 1996). A, 
hepatocytes are zonated and can be classified on their location along the porto-central axis (space 
between portal vein and central vein). Zone I hepatocytes reside in the portal triad region (within 
6-cells radius), zone II hepatocytes reside between the two regions, and zone III hepatocytes 
reside within a 3 cell radius of the central vein. B, cellular processes which are expressed in a 
zonal manner (rectangles are expressed equally between regions). C, cellular proteins which are 
expressed in a zonal pattern. 
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1.3 DRUG-INDUCED LIVER INJURY 
The liver is highly susceptible to DILI as it is the main organ responsible for the 
detoxification/metabolism of xenobiotics and natural toxins (Park et al. 2011). To date, over 
1000 different drugs have been associated with hepatotoxicity, independent of class or 
indication (Hoofnagle et al. 2013). DILI, similarly to other ADR’s can be can be divided into 
Type A, predictable and Type B, idiosyncratic reactions. Type A DILI is commonly caused 
by overdoses of compounds such as paracetamol, in which there is a clear dose-dependent link 
the drug and the onset of toxicity (Watkins et al. 2006), which will be discussed in further 
detail in a later section.  
Type B reactions are less common, often severe and have been associated with a plethora of 
different drugs, including troglitazone (Murphy et al. 2000), flucloxacillin (Koek et al. 1994; 
Daly et al. 2009), diclofenac (Boelsterli et al. 2003) and amiodarone (Simon et al. 1984) to 
name only a few examples. The mechanisms behind type B DILI are complex and there is not 
one unifying mechanism between toxicities caused by different compounds (Watkins et al. 
2006). In addition, these mechanisms are difficult to investigate due to the lack of test systems 
available to detect this type of DILI, which is further compounded by the low overall incidence 
of these reactions (1 in 10,000 to 1 in 100,000 patient-years) making it difficult to detect these 
reactions in clinical trials (Watkins et al. 2005). Several mechanisms have been suggested to 
play a role in the development of idiosyncratic DILI including mitochondrial heteroplasmy 
(Boelsterli et al. 2007), bile-salt export pump (BSEP) inhibition (Funk et al. 2011) and human 
leukocyte antigen (HLA) genotypes (Daly et al. 2009), however, no one overriding 
mechanism common to all type II reactions has been discovered.  
A notable example of a type II toxin is troglitazone, a first-in-class PPAR-γ agonist used for 
the treatment of type II diabetes, which was initially enthusiastically received by doctors and 
patients. However, within 1 year of product launch, reports of acute liver failure associated 
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with this drug were being reported (Watkins et al. 1998). Troglitazone DILI was characterised 
by a relatively acute onset of hepatocellular-injury generally occurring after 1-7 months of 
treatment, with delayed jaundice and serum bilirubin elevations, which would lead to severe 
liver failure if treatment was not stopped in time (Graham et al. 2003a; Graham et al. 2003b). 
The mechanisms behind troglitazone DILI are now well investigated and yet still disputed, 
with some groups suggesting that mitochondrial dysfunction was an underlying mechanism 
(Ong et al. 2007), and other suggesting that troglitazone has bile salt export pump (BSEP) 
inhibitor activity, leading to a gradual build up of bile salts and eventually hepatocellular 
damage through cholestasis (Funk et al. 2001), highlighting the complexity of these types of 
reaction. 
DILI can also be classified as hepatocellular, cholestatic or mixed (hepatocellular-cholestatic) 
depending on the histological features of the injury. Hepatocellur injury most commonly 
resembles acute viral hepatitis, typified by a large level of hepatocyte necrosis and 
inflammation with only minimal cholestasis (Zimmerman et al. 1976i). Compounds such as 
isoniazid (Bernstein et al. 1980), green tea (Molinari et al. 2006) and methyldopa (Seggie et 
al. 1979) most commonly lead to hepatocellular injury. Conversely, cholestatic injury usually 
resembles bile duct obstruction or choledocolithiasis, and involves bile stasis, portal 
inflammation and proliferation or injury of the biliary epithelium (Padda et al. 2011). 
Clinically this pathology usually presents as jaundice, with right upper quadrant pain and 
itching. Examples of compound which lead to cholestatic injury include 
amoxicillin/clavulanate (Stricker et al. 1989), ciprofloxacin (Labowitz et al. 1997) and the 
sulfonylureas (Frier et al. 1977). Mixed injury involves a mixture of the symptoms and 
features of both hepatocellular and cholestatic injury, and is the typical clinical presentation 
of DILI caused by the majority of drugs (Bjornsson and Jonasson. 2013). Drugs which cause 
a mixed pattern of injury include the sulphonamides (Westphal et al. 1994), phenytoin (Parker 
et al. 1979; Taylor et al. 1984) and enalapril (De La Puente et al. 2001). Clinically, the type of 
DILI is distinguished using the R value, which is derived from the ratio of serum ALT to 
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serum alkaline phosphatase, a marker of biliary function. Values of 5 or more are classed as 
hepatocellular, 2-5 as mixed and <2 as cholestatic (Aithal et al. 2011). 
1.4 DRUG METABOLISM 
1.4.1 Phase I Metabolism 
Phase I metabolism is the unmasking of reactive functional groups (-OH, -CO2H, -NH2, -SH) 
via hydrolysis, hydration, reduction or oxidation, which in turn facilitates the process of 
conjugation and excretion (Phase II). These reactions are catalysed by enzymes, such as the 
cytochrome P450s (CYP450), alcohol dehydrogenases, flavin monooxygenases (FMO), and 
monoamine oxidases (MAO).  CYP450 and FMOs are mixed-function oxidases which require 
both oxygen and NADPH as substrates in order to function. CYP450 are critical in phase I 
metabolism and reflect the enormous variety in endogenous and exogenous substances, in 
their broad and overlapping substrate specificities (Gibson and Skett 2001; Rang et al. 2014). 
CYP450 are located in both the endoplasmic reticulum and in the mitochondria, as the terminal 
component of the electron transport system. CYP450 are sub-divided into 42 subfamilies 
located across 60 distinct genes, in the human genome. The CYP450 families 1 to 3 are mainly 
implicated in drug metabolism, whilst other families are involved in the metabolism and 
production of endogenous substances, such as steroid metabolism. CYP450s can be classed 
as haem-containing enzymes which catalyse the basic reaction, monooxygenation. CYP450 
are the family of enzymes responsible for the bioactivation of paracetamol into NAPQI, a 
hepatotoxic reactive metabolite (Lee et al. 1996). 
There is a level of interspecies variation in the variety of CYP450s and their function, notably 
between rodents and humans (Lewis et al. 1998), which is of particular importance when it is 
considered that most pre-clinical studies are performed in rodents. Because of this it is 
important to be cautious when extrapolating results from animal models in which the 
translational similarity of the CYP450 isoforms involved is not understood. To address this a 
study has been carried out examining the interspecies differences in CYP450 expression and 
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function (Bogaards et al. 2000) with the aim of providing a tool to select the most relevant 
species model for use in pre-clinical testing. An example of the poor extrapolation model can 
be seen in that of coumarin-induced hepatotoxicity, which was highly prevalent in rats, due to 
the formation of an epoxide intermediate metabolite, which was not seen in other species 
(Vassallo et al. 2004). In addition, some CYP450s are highly polymorphic within species, an 
example of which is CYP2D6 in humans, a drug which is responsible for the metabolism of 
around 40 clinically relevant drugs (Aiklillu et al. 1996). In certain populations, such as the 
Ethiopian population a polymorphism causing an ultra-rapid metabolism phenotype is highly 
common (Aiklillu et al. 1996), whereas a polymorphism causing a slower metaboliser 
phenotype is more common in the African-American population (Bradford et al. 1998). 
FMOs share many similarities to CYP450s, however their major difference is their inability 
to oxidise carbon atoms, and their lack of induction by exposure to drugs, or pollutants (Woolf. 
1999). They are mainly located within the microsomal fraction of the liver and are able to 
oxidise nitrogen, phosphorous and sulphur containing compounds (Tynes and Philpot 1987). 
Alcohol dehydrogenases facilitate the conversion of alcohols to aldehydes and ketones, and 
MAOs are oxidases which are able to remove the amine group of a compound using an oxygen 
molecule. Phase I metabolism is somewhat important in several forms of DILI, as it is a 
method by which drugs can be transformed into toxic metabolites. The ability of these 
enzymes to reveal free-radical function groups presents the risk of covalent binding to cellular 
proteins, and a shift in the redox-balance of the cell, all of which could lead to DILI (Yu et al. 
2014).  
1.4.2 Phase II Metabolism 
Phase II metabolism is the process of adding endogenous co-factors in order to increase the 
polarity of the molecule, causing it to become more hydrophilic, aiding excretion. Phase II 
reactions include glucoronidation, sulfation, acetylation, methylation, amino acid conjugation 
and GSH conjugation (Gibson and Skett 2001; Rang et al. 2014; Timbrell 1999). These all 
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involve the conjugation of a molecule to a reactive metabolite in order to produce a more 
hydrophilic unreactive compound.  
Glucuronidation, the major phase II conjugation pathway involves a glucuronide acting as a 
conjugation molecule which binds to a substrate via the catalysis of glucuronosyltransferases. 
First, the co-substrate uridine diphosphate glucuronic acid (UDPGA) is formed through a 
series of reactions. Glucuronosyltransferases (UGTs) then catalyse the transfer of glucuronic 
acid from UDPGA to a substrate resulting in a glucuronidated substrate. UGTs play an 
important role in xenobiotic metabolism, because glucuronic acid can be coupled to a diverse 
range of functional groups (Testa and Krämer. 2008). 
GSH is another method of conjugation and cellular protection following phase I activation of 
compounds. Conjugation of GSH to electrophilic species is facilitated by the phase II 
metabolism enzymes glutathione S-transferases (GSTs). GSTs are either cytosolic (alpha, mu, 
pi, theta and zeta) or microsomal, with the former accounting for 95% of GSTs (Raha and 
Tew. 1996). GSH conjugation involves the formation of a thio-ether bond between the 
cysteine residue of the GSH molecule, and the electrophile. GSH-conjugates are then excreted 
in bile and converted cysteine/mercapturic acid conjugates in the intestines/kidneys (DeLeve. 
1997). Similarly to Phase I metabolism, species variation in GSH conjugation should be 
considered due to the increased activity of this pathway in some species (Hengstler et al. 
1999).  
1.5 CELLULAR DEFENCE MECHANISMS  
The liver is the most adaptive and regenerative of the organs within the body, in order to allow 
it to be an effective first line of defence in the body against exogenous toxins, and endogenous 
waste. During chemical stress the liver is able to activate endogenous ‘stress response’ 
pathways through detection of reactive metabolites or reactive oxygen species. This response 
is able to initiate de novo synthesis of antioxidant/stress proteins which are expressed at low 
levels under normal homeostasis, in an attempt to reverse the oncoming toxic insult. This 
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response can result in the return to homeostasis, proliferation of cells, differentiation, or if the 
damage is too severe for recovery, the initiation of cell death pathways.  
1.5.1 Glutathione  
Glutathione (GSH) is an intracellular tripeptide made up of a glutamate, cysteine and glycine 
residues, which is contained at high levels (0.5-10mM) within the cytoplasm of the hepatocyte 
(Meister and Anderson 1983). GSH plays an important role in the maintenance of the redox-
state of the cell through performing antioxidant and free-radical scavenging functions (Hayes 
and McLellan 1999). Its presence during toxic stress is critical to avoid the loss of function of 
important cellular proteins. GSH is able to perform this function as a result of containing a 
sulphydryl group within its cysteine residue, which is able to act as a nucleophilic scavenger, 
and electron donor. And because of its high cellular content, reactive metabolites favourably 
react with GSH over cellular proteins, allowing these proteins to remain in their reduced state, 
which is critical to their function.  
GSH is present within the cell in both reduced and oxidised (GSSG) forms, with the former 
accounting for the majority, due to the presence of GSSG-reductase, an enzyme which 
catalyses the reduction of GSSG. GSH is the first line of defence against electrophilic reactive 
metabolites; it is able to detoxify these through the donation of a proton through a nucleophilic 
attack, resulting in an inactive metabolite and GSSG, or it is able to directly bind to the reactive 
metabolite to increase its excretion (DeLeve. 1997). GSH is able to react with aliphatic-, 
aromatic- (halo- and nitro-), alkene- and epoxide-containing compounds (Gibson and Skett 
2001). GSH-conjugation can either occur spontaneously, or it can be catalysed by GST 
enzymes, as discussed previously. Upon depletion of GSH, or when the ability of GSSG-
reductase to reduce GSSG is surpassed, de novo GSH synthesis is induced. GSH synthesis 
occurs through a two-step reaction process which involves the synthesis of γ-glutamylcysteine 
from L-glutamate, facilitated by γ-glutamylcysteine synthetase, followed by the addition of a 
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glycine residue by GSH synthetase, to form γ-glutamyl-cysteine-glycine (Raha and Tew. 
1996).   
1.5.2 The Nrf2 pathway 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a basic leucine zipper transcription factor 
is the master regulator of the cells antioxidant response. Under homeostasis, Nrf2 is present at 
low levels in the cell due to it undergoing rapid degradation. In normal conditions Nrf2 is 
located in the cytoplasm, and is bound to Kelch-like ECH-associated protein-1 (Keap1), which 
directs it for degradation via the proteasome (Dinkova-Kostova et al. 2002; Reviewed by 
Copple et al. 2010). Under oxidative stress conditions, Keap1 is able to sense the presence of 
oxidants through highly reactive cysteine residues. Under these conditions, Keap1 then 
releases Nrf2 which allows its translocation to the nucleus of the cell, where it is able to bind 
to and activate the ARE (antioxidant response element) promoter which leads to an up 
regulation of ARE-driven genes, including GSTs, GCL, heam oxygenase 1 (HO-1) and 
NAD(P)H:quinine oxidoreductase (NQO1) (Alam et al. 1999; Nguyen et al. 2003; Rushmore 
and Kong. 2002). HO1 is a member of the heat shock protein family (Hsp32) and plays a role 
in stabilising protein formation within the cell, and NQO1 catalyses the 2-electron reduction 
of quinones into a less toxic hydroquinone. The function of GCL and GSTs has previously 
been discussed in other sections. Induction of these genes increases the defences of the cell 
with the aim of reducing the toxic burden and returning the cell to homeostasis.    
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1.6 MECHANISMS OF DRUG-INDUCED HEPATOTOXICITY 
Drug-induced liver injury is used as an umbrella to describe all forms of hepatic damage 
caused by an exogenous drug or chemical, however, the route and outcome of the injury can 
be highly varied. Toxicity can involve the parent compound, or the metabolism of parent 
compounds to reactive metabolites, which may lead to covalent binding of macromolecules, 
oxidative stress and GSH depletion. These can all contribute to the damage of cellular 
organelles, such as the mitochondria or endoplasmic reticulum which can in turn lead to cell 
death, either through apoptosis or necrosis, or a combination of these processes. 
1.6.1 Covalent binding 
Covalent binding in DILI usually occurs through the activation of a compound by CYP450 
mediated metabolism to a reactive metabolite (usually an electrophile), which can then in turn 
react with residues of proteins and macromolecules to form stable drug adducts. Covalent 
binding to cellular proteins may cause an alteration of the proteins function, which if deemed 
as a critical protein for cellular function, may cause the initiation of cell death. It has also been 
suggested that if sufficient levels of protein function are altered through covalent binding, the 
cells ability to maintain homeostasis may be reduced, which will cause an altered redox 
balance, eventually leading to cell death. Covalent binding has been proposed as one 
mechanism for the toxicity of paracetamol (Minamide et al. 1998). Additionally, covalent 
binding of hepatotoxic drugs is thought to be involved in the triggering of the immune system 
which often results in a worsening pathology, which is what has been demonstrated to be the 
mechanism in halothane-induced hepatitis (Kenna et al. 1987).  
1.6.2 Oxidative Stress 
Oxidative stress is the imbalance redox state of the cell, due to an increase in the level of ROS 
above the cells capacity to reduce these molecules to H2O. Examples of ROS include 
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superoxide, hydroxyl radicals, peroxynitrite and hydrogen peroxide. The immediate result of 
the build-up of these molecules is lipid peroxidation, reduced membrane functionality, and in 
turn, the loss of the cells ability to generate its own energy, and maintain ionic homeostasis 
(Buege and Aust. 1978; Radi et al. 1991). ROS are formed under normal homeostasis in the 
mitochondria, through a 1-electron transfer in the electron transport chain. However, under 
pathological conditions, this chain can become uncoupled, leading to the accumulation of ROS 
within the cell. Oxidative stress in clofibrate-induced hepatocyte cell death has been 
demonstrated to cause damage to mtDNA, leading to mitochondrial dysfunction and cell death 
(Qu et al. 2001).   
1.6.3 Glutathione depletion 
It has been suggested that depletion of cellular GSH is a prerequisite for the onset of toxic 
events for certain hepatotoxins (Jollow et al. 1973; Mitchell et al. 1973; Reed and Fariss 1984). 
Depletion of GSH in paracetamol-DILI is a well characterised event, occurring as early as 1H 
after administration of a toxic dose of paracetamol by I.P. injection in rodents. NAPQI, the 
reactive metabolite of paracetamol is able to bind covalently to the cysteine residue of GSH, 
by which it is detoxified and excreted, along with the GSH molecule. It has been demonstrated 
that GSH needs to be depleted by at least 80% or more in order for toxicity to ensue in 
paracetamol-injury (Jollow et al. 1973).  
1.6.4 Mitochondrial damage 
Mitochondria are the organelle responsible for the production of cellular energy, mainly in the 
form of ATP. Other roles of the mitochondria are maintenance of redox homeostasis, 
proliferation, and steroid synthesis. Mitochondria are also the target of hepatotoxins and have 
the ability to initiate cell death. Many drugs have been shown to cause mitochondrial 
dysfunction in hepatocytes through a myriad of different mechanisms, reviewed in Labbe et 
al. (2008). Drug-induced mitochondrial dysfunction can cause adverse events such as 
steatosis, hepatitis and steatohepatitis, leading to cirrhosis, fibrosis and liver failure. The 
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failure to detect mitochondrial hazards during drug development has led to patient morbidity 
and mortality during clinical trials plus the termination of numerous drug projects. 
Mitochondrial dysfunction can lead to the uncoupling of the electron transport chain, 
producing a build-up of ROS within the mitochondrial membrane. ROS are then able to bind 
to critical mitochondrial proteins to disrupt cellular energy production, which in-turn leads to 
release of pro-apoptotic proteins. The mitochondria are able to initiate apoptosis through the 
opening of the mitochondrial permeability transition (MPT) pore, which leads to an increase 
in the permeability of the mitochondrial membrane to proteins under 1.5KDa. This results in 
a loss of membrane potential and the release of cytochrome C into the cytoplasm. Activation 
of the MPT is also able to lead to necrosis, as well as apoptosis. Apoptosis is an energetic 
process that requires the function of a Na+/Ca2+ exchanger to rid the cell of excess calcium, 
however if the toxicity is such that the mitochondria are no longer able to produce ATP, cell 
death will proceed to necrosis. If cellular ATP is depleted during apoptosis, cell death will 
then proceed to necrosis, causing so called necro-apoptosis (Kanduc et al. 2002). It has also 
been suggested that mitochondrial injury is able to silently accumulate over time, seemingly 
without effect, eventually reaching a critical threshold, abruptly triggering idiosyncratic DILI 
(Boelsterli and Lim 2007). 
1.6.5 Endoplasmic reticulum stress and the unfolded protein response 
The endoplasmic reticulum (ER) has two main functions within the cell, the translation of 
protein, and the metabolism of xenobiotics (Reviewed extensively in (Cribb et al. 2005; 
Malhotra and Kaufman 2007). In times of translational stress, due to a heavy burden on the 
translational machinery, or through ER protein damage by toxicants, the ER can elicit a stress 
response, the unfolded protein response (UPR) (figure 1.3). The UPR’s function is to reduce 
translational stress; however, in severe cases the UPR can activate destructive cell death 
pathways. A number of studies have demonstrated that drugs are able to elicit an ER stress 
response in vitro, and in vivo, including carbamazepine (CBZ) (Fredriksson et al. 2014), 
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paracetamol (Uzi et al. 2013), non-nucleoside reverse transcriptase inhibitors (Apostolova et 
al. 2013), HIV protease inhibitors (Zhou et al. 2006), and methapyrilene (Auman et al. 2007). 
Arylating quinones are particularly susceptible to inducing the UPR (Wang et al. 2006). 
Under low levels of ER stress, the UPR acts to down-regulate global protein synthesis, through 
phospho-activation of Eukaryotic Initiation Factor 2α (EIF2α) by Protein Kinase ds-RNA-
Dependent-Like ER Kinase (PERK) (DuRose et al. 2009), and also through up regulation of 
the Endoplasmic reticulum to nucleus signalling 1 (IRE1) pathway. The UPR also increases 
expression of protein chaperones, such as Glucose Regulated Protein 78 (GRP78) and GRP94 
(Bedard et al. 2004), through nuclear translocation of Activating Transcription Factor 6 
(ATF6), as part of a negative feedback-loop, and also decreases cellular oxidative stress, 
through activation of the Nrf2 pathway by PERK (Cullinan and Diehl 2004; Cullinan et al. 
2004; Cullinan et al. 2003).  
Under conditions where stress exceeds the capacity of the cells defences, the UPR initiates a 
pro-apoptotic cascade which leads to the death of the cell (Rao et al. 2004). This can be 
initiated by xenobiotics or reactive metabolites which covalently bind to, or damage proteins 
involved in the endogenous function of the ER, such as GRP78/94. This in turn activates the 
C/EBP homologous protein (CHOP), through the PERK and ATF6 pathways, which converge 
leading to BAX/BAC mediated apoptosis (Marciniak et al. 2004). Severe ER stress is also 
able to lead to calpain mediated apoptosis (Sanges and Marigo 2006), through the release of 
intraluminal calcium stores through Inositol Triphosphate -3 receptor (IP-3R) activation, and 
also activation of the IRE1 pathway, which both lead to mitochondrial membrane 
depolarisation. 
Fredriksson et al (2014) was able to demonstrate, using siRNA to knock-down elements of 
the UPR in a HepG2 CBZ/diclofenac (DCN) model of DILI that the protective, and destructive 
elements of the UPR are divergent pathways, which can act independently of each other. 
Another study examining the mechanisms of efavirenz-induced liver injury in Hep3B, and 
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primary human hepatocytes, was able to demonstrate increased expression of pathways related 
to UPR-induced apoptosis. Importantly however, this study was able to demonstrate, using 
Rho0 cells without functional mitochondria, that the mitochondria are required for full 
activation of the UPR, suggesting the importance of cross-talk between the mitochondria and 
ER (Apostolova et al. 2013).  
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Figure 1.3 The protective and destructive functions of the UPR response. (Adapted from Chen et al. 2014 
and Schonthal et al. 2012). (A). Under low levels of transcriptional/ER stress, the chaperones GRP78/94 release 
IRE-1, PERK and ATF6 to initiate downstream signalling events which result in reduced mRNA translation, 
increased antioxidant response through the Nrf2 pathway, and an increase in chaperone expression, as a negative 
feedback pathway. This is all with the goal of reducing the translational load on the ER in times of stress. (B). 
After prolonged or severe ER stress, or damage due to covalent binding of reactive metabolites/drugs to ER 
proteins, the UPR pathway can become destructive. Briefly, damage to, or down-regulation of chaperones 
(GRP78/94) during severe ER stress leads to activation of the CHOP and TRAF2 pathways, which lead to the 
down-regulation of anti-apoptotic signalling mechanisms and the activation of the pro-apoptotic Bid, and Bax. 
Prolonged stress can also cause release of intraluminal calcium stores from the ER, through the IP3 receptor, 
which can initiate caspase mediated apoptosis through a mitochondrial signalling route. This leads to increased 
oxidative stress, through release of ROS through the MTP, and an increase in inflammation through activation 
of NF-κB. 
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1.6.6 Apoptosis 
Apoptosis is the programmed death of the cell, in order to prevent the transfer of damaged 
DNA to future lineages of cells. Cellular apoptosis is identifiable by characteristic nuclear 
condensation, DNA fragmentation and ‘blebbing’ of the plasma membrane. The blebbing 
plasma membrane then forms apoptotic bodies, small vesicles made up of the plasma 
membrane and the contents of the cytosol. These go on to be phagocytosed by scavenger cells 
such as macrophages, which recognise the externalised phosphatidylserine groups on the 
surface of the apoptotic bodies. This occurs in an efficient and ordered manner in order to not 
illicit an immune response (Savill et al. 1993). 
Apoptosis can be initiated through two separate pathways, the intrinsic mitochondrial 
pathway, and the external death receptor pathway (Green and Reed 1998). The latter can be 
activated through the binding of a death receptor ligand (Fas-ligand, TRAIL, TNFα) to their 
receptor on the surface of the affected cell. Upon activation these receptors induce a signalling 
cascade which results in the formation of the death-induced signalling complex (DISC), which 
acts via adaptor proteins, FAD or TRADD to induce the caspase activation cascade. Caspases 
are a group of cysteine-aspartic-acid proteases which are able to cleave critical proteins 
containing aspartate residues, resulting the ceasing of cellular function and cell death (Cohen 
1997; Earnshaw et al. 1999). The intrinsic pathway is mediated by the mitochondria as a result 
of cellular DNA damage by external factors, such as UV damage or chemical stress (Green 
and Reed 1998; Zamzami and Kroemer 2001), resulting in the MPT. This can also be activated 
by a shift in the balance of pro-apoptotic (BAX, BID) and anti-apoptotic (Bcl-x1, Bcl-1) 
proteins within the cell. Once activated, the MPT causes a shift the permeability of the 
mitochondria, allowing the release of cytochrome C. Cytochrome c is a small heme protein 
associated with the mitochondrial membrane, its release from the mitochondria is able to 
activate the apoptosome, through binding of Apaf-1 and ATP, and the recruitment of pro-
caspase 9. The apoptosome is able to cleave pro-caspase 9 to form caspase-9, which is then 
able to activate the effector caspases 3 and 7. Activation of these effectors leads to the cleavage 
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of other protein substrates which results in the apoptotic process. Cleavage of ICAD/DFF45 
leads to DNA fragmentation carried out by Caspase Activated DNase (CAD), causing the 
characteristic DNA ladder formation. Apoptosis is not limited to pathological situations, it a 
key regulator in the development of organisms and is also involved in regulating the number 
of cells within an organ (Williams and Smith 1993).  
1.6.7 Necrosis 
Unlike apoptosis, Necrosis is a process of cell death which is not ordered and does not require 
the function of cellular energy production mechanisms (Kanduc et al. 2002). It is a process 
that is caused by acute cellular injury and results in the release of cellular contents into the 
surround area, due to plasma membrane damage. Characteristics of necrosis are mitochondrial 
swelling and loss of plasma membrane integrity, without any morphological changes to the 
nuclei. Necrosis is the pathway by which hepatocytes undergo cell death in paracetamol-DILI. 
However, in this form of injury there is also evidence for activation of apoptosis pathways, 
but no morphological sign of this, suggesting that neither form of cell death is mutually 
exclusive (Shen and Vandenabeele. 2014).   
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1.7 MODEL COMPOUNDS FOR THE ASSESSMENT OF DILI 
1.7.1 Paracetamol 
Paracetamol is one of the most commonly used over-the-counter analgesic and antipyretic 
drugs in the world, largely due to its wide availability and the contraindication of aspirin-
containing products for paediatric use (Ward et al. 2001). Although paracetamol has an 
excellent safety profile, it is one of the most commonly associated compounds with intentional 
and unintentional overdoses (Penna et al. 2001), being the most common cause of acute liver 
failure, replacing viral hepatitis and the second most common cause of liver failure requiring 
liver transplant (Fontant et al. 2008). The US National Poison Data System reports of over 
50,000 exposures (per annum.) related to paracetamol alone and 20,000 related to paracetamol 
in combination with another drug, which led to 65 and 42 deaths respectively (Mowry et al. 
2015). Clinical symptoms often feature nausea and vomiting in the early stages of toxicity, 
followed by abdominal pain, tachycardia and hypotension at around 18h following ingestion. 
This is then followed by the hepatic phase, in which wide-spread hepatic necrosis and 
dysfunction is apparent, associated with jaundice, coagulopathy, hypoglycaemia and hepatic 
encephalopathy. After this secondary organ failure leading to death may occur if an 
appropriate therapeutic intervention is not put in place (Fontana et al. 2008). The standard 
approach to treatment often involves the use of activated charcoal, if presentation is <1h after 
ingestion, or an intravenous course of N-acetylcysteine, which is almost 100% 
hepatoprotective if administered within 8h of ingestion (Woodhead et al. 2012). 
Paracetamol is an important model hepatotoxin. It produces predictable, dose-dependent liver 
injury in man and a strikingly similar hepatotoxicity in rodent models. An enormous amount 
of work to elucidate the molecular mechanisms that underpin paracetamol-induced ALI has 
been conducted in order to better understand the basis of DILI in a wider context. This work 
has been reviewed previously (Jaeschke and Bajt. 2006; James et al. 2003). At therapeutic 
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doses, the majority of paracetamol is directly conjugated by phase II metabolising systems. 
Approximately 50% of the dose is glucuronidated by several members of UGTs to form a 
stable glucuronide whilst a smaller proportion, approximately 30%, is sulphated by members 
of the SULT enzymes (Schenker et al. 2001). These non-toxic metabolites can be detected in 
serum and are excreted in the urine alongside a small proportion of parent drug and other 
minor metabolites. A small but significant proportion of the therapeutic dose (5-15%) 
undergoes oxidative metabolism via cytochrome P450-2E1 (CYP2E1) (and to a lesser extent 
by CYP1A2 and CYP3A4) (Chen et al. 1998; Patten et al. 1993; Thummel et al. 1993) (Figure 
1.4). This oxidative metabolism yields a reactive electrophilic intermediate, n-acetyl-p-
benzoquinone imine (NAPQI), which has the propensity to bind macromolecular components 
of the cell and elicit toxicity. The excellent safety profile of paracetamol is afforded by the 
vast levels of glutathione (GSH) in the hepatocyte which quench and detoxify the relatively 
small levels of NAPQI at therapeutic doses.  
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Figure 1.4 Metabolism of paracetamol. Paracetamol is conjugated, in the liver, to glucuronides 
(60%) and sulphates (35%), which are inert. 5-15% is converted by CYP2E1 to the reactive 
metabolite N-acetyl-P-benzoquinone (NAPQI). At normal doses NAPQI is conjugated to glutathione 
(GSH), at high doses the cell is GSH deficient and NAPQI accumulates. NAPQI can also be converted 
back to paracetamol by NADPH dehydrogenase quinone 1 (NQO1). 
  
OH 
GSH 
UDP-glucuronosyltransferase 
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1.7.2 Furosemide 
Furosemide (FS) is a carboxylic acid based loop diuretic used routinely for the treatment of 
oedematous states and hypertension (Ponto and Schoenwald 1990). FS has been shown to 
possess a hepatotoxic risk in rodent models, through a mechanism independent from its 
pharmacological action, whereas it is not generally recognised as being hepatotoxic in humans 
(Mitchell et al. 1976). FS displays a varied hepatotoxic potential between rodent species. 
Initial studies in mice found that FS causes severe hepatic centrilobular necrosis at high doses 
through the generation of a chemically-reactive metabolite (Mitchell et al. 1976; Mitchell et 
al. 1974). Later studies showed that rats could develop mild diffuse necrosis which could be 
exacerbated by pre-treatment with phenobarbital whereas hamsters appeared highly resistant 
to FS-induced hepatotoxicity (Lagarriga et al. 1976). A recent study found that the ability to 
form FS-glutathione conjugates in vivo may explain the species differences in toxicity between 
rats and mice (Williams et al. 2007). 
FS contains several well-defined toxicophores including a furan ring, carboxylic acid and a 
primary amine group. Several studies have shown that the toxic metabolite is mediated by 
cytochrome P450s (Mitchell et al. 1976). Hepatotoxicity in mice appears to be associated with 
oxidation of the furan ring through an epoxide intermediate (Mitchell et al. 1976; Williams et 
al. 2007). Inhibition of epoxide hydrolase and subsequent covalent binding data support the 
theory that epoxide formation is the primary step in FS metabolism mediated hepatotoxicity 
(Wirth et al. 1976) (Figure 1.5).  The extent of FS covalent binding also appears to correlate 
with the severity of liver injury (Mitchell et al. 1976) suggesting that the reactive intermediate 
can bind to macromolecules in the cell and exert toxicity. To date, no protein adducts have 
been reported with FS, however inhibition of mitochondrial enzymes has been found 
following FS treatment suggesting that the toxic intermediate can bind to and perturb 
endogenous protein function (Thorgeirsson et al. 1976).  Disaggregation of polyribosomes, 
vesiculation of the rough endoplasmic reticulum, and dilation of the smooth endoplasmic 
reticulum have been reported as early histopathological findings during FS-induced liver 
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injury (Walker and McElligott 1981). The finding that FS does not deplete glutathione (GSH), 
an important thiol-containing antioxidant, distinguishes FS from other typical hepatotoxins 
like paracetamol and carbon tetrachloride (Mitchell et al. 1974). Wong and colleagues 
reported that both cytosolic and mitochondrial GSH levels were unaffected by FS treatment 
(Wong et al. 2000) suggesting that the mitochondria may not play a major role in FS-mediated 
liver injury. Furthermore, recent studies have shown that FS causes serum ALT activity rises 
(a signal of hepatocellular necrosis) but only modest concomitant glutamate dehydrogenase 
(GLDH) rises (a signal of mitochondrial dysfunction) in mice (McGill et al. 2012). These 
findings suggest that FS may initiate toxicity through a mechanism independent of the 
mitochondria, possibly through endoplasmic reticulum stress. 
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1.8 3-NITROTYROSINE AND HEPATIC PROTEIN TYROSINE NITRATION  
The role of nitric oxide (NO) as an important signal transducer in the vasculature and nervous 
system has been well established. However, NO is also implicated in the development of a 
range of pathologies due to the propensity to form highly potent reactive nitrogen species 
(RNS). RNS can chemically modify specific amino acids on proteins by nitrating tyrosine 
residues (or nitrosylating cysteine residues) leading to a possible loss of protein function. 
Protein tyrosine nitration (PTN) is a covalent post-translational modification of a tyrosine 
residue at the ortho-carbon position of the phenolic ring, in which a nitro- group is substituted 
in place of a hydrogen molecule (figure 1.6). For this reaction to occur, a nitro- group must be 
produced, with nitric oxide providing the source (Radi et al. 2004). PTN can occur through 
several mechanisms and can be caused by more than one nitrating agent, the most common of 
which is peroxynitrite anion (ONOO-), formed through the reaction of endogenous nitric 
oxide and superoxide. ONOO- is a potent nitrating and oxidising agent, able to react with 
proteins (at tyrosine and cysteine residues), lipids and DNA (Figure 1.6). Under normal 
physiological conditions, peroxynitrite forms a carboxylate radical through homolysis and 
reaction with carbon dioxide, which is in turn able to nitrate oxidised tyrosine residues on 
proteins (Radi et al. 2004). Recently, other nitrating agents have been identified such as the 
formation of nitrogen dioxide by hemeperoxidases/transition metal complexes during nitrite 
metabolism (Pfeiffer et al. 2001; Pfeiffer et al. 2000; Thomas et al. 2002).  
PTN has been shown to be present and in some cases implicated in a diverse set of disease 
states, including, neurodegenerative disorders (Lee et al. 2009) cardiovascular disease (Turko 
and Murad 2002) and diabetes. PTN has also been shown to be involved in the development 
of a range of liver diseases.  PTN was evidenced in 54 patients with chronic viral hepatitis 
(HBV and HCV) (García-Monzón et al. 2000). Importantly, the levels of PTN correlated with 
the severity of hepatocellular injury in these patients, as determined by the histological activity 
index. This study also showed that PTN could distinguish between chronic viral hepatitis and 
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alcohol steatosis suggesting that PTN is involved in specific mechanisms of liver injury. In a 
separate study, PTN levels were raised in patients with primary biliary cirrhosis and patients 
with autoimmune hepatitis (Sanz-Cameno et al. 2002). Visual scoring of both PTN and iNOS 
levels correlated with the histological grade of liver injury. These studies show that PTN is a 
clinically-relevant phenomenon that can contribute to the severity and development of liver 
disease in patients. Similar findings have been reported in experimental models of liver 
disease. In a diabetic rat model, PTN was found to be elevated in the mitochondria of 
hepatocytes which were associated with ultrastructural damage to the mitochondria (Ren et al. 
2008). Another study showed that in mice fed on a high-fat diet that develop non-alcoholic 
steatohepatitis (NASH), mitochondrial function was diminished (Mantena et al. 2009). 
Importantly, PTN levels were increased in mitochondrial proteins and closely reflected the 
hypoxia gradient. Mitochondrial proteins are particularly susceptible to PTN due to these 
Figure 1.6 Mechanisms of reactive nitrogen species production and formation of 3-nitrotyrosine. Nitric oxide 
is endogenously produced by iNOS/nNOS and under pathological conditions can react with oxygen containing 
compounds to form highly reactive nitrogen species. Under oxidative stress conditions high levels of superoxide 
are produced by mitochondrial respiration or NADPH oxidase. Superoxide is able to react with nitric oxide in a 
spontaneous reaction to form peroxynitrite, a highly reactive nitrogen species. In conditions in which low levels of 
superoxide are produced, superoxide dismutase (SOD), an enzyme present in the cytosol and mitochondria, is able 
to metabolise superoxide to oxygen and hydrogen peroxide, thus reducing levels of nitrosative stress. Nitrogen 
dioxide, another reactive nitrogen species can also be produced through the formation of nitrite from a reaction 
between nitric oxide and oxygen, which can be enzymatically transformed, by myeloperoxidase (MPO) into the 
reactive species, nitrogen dioxide. Reactive nitrogen species are able to react spontaneously with certain tyrosine 
residues of proteins and form 3-nitrotyrosine residues. 
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organelles being the major intracellular source of superoxide, other ROS and neuronal NOS 
(nNOS).  It was recently shown that in a mouse model of acute alcohol liver dysfunction, 
tyrosine residues in complex V proteins of the mitochondrial respiratory chain were nitrated 
causing loss of function (Larosche et al. 2010). These effects were prevented in mice with 
induced expression of manganese superoxide dismutase (MnSOD), an enzyme implicated in 
the detoxification of reactive oxygen species. Clearly, whilst an unequivocal role in disease 
pathogenesis remains to be shown, PTN may contribute to the development of liver injury in 
specific liver diseases.  
PTN is a selective process, in which specific tyrosine residues are nitrated, e.g. residue Y115 is 
preferentially nitrated on ribonuclease A and residue Y102 is nitrated on phospholipase A2 
(Souza et al. 1999). Unlike phosphorylation, the primary protein sequence does not affect this, 
but factors such as the proximity to reactive cysteine residues or negatively charged amino 
acids, steric hindrance, tyrosine surface exposure and the location of tyrosine residues within 
the tertiary structure of the protein can influence the pattern of PTN. Additionally, the nature 
of the nitrating agent also affects the pattern of PTN, an example of which is ribonuclease A 
which is preferentially nitrated by nitrogen dioxide, whereas phospholipase A2 is preferentially 
nitrated by peroxynitrite (Souza et al. 1999). PTN can cause loss of protein function; however 
some proteins retain function after nitration has occurred. The site of nitration appears to be 
an important factor on protein function. MnSOD, an important mitochondrial enzyme is 
nitrated at Y34, which is located directly in the catalytic side of the protein and leads to a loss 
of enzymatic function (MacMillan-Crow et al. 1998). However, mitochondrial aconitase is 
nitrated at residues Y151 and Y452 (Tórtora et al. 2007). These residues are located far from the 
catalytic site of the protein and cause no functional change. PTN may also cause a change of 
protein function; nitration of cytochrome C abolishes its function in the apoptosome, however 
cytochrome C gains peroxidise activity (Figure 1.7).   
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Figure 1.7 Nitration of tyrosine residues within cellular proteins can have mixed 
consequences. Manganese superoxide dismutase (mnSOD) is nitrated within its active catalytic 
site and loses its function. Cytochrome C gains peroxidase activity after nitration, and nitration 
of aconitase has no effect on the proteins function.  
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1.9 BIOMARKERS OF DILI 
 
1.9.1 Current biomarkers of DILI  
The current gold-standard biomarkers of liver injury are ALT and aspartate transaminase 
(AST) (Ozer et al. 2008). These enzymes are involved in amino acid biosynthesis and are 
released into the circulation following hepatocyte cell membrane breakdown during necrosis. 
Despite these markers being the gold standard, they suffer from a lack of liver specificity. 
ALT exists in two isoforms (ALT1 and ALT2), which are expressed in heart, kidney and 
muscle tissue to different degrees, therefore, these enzymes may not only report on liver 
injury. ALT1 has been demonstrated to be expressed in high levels in human liver tissue, as 
well as being the most abundant isoform detectable in human serum. Importantly however, 
ALT1 is also detectable in high levels in kidney and muscle tissue, hampering the use of an 
isoform- specific assay (Lindblom et al. 2007). As a product of this, ALT has previously been 
demonstrated to be elevated in cases of muscle injury (Zhang et al. 2010). A variety of studies 
have also demonstrated that ALT levels may become raised in humans undertaking extreme 
endurance sports events (Koutedakis et al. 1993). Additionally, ALT can be raised by 
hyperalimentation (Kubo et al. 2007) and basal expression can be induced by drugs (Lee and 
Kenney 1970). ALT2 does not offer use as a biomarker of liver injury, as it is expressed at 
negligible levels in the liver (Lindblom et al. 2007). 
Due to the clear lack of an appropriate clinical biomarker to detect DILI, the usual method of 
practice in clinics in the UK is to establish a causal relationship between the drug in question 
and the possible diagnosis of liver damage. To establish this relationship, several qualitative 
scoring systems have been developed, a commonly used example of which is the Roussel 
Uclaf Causality Assessment Method/Council for International Organizations of Medical 
Sciences scale (RUCAM/CIOMS) (Benichou et al. 1993; Lewis et al. 2008; Rochon et al. 
2008). The RUCAM/CIOMS scale takes the type of liver injury into account (hepatocellular, 
cholestatic or mixed) and is a qualitative system that scores on seven criteria: temporal 
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relationship, clinical course, risk factors, concomitant drugs, non-drug aetiologies, likelihood 
of reaction based on published research and response to re-challenge (Benichou et al. 1993). 
The score developed from this scale then allows clinicians to categorise patients based on their 
risk of developing DILI. The limitations of this system have now been highlighted in several 
studies which suggest that the lack of a clear scoring method and non-intuitive output have 
limited the reliability of this system (Tajiri et al. 2008; Rochon et al. 2008). In the UK, the 
standard method of practice is to assess the risk of poor outcome (i.e., development of liver 
failure) in cases of liver injury using the King’s College Criteria, developed at the Liver Unit, 
King’s College Hospital (London, UK) (O’Grady et al. 1989). The King’s College Criteria is 
also qualitative system, which takes into account blood pH, serum creatinine, grade of 
encephalopathy and prothrombin time to assess patient’s prognosis of outcome (Anand et al. 
1997; O’Grady et al. 1989). 
Outside of the clinic in drug development, the current FDA- and EMA-endorsed approach is 
the combined use of four markers, ALT, AST, alkaline phosphatase and total bilirubin, 
providing an integrated assessment of liver function. This approach is based on Hy’s law, 
which states that if a drug causes ALT/AST levels to increase to >3x upper limit of normal 
(ULN) and total bilirubin levels to increase above 2x ULN and there is not an obvious 
indication of viral hepatitis or other obvious cause, a drug is likely to cause hepatotoxicity. 
Despite this approach, each of these markers is limited by the possibility that they may also 
rise in other indications, aside from liver injury (Shi et al. 2010). AST, similar to ALT, is liable 
to rise in muscle injury (Ozer et al. 2008); bilirubin detection can also be a by-product of 
erythrocyte haemolysis through macrophage-mediated recycling of the released haemoglobin 
into unconjugated bilirubin and also several other non-DILI-related conditions (Fabris et al. 
2009; Ohmori et al. 2003). Serum alkaline phosphatase, a marker of cholestasis, is also not 
liver-enriched and may rise in bone diseases and in pregnancy 
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1.9.2 Serum GLDH 
Glutamate dehydrogenase (GLDH) is an enzyme that is enriched in the mitochondria of 
hepatocytes, with smaller amounts contained within the mitochondria of kidney and muscle 
tissue. GLDH plays an endogenous role in the detoxification of urea, as well as supporting 
amino acid metabolism (Mühlberger and Kraft 1994). A spectrophotometric assay exists that 
allows GLDH activity to be measured in serum, analogous to serum ALT activity 
measurement (Passonneau et al. 1993). Due to the large size of GLDH (330 KDa), it is 
restricted within the cell after release from a damaged mitochondrion. GLDH elevations can 
only be detected in the circulation after cell necrosis. In humans, GLDH was demonstrated to 
be a sensitive marker of DILI when tested with a range of different hepatotoxic compounds, 
including paracetamol (Schomaker et al. 2013). The same study demonstrated that serum 
GLDH levels return to baseline before that of ALT, suggesting that GLDH has a shorter 
circulatory half-life. GLDH may therefore reflect more closely the true morphology of the 
liver compared to ALT. However, in a previous study in both humans and mice, it was 
suggested that GLDH was a mechanistic marker of mitochondrial injury (McGill et al. 2012). 
An in vivo mouse study demonstrated that after administration of paracetamol (McGill et al. 
2012), serum GLDH levels were vastly increased alongside mitochondrial DNA (mtDNA) 
levels. Interestingly when FS was administered at a toxic dose, serum GLDH and circulating 
mtDNA levels remained in the normal range, even at peak toxicity when ALT levels were 
high. In a clinical setting, GLDH offers much promise as a sensitive marker of liver injury. 
However, a recent letter highlighted that a meticulous methodology for the preparation of 
serum samples is essential to measure GLDH activity appropriately (Jaeschke et al. 2013). It 
was suggested that GLDH levels may become falsely elevated in serum if intact circulating 
mitochondria released from cells are not extracted first before freezing. Nevertheless, GLDH 
is a potentially valuable biomarker of hepatic mitochondrial dysfunction due to hepatic 
enrichment and the ability to provide mechanistic insight into the basis of liver injury. 
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1.9.3 MicroRNAs 
MicroRNAs (miRNA) are short, non-coding sections of RNA, usually 18-22 nucleotides in 
length (Arasu et al. 1991; Wightman et al. 1991), which have been suggested to play a role in 
the pathology of a wide range of diseases. miRNAs are also present and highly stable in bio-
fluids, such as blood and urine, so can be easily accessed in a non-invasive manner. The 
stability of miRNAs has been attributed to the various forms in which they are released from 
cells, including in vesicle-encapsulated forms (Arroyo et al. 2011) and protein-bound 
complexes (Arroyo et al. 2011; Turchinovich et al. 2011). Additionally, some miRNAs 
demonstrate remarkable tissue enrichment, such as miR-1 in the heart (Ai et al. 2010) and 
miR-122 in the liver, representing approximately 70% of the total liver miRNA content 
(Lagos-Quintana et al. 2002). All of which together suggests that miRNAs hold many of the 
properties required of successful circulating biomarkers of disease and injury. 
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1.9.4 MicroRNA Biogenesis (Figure 1.8) 
miRNAs are usually encoded by intron sections of DNA and are initially formed as pri-
miRNAs (~thousands of nucleotides in length). These are cleaved within the nucleus by 
Drosha, a class 2 RNase III enzyme (Lee et al. 2003), to form pre-miRNAs (~70 nucleotides). 
Pre-miRNAs are actively exported from the nucleus to the cytosol through transporters such 
as exportin 5 (Bohnsack et al. 2004). Within the cytosol, pre-miRNAs form a RNA-induced 
silencing complex (RISC) with proteins such as argonaute 2 (Ago2) (Chendrimada et al. 
2005), which leads to their cleavage by Dicer, an endoribonuclease, to liberate mature single-
stranded miRNAs (microRNA biogenesis is reviewed extensively in (Cullen 2004)). Mature 
miRNA/RISC complexes target specific mRNAs through antisense recognition via the 
Figure 1.8 MicroRNA biogenesis and release into the circulation. A, microRNAs are 
transcribed within the nucleus as pri-microRNAs, which are then cleaved to form pre-
microRNAs. Pre-microRNAs are then exported from the nucleus and further cleaved to form 
a mature microRNA. Mature microRNAs then form a functional RISC (RNA-induced 
silencing complex) with proteins such as Ago2. B-D, microRNAs can be released into the 
circulation in several forms, protein complexes, exosomes and microparticles (microvesicles).  
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miRNA sequence and thereby regulate RNA translation through a variety of mechanisms 
(Ørom et al. 2008; Xu et al. 2010). miRNAs play an important role in embryogenesis (Pauli 
et al. 2011), cell differentiation (Tay et al. 2008), tissue homeostasis (Miyaki et al. 2010), 
carcinogenesis (Datta et al. 2008), cardiotoxicity (Horie et al. 2010) and viral infections 
(Stern-Ginossar et al. 2007). Importantly, miRNAs can be also highly conserved between 
species (Pasquinelli et al. 2000). Because of this, they have great potential as translational 
biomarkers in pre-clinical models, as well as in the clinic. 
1.9.5 MiR-122: a liver enriched microRNA 
Several liver-enriched microRNAs have previously been identified which provided the first 
suggestion that microRNAs may be specific markers of the liver. miR-122 (mature strand of 
miR-122-5p) was first identified to be highly enriched in mouse liver tissue by (Lagos-
Quintana et al. 2002), and is has since been suggested that it makes up almost 70% of the 
microRNAs contained within the liver of humans. Its sequence has since been shown to be 
highly conserved between 18 species, as well as between adult and foetal liver (Kozomara et 
al. 2011).  
A growing body of evidence shows that miR-122 plays an important role in the physiology of 
the hepatocyte. Several web-based algorithms predict that miR-122 may target several 
thousand genes but most of these are yet to be experimentally verified.  Studies utilizing anti-
sense oligonucleotides in mice to inhibit miR-122 have established its role in the regulation 
of lipid and cholesterol metabolism.  It was observed that when miR-122 function is abolished, 
the translation of important enzymes in these processes becomes deregulated, such as 
cholesterol 7α-hydroxylase (CYP7A1) (Esau et al. 2006). However, in pathological states it 
has been also shown that miR-122 may play a role in the development of cancerous tumours 
and in Hepatitis C infection (Girard et al. 2008; Jopling et al. 2005). In a study examining the 
replication of hepatitis C (HCV), it was observed that HCV was unable to replicate in cell-
lines which did not express miR-122 (HepG2) when compared with lines that were miR-122 
Chapter 1 – General Introduction 
	  
43	  
	  
positive (Huh 7). This was further explored utilising antisense strategies to knock-down miR-
122 expression, which consistently noted impaired HCV replication (Jopling et al. 2005). 
Interestingly, miR-122 is now being investigated as a drug target for HCV in phase II studies 
(Horie et al. 2010). In HCC, miR-122 is specifically down regulated in both humans and 
rodents (Kutay et al. 2006), and interestingly, has been demonstrated to modulate cyclin G1in 
HCC derived cell lines. Further studies in primary tumour cells lines have demonstrated an 
inverse expression relationship between miR-122 and cyclin G1, suggesting that down 
regulation of miR-122 in HCC may affect the cell cycle (Gramantieri et al. 2007). Mice that 
are genetically deficient of miR-122 are viable but develop spontaneous liver lesions and 
hepatocellular carcinomas early in life (Kutay et al. 2006). Therefore, it is clear that miR-122 
plays an important role in liver biology and defines the phenotype of the mature hepatocyte. 
1.9.6 MicroRNAs as novel biomarkers of liver injury 
Initially, many of the studies examining the potential of miRNAs to serve as biomarkers 
focussed on the use of these molecules to detect cancer (Mitchell et al. 2008). However, recent 
studies have demonstrated the utility of some liver-enriched miRNAs, in particular miR-122, 
as possible markers of DILI and other forms of liver injury. Due to the large abundance and 
remarkable liver-enrichment of miR-122, several studies examined the use of this miRNA to 
serve as a circulating biomarker of liver injury. In a study examining paracetamol-induced 
liver injury in mice, the authors were able to demonstrate that miR-122 as well as another 
liver-enriched miRNA, miR-192, detected liver injury earlier and at lower toxic doses, than 
serum ALT activity when measured in serum (Wang et al. 2009). To test the translational 
potential of miR-122 and miR-192 as biomarkers of DILI, a study examining these markers 
in 53 patients admitted to hospital after taking an paracetamol overdose was performed. We 
demonstrated that both miR-122 and -192 were raised in serum when compared with healthy 
controls. Another observation in this study was that miR-122 levels returned to baseline 
between 3 and 7 days after initial hospitalisation, whereas serum ALT levels remained 
elevated (Starkey Lewis et al. 2011). This suggests that miR-122 has a shorter circulatory half-
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life, which may allow miR-122 to closely reflect the actual state of the liver more than a 
biomarker which remains in the circulation for a long period of time without degradation. 
More recently, a study examining the utility of several mechanistic biomarkers of DILI in 
patients which had ingested a single toxic dose of paracetamol demonstrated that initial miR-
122 levels at hospital presentation provided a significant correlation with both the maximum 
ALT activity and peak international normalised ratio (INR) score during the hospital stay of 
the patient. This highlighted for the first time that miR-122 is raised very early during liver 
injury in man, and may provide prognostic value to identify at patients who develop liver 
injury (Antoine et al. 2013a). Moreover, miR-122 was raised as early as 4 hrs after a toxic 
paracetamol dose, almost 8 hrs before ALT levels usually detected in serum, Since those initial 
studies, miR-122 has been found to report on a number of different drugs associated with liver 
injury, including heparin (Harrill et al. 2012), galactosamine and alcohol (Zhang et al. 2010). 
This data collectively suggests that miR-122 could be a liver-specific, early and sensitive 
marker of DILI within the clinic, which may be able to predict the severity of the pathology.  
Additionally, to the utility of miR-122 as a biomarker of DILI, it has also been demonstrated 
to have use as a marker of hepatitis. Zhang et al was able to show that plasma miR-122 levels 
change in a disease-severity relationship in patients infected with hepatitis B (HVB), showing 
a strong correlation with plasma ALT activity (Zhang et al. 2009). Additionally, to this, miR-
122 levels were raised earlier in the plasma and correlated strongly with histological grading. 
The strength of miR-122 as a biomarker (versus ALT) was tested using a ROC analysis and a 
multivariate logistic regression analysis, which suggested that miR-122, is a more sensitive 
biomarker of HVB-associated liver injury, than ALT (Zhang et al. 2009).  In a different study 
examining patients with chronic hepatitis C (CHC), serum miR-122 levels were shown to 
strongly correlate with serum ALT levels in patients undergoing necro-inflammation 
associated with CHC (Bihrer et al. 2011). However, miR-122 did not correlate with changes 
in liver function and also the fibrosis stage of hepatitis, suggesting in CHC, miR-122 is a 
marker of cellular damage and not overall liver function (Bihrer et al. 2011). An additional 
Chapter 1 – General Introduction 
	  
45	  
	  
study testing the value of miRNAs as biomarkers to distinguish between hepatocellular 
carcinoma (HCC) and chronic hepatitis using a ROC analysis was able to support the use of 
miR-122 as a suitable biomarker of cellular damage. However, miR-122 was only able to 
distinguish patients with chronic hepatitis from healthy controls and not from patients with 
HCC, once again suggesting that miR-122 is a marker of hepatocyte damage (Xu et al. 2011). 
1.9.7 miRNA stability in circulation and forms of release 
Despite the RNA-based structure of miRNAs, which can be degraded quickly by cellular 
RNases, miRNAs are extremely stable in blood-based biofluids (Mitchell et al. 2008). Good 
stability is an ideal quality for a biomarker, as clinical samples in their very nature are unlikely 
to be collected, processed, and stored in exactly the same way, especially without an accepted 
universal protocol. Previous work has attributed this stability to the various forms in which 
miRNAs exist in the circulation (Arroyo et al. 2011). Previously miRNAs have been detected 
in the circulation within various biofluids, such as serum, plasma and urine, enveloped within 
small vesicles (Cortez and Calin 2009; Nilsson et al. 2009). More recently however, miRNAs 
have been detected circulating in a vesicle-free form, in which miRNAs are in complex with 
a protein or lipoprotein complex (Arroyo et al. 2011; Turchinovich et al. 2011; Vickers et al. 
2011). 
1.9.8 Vesicle-based miRNAs 
1.9.8.1 Exosomes 
Exosomes are a class of phospholipid nanovesicle, around 30-150nm in diameter which are 
formed within endocytic compartments called multivesicular bodies (MVB) and are then 
released into the circulation through exocytosis (Conde-­‐‑Vancells et al. 2010). Exosomes were 
initially thought to be cellular debris and harbour no function. However, now it is understood 
that exosomes play a distinct role in cellular signalling, which allows them to play a role in 
the development of malignancies (Taylor and Gercel-Taylor 2005) and in the spread of viral 
infections (Ramakrishnaiah et al. 2013). Their full endogenous role still requires study due to 
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their relatively recent discovery (Pan and Johnstone 1983). Exosomes are released from a 
myriad of cell types, including hepatocytes (Conde-­‐‑Vancells et al. 2010) and inflammatory 
cells (Brooks 1986), and have been demonstrated to contain cellular proteins, DNA, 
mitochondrial DNA (Sharma et al. 2013) RNA, lipids, as well as miRNAs (Exocarta provides 
an encyclopaedia of recorded exosome contents; www.exocarta.org). MiRNAs can associate 
with MVBs at the pre-miRNA stage, controlled by the presence of specific sequence motifs 
in the miRNAs (Villarroya-Beltri et al. 2013) and are then packaged into exosomes before 
release into the circulation, which is controlled by a ceramide-secretory system (Cocucci et al. 
2009). Exosomes can be extracted from circulating biofluids through a variety of methods 
including ultracentrifugation (Pisitkun et al. 2004), immunoprecipitation (Taylor et al. 2011) 
and through use of specific exosome isolation solutions (Exoquick, SBI, Cambridge 
bioscience/Total exosome extraction solution, Life Technologies). The presence of exosomes 
in solution can be accessed through monitoring the presence of specific exosome markers such 
as CD63 (Valadi et al. 2007) or TSG101 (Conde-Vancells et al. 2008), using molecular 
biology techniques such as western blotting or through visualisation and measurement using 
electron microscopy or nanoparticle tracking analysis (Conde-Vancells et al. 2008; 
Oosthuyzen et al. 2013; Pisitkun et al. 2004).  
A recent in vivo study examining drug-induced, alcoholic and inflammatory liver injury, 
demonstrated that miR-122 was detected in different fractions of blood during the different 
forms of injury. In paracetamol-DILI, miR-122 was largely detected in the ‘protein-rich’ 
fraction (remainder of serum, minus exosomes). They hypothesised that this was due to the 
necrotic injury phenotype of paracetamol, which allowed this marker to leak into the 
circulation in complex with the RISC, the functional unit of microRNA translation silencing, 
upon breakdown of the hepatocytes plasma membrane. In contrast, miR-122 was largely 
detected in the exosome-bound fraction in alcoholic liver injury, which was suggested to be 
due to the slower injury phenotype, involving activation of the cells adaptive processes, and 
recruitment of the immune system. This is also supported by the presence of miR-155, a 
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miRNA implicated in inflammation and immune regulation, in the exosomal-fraction, 
suggesting a possible role for exosomes in activating the inflammatory process (Bala et al. 
2012).  This together suggests that exosomes may offer a novel method for the cell to promote 
adaptation to liver injury, through both selective loss of cellular contents, and through cell-
cell signalling.  
1.9.8.2 Microparticles 
Microparticles are a class of secretary vesicle, above 100 nm in diameter which are formed 
through ‘blebbing’ of the plasma membrane and are distinctly different from exosomes in their 
qualitative/quantitative content (Jy et al. 2004). This process is regulated by intracellular 
calcium levels, cytoskeleton protein reorganisation and changes in membrane lipid asymmetry 
(Yano et al. 1994). Microparticle release has been documented to take place during cellular 
apoptosis and is thought to be a cellular response to attempt to reverse apoptosis (Boulanger 
et al. 2006). Changes in the levels of plasma microparticles have been associated with many 
disease states, including cardiovascular disease (Boulanger et al. 2006), metabolic syndrome 
(Agouni et al. 2008) and diabetes (type 1 and 2) (Sabatier et al. 2002). Similarly to exosomes, 
microparticles have been shown to be implicated in cell-cell signalling, showing function in 
recipient cells (Mesri and Altieri 1999). Witek et al, demonstrated that liver-derived 
microparticles can alter gene expression in recipient liver endothelial cells through hedgehog 
signalling (Witek et al. 2009). Microparticles, like exosomes, have been demonstrated to 
contain protein, DNA, RNA and lipids. In a study examining the content of microparticles 
secreted from mesenchymal stem cells, the RNA content of microparticles was almost 
exclusively consisted of miRNAs, demonstrating that packing of these vesicles is a selective 
process which does not necessarily reflect the donor cell content (Chen et al. 2010). 
Interestingly, this study found hsa-let-7b and hsa-let-7g are secreted in their immature pre-
miRNA forms, which would allow them to form a mature-miRNA/RISC complex in effecter 
cells and elicit an effect on RNA translation (Chen et al. 2010). This role is still yet to be 
understood fully and much work is still required before the role of microparticle packaged 
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miRNA is understood. Previous studies examining microparticles have focussed on the use of 
ultracentrifugation techniques to separate these vesicles from other vesicles such as exosomes 
and also from the microparticle depleted supernatant of biofluids. The success of this 
extraction is usually then assessed through measuring the expression of microparticle markers, 
such as phosphatidyl serine and annexin V in both the extracted microparticle solution and the 
supernatant (Théry et al. 2001). 
1.9.9 Protein and lipid complexes 
miRNAs have also been detected in the circulation in protein complexes usually formed with 
associated Ago2 proteins, a member of the RISC complex that mediates miRNAs function 
(Arroyo et al. 2011). Turchinovich et al (2011) demonstrated for the first time that miRNAs 
are almost exclusively present within the serum, under normal conditions in protein complexes 
associated with Ago2. This suggests that circulating miRNAs on the most part are a by-product 
of dead cells that remain in the extracellular space. However, recent work demonstrated that 
this association does not seem to be a random occurrence and that some miRNAs associate 
either with protein-complexes or with extracellular vesicles. Arroyo et al (2011) demonstrated 
through differential-centrifugation and size-exclusion chromatography of human serum, that 
different miRNAs exist within vesicles or associated with protein-bound complexes (Arroyo 
et al. 2011). In the serum of healthy volunteers, miR-122 was found predominantly in a 
protein-bound form, whereas let-7a was found almost exclusively within 
exosomes/microparticles supporting the initial study by Turchinovich et al that miRNAs are 
present within the circulation in vesicle-free form. However, the mechanism through which 
these protein complexes are released remains poorly understood (Arroyo et al. 2011; 
Turchinovich et al. 2011).  
High density lipoproteins (HDL), have also been demonstrated to transport miRNAs, through 
a neutral sphingomyelinase dependent mechanism (Vickers et al. 2011). MiRNA/HDL 
complexes travel to recipient cells and undergo endocytosis through a Scavenger receptor type 
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class 1 dependent mechanism. Notably in this study, the delivered complexes were able to 
modify RNA translation in hepatocyte model of atherosclerosis, suggesting that these 
complexes are a form of cell-cell signalling pathway (Vickers et al. 2011). However, work 
still needs to be done to assess the relevance of these complexes in biomarker release and 
function in DILI.  
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Project Aims 
DILI is a leading form of ADR seen within the clinic and the number one cause of clinical 
drug trial failure, costing both the NHS, and the pharmaceutical industry hundreds of millions 
of pounds per year. Because of this, better biomarkers to aid in the early diagnosis of liver 
injury, and in pre-screening hepatotoxic compounds in drug-development. miR-122 has been 
shown to be a potentially useful biomarker of liver injury (Starkey Lewis et al. 2011; Antione 
et al. 2013), however little is understood about how it is released into the circulation, and how 
it is able to become elevated above baseline, earlier than conventional liver injury biomarkers. 
Additionally, although miR-122 is well characterised in the circulation, little is known about 
changes in hepatic miR-122 and other miRNAs under basal and injury conditions. Therefore, 
this thesis aims to: 
•   Establish whether exosomal transport plays a role in the release of microRNAs in 
drug-induced liver injury 
•   Examine the role of hepatic zonation in microRNA expression, including whether 
microRNAs are expressed zonally, and whether this can be linked to liver phenotype. 
•   Establish whether microRNAs have the potential to be used as biomarkers of injury 
in hepatic non-parenchymal cells.  
It is now understood that formation of 3-NT protein adducts occurs in paracetamol-DILI 
(Hinson et al. 2000), however little is known about the route by which these occur and their 
overall function within the pathology. Therefore, this thesis aims to build on previous work 
examining 3-NT in paracetamol-injury, by comparing and contrasting this type of injury to 
FS-injury, in order to gain a greater understanding of the role of these adducts. Both 
paracetamol and FS are well-known pericentral hepatotoxins in rodents; however, they both 
cause injury through divergent pathways. paracetamol is known to target the mitochondria, 
whereas it is thought that FS targets the endoplasmic reticulum. 3-nitrotyrosine adduct 
formation has now been demonstrated to play a role in paracetamol-DILI; however, it remains 
unclear as to whether this cellular process plays a role in FS-DILI. Therefore, we aim to 
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investigate whether 3-NT is present in FS-DILI in order to further understand where the two 
pathways of toxicity diverge.   
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Hypothesis 1  
Paracetamol and FS both produce necrosis in zone III of the liver, but both compounds cause 
this toxicity through distinct routes. We hypothesise that formation of 3-nitrotyrosine adducts, 
a marker of oxidative stress, will occur during paracetamol injury, but will not occur during 
FS injury, due to lack of mitochondrial damage in FS injury.  
Hypothesis 2 
miR-122 is detectable earlier in the course of DILI than conventional DILI markers due to its 
mechanism of release. We hypothesise that miR-122 is released actively from the liver in 
exosomes upon receiving a toxic insult in order to adapt to circumvent DILI. 
Hypothesis 3 
Liver microRNAs are expressed zonally depending on their proximity to a portal or ventral 
vein, and these expression changes will be related to hepatocyte phenotype and function in 
these regions. Upon liver injury by paracetamol, we expect to observe changes in microRNA 
expression in the region surrounding the central vein, however we also hypothesise that 
expression changes may occur away from this region in order to adapt to the oncoming 
toxicity.  
Hypothesis 4 
Intrahepatic biliary epithelial cells, which undergo damage during cholestatic injury, will 
contain a unique microRNA profile, differing from the surrounding hepatocytes. This profile 
will allow the selection of specific markers of ihBEC which will provide use as biomarkers of 
damage to this cell type in cell models, pre-clinical animal models, and possibly within 
therclinic. 
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3-NITROTYROSINE FORMATION IS PRESENT IN BOTH 
PARACETAMOL- AND FUROSEMIDE-DILI IN THE MOUSE 
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2.1 INTRODUCTION 
Protein tyrosine nitration (PTN) is the formation of 3-nitrotyrosine (3-NT) adducts in cellular 
proteins mediated by peroxynitrite, a reactive species formed by the rapid reaction of nitric 
oxide (NO) with superoxide (Ohshima et al. 1990). PTN has mixed functional effects on the 
target protein, depending on the site of nitration. Effects of PTN can include changing the 
proteins cellular function or abolishing their function altogether. PTN has previously been 
shown to be present early in paracetamol-DILI in mice (Hinson et al. 1998). It has since been 
demonstrated that PTN-adducts form in a number of critical mitochondrial and cytosolic 
proteins, including manganese superoxide dismutase, GSH peroxidase and mitochondrial 
alcohol dehydrogenase during paracetamol-injury in vivo (Abdelmegeed et al. 2013). In vitro 
studies in primary mouse hepatocytes aiming to examine the mechanisms behind PTN in 
paracetamol-DILI, have suggested a role for mitochondrial toxicity and the mitochondrial 
permeability transition (MPT), in the formation of PTN in paracetamol-DILI (Burke et al. 
2010). Administration of cyclosporine A, an MPT inhibitor was able to abolish PTN and 
eliminate toxicity in a model examining the role of reactive oxygen/nitrogen species in 
paracetamol-toxicity. Whereas inhibitors of iNOS had little or no effect on the levels of PTN 
or toxicity, suggesting that the causative factor in PTN could be superoxide generated by the 
failing mitochondria. In order to examine this further, and confirm the role of the mitochondria 
in PTN formation, we chose to compare paracetamol, to furosemide (FS), a zone III 
hepatotoxin, which has previously been suggested not to target the mitochondria (Antoine et 
al. 2008; McGill et al. 2012), in contrast to paracetamol, which is known to cause 
mitochondrial injury, in order to assess whether mitochondrial perturbation is necessary for 
PTN formation. We hypothesise that FS-DILI in mice will not lead to PTN formation, as it is 
thought that this process is dependent on mitochondrial perturbation, which is not thought to 
occur in this type of toxicity.  
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2.2 METHODS 
2.2.1 Experimental Animals 
The protocols described within this chapter were performed by personal licence holders 
according to the regulations defined within the project licence granted under the Animals 
(Scientific Procedures) Act 1986 and approved by the University of Liverpool ethics 
committee. CD-1 mice were purchased from Charles River (Manston, UK) and housed at a 
constant temperature and humidity with free access to food and water. Animals were allowed 
to acclimatise for at least 7 days before any experimental procedure and were kept in a 12-
hour light/dark cycle (Lights on: 08:00/Lights off: 20:00). Animals were humanely culled 
using a rising concentration of carbon dioxide before exsanguinations according to the Killing 
of Animals Under Schedule 1 to the Animals (Scientific Procedures) 1 Act 1986. 
2.2.2 Serum ALT Activity Determination 
Blood was taken from mice through cardiac puncture using a 25-gauge needle and was then 
allowed to clot at 4 ºC overnight. Serum was then extracted by centrifugation to initially 
remove the clot (1500 g, 5 min, 4 ºC), followed by another centrifugation step to purify the 
serum (10,000 g, 5 min, 4 ºC). Serum ALT levels were determined immediately using a 
Thermo Infinity ALT Liquid Stable Reagent-based (Thermo, Waltham, MA, USA) kinetic 
assay, at 37 ºC, according to the manufacturers protocol. 
2.2.3 FFPE Tissue Preparation 
NB: FFPE tissue blocks were kindly prepared by Julie Haigh and Valerie Tilston in a 
collaborative effort between the CDSS and the University of Liverpool Veterinary Pathology 
Department.  
In brief, liver obtained during in vivo experiments was dissected into individual lobes and a 
section of the large lobe was preserved in 4% paraformaldehyde (PFA) for 24-96 h. The liver 
tissue was then removed from PFA and dehydrated using increasing concentrations of ethanol. 
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The dehydrated liver was then washed using xylene and infiltrated with molten paraffin wax 
(Ultraplast Polyisobutylene Histological Wax, Solmedia). 
2.2.4 Haematoxylin and Eosin Staining (H&E 
NB: H&E staining was performed by Julie Haigh in collaboration with the University of 
Liverpool Veterinary Pathology Department 
Briefly, tissue sections were dewaxed in xylene and gradually rehydrated using descending 
concentrations of ethanol down to distilled water. Tissue sections were then stained in Mayer’s 
haematoxylin (TCS Biosciences Ltd) for 5 minutes and were then washed under running water 
for 6 minutes. Sections were then stained with Eosin Y (CellPath) for 2 minutes and were then 
washed 3 times in 96% ethanol for 1 minute each. This washing process was then repeated 
with 100% ethanol (3x) and xylene (2x). The sections were then mounted in DPX mounting 
medium and a coverslip was placed on top. Sections were then imaged on a light microscope 
and the severity of injury was graded by a trained pathologist. Sections were given a grading 
between 1 and 6, with 1 being assessed as normal liver and 6 being massive hepatocellular 
necrosis involving entire lobules, and numbers in between being intermediary grades of 
necrosis. 
2.2.5 Immunohistochemistry 
NB: Immunohistochemistry work was solely done by Julie Haigh in a collaborative effort 
between the CDSS and the University of Liverpool Veterinary Pathology Department.  
Immunohistochemical analyses were performed as described previously (Cowan et al. 1998) 
with the following modifications: slides were heated at 60°C for 1 h before de-parafinisation, 
rehydration, and quenching of endogenous peroxidase activity (3% hydrogen peroxide in 
methanol). The hydration process was completed by rinsing for 5 min in DAKO Tris buffered 
saline buffer (DAKO Corporation, Carpinteria, CA) containing 0.05% Tween 20 (DAKO 
Corporation). During heat-induced epitope recovery, sections were steam-heated in a standard 
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steamer (Black and Decker) while submerged in antigen-retrieval Citra buffer (BioGenex, San 
Ramon, CA) for 30 min. Sections were blocked in normal horse serum (Vectastatin Elite kit; 
Vector Laboratories, Burlingame, CA) for 15 min and then incubated with anti-3-nitrotyrosine 
monoclonal antibody (1:250; Merck Millipore) overnight at 4 °C in a humidity chamber. 
Sections were washed in DAKO Tris buffered saline buffer containing 0.05% Tween 20 and 
then loaded into the DAKO Autostainer (DAKO Corporation) for application and incubation 
of the biotinylated horse anti-rabbit IgG (Vectastatin Elite kit, Vector Laboratories) for 30 min 
at room temperature followed by avidin-biotin complex (Vectastatin Elite kit) for 30 min at 
room temperature. The chromogenic reaction was performed with SG (Vector Laboratories) 
for 10 min at room temperature. Slides were removed from the autostainer and counterstained 
with Nuclear Fast Red (Vector Laboratories) for 10 min and coverslipped with Permount 
(Richard-Allan Scientific, Kalamazoo, MI). Positive and negative controls were included with 
each run. 
2.2.6 Determination of Total Hepatic GSH 
The kinetic 5,5’dithiobis(2-nitrobenzoic acid)-GSH disulphide recycling assay was used to 
determine hepatic GSH abundance from livers obtained during in vivo studies. This method is 
described in detail by Vandeputte et al (1994).  
2.2.7 Immunoblotting for 3-nitrotyrosine 
Snap frozen livers were removed from storage in a -80 °C freezer and 50 mg of the left liver 
lobe was excised. The excised liver tissue was then suspended in 500 µL 1x PBS and subject 
to homogenisation using a Retsch Homogeniser (Retsch GmbH, Haan, Germany). 
Alternatively, cells were incubated with 200 µL (per well of a 6-well flat bottomed cell culture 
plate) of RIPA buffer (Sigma Aldrich) and placed on a rocker for 2 minutes before snap 
freezing on liquid nitrogen. Total protein concentration was determined using either method 
described by Lowry et al (1951), BCA assay or Bradford assay (Bradford et al. 1976), 
depending on the lysis buffer of choice. It is important to note that when using lysis buffers 
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containing SDS, the Lowry assay should be avoided due to the possibility of SDS interference 
with the reaction leading to inaccurate results (Dulley et al. 1975). Samples were diluted in 
double distilled water to a concentration of 100 µg protein/5 µL and then mixed with 4x LDS 
sample buffer and 10x reducing agent (Life Technologies, Foster City, CA). Samples were 
then denatured at 80 ºC for ten minutes and then separated on NuPage LDS polyacrylamide 
gels, according to the manufacturers protocol (Life Technologies). Separated proteins were 
then transferred to nitrocellulose membrane (GE Healthcare) using a Bio-Rad transfer module 
(Bio-Rad). The success of the transfer was then tested using Ponceau S to stain the total protein 
content of the membrane and then membranes were blocked in either 10% fat-free milk 
powder or bovine serum albumin in Tri-buffered Saline 0.1% Tween buffer (TBS-T). A 
primary antibody raised against 3-nitrotyrosine (06-284 Merck Millipore) was incubated at a 
dilution of 1:400 in 2% fat-free milk TBS-T buffer for 48 hours, followed by incubation with 
a secondary antibody targeted against rabbit proteins (A0545 Sigma Aldrich; 1:3000) for one 
hour. Blots were developed either in a dark room using an enhanced chemiluminescence 
method (Fisher Scientific) or using a Licor Odyssey with specific luminescent secondary 
antibodies (Licor Bioscience, Cambridge, UK). Densitometry was then performed using Licor 
software or Bio-Rad 1D software. The density of the entire well was used for the assessment 
of 3-nitrotyrosine presence. 
2.2.8 Culture of hepa1c1c cells, GSH depletion using buthionine sulfoximine (BSO) and 
incubation with peroxynitrite 
Mouse hepatoma cells (Hepa1c1c) were seeded at a density of 30,000 cells/cm2 in DMEM 
containing 10% Foetal Bovine Serum and 5% penicillin-streptomycin and were split using 
0.25% trypsin every 3 days or whenever confluent. Buthionine sulfoximine (BSO) was used 
to deplete cellular GSH levels, with the ideal dose being calculated using a standard curve of 
BSO with concentrations ranging from 0 to 500 µM for 24 h prior to dosing. 300 µM was 
found to cause a 70% depletion in the level of GSH and so was chosen for further use. Before 
cells were incubated with peroxynitrite, the serum was removed from the media immediately 
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prior to dosing, followed by administration of peroxynitrite (0-1 mM) for 30 minutes before 
harvesting. 
2.2.9 Determination of Serum Glutamate Dehydrogenase (GLDH) Activity 
 GLDH activity levels were measured spectrophotometrically using the DGKC kit (Randox 
Laboratories, Kearneysville, WV, USA) as previously described in Harrill et al (2012). A 
decrease in absorbance was measured in each sample caused by the oxidation of nicotinamide 
adenine dinucleotide at 340 nm, as per the manufacturer’s protocol.  
2.2.10 Statistical analysis 
Each data group was tested for normality using the Shapiro-Wilk normality test. Descriptive 
statistical analysis was performed on each data group. For normal data sets, the mean and 
standard deviation was determined and for non-normal data sets, the median and inter-quartile 
range was determined for each group. To determine statistical significance, comparisons were 
made using the Student’s t-test (for two parametric groups), the Mann-Whitney U test (for two 
nonparametric groups), the ANOVA (for more than two parametric groups) and the Kruskall-
Wallis test (for more than two nonparametric groups) (GraphPad Software, La Jolla, CA). For 
graphical interpretation GraphPad Prism 5 software was used (GraphPad Software, La Jolla, 
CA). Statistical significance was set at P <0.05. 
 
  
Chapter 2 – 3-nitrotyrosine formation is present in both paracetamol- and FS-DILI 
	  
60	  
	  
2.3 RESULTS 
2.3.1 530mg/kg paracetamol and 400mg/kg FS cause necrosis in pericentral regions of the 
liver in a time-dependent manner in CD-1 mice 
Groups of CD-1 mice were administered (i.p.) either 530 mg/kg paracetamol (n = 4), 400 
mg/kg FS (n = 5) or vehicle for up to 8 h and 24 h respectively. Liver tissue slice preparation 
and H&E staining of liver was then performed for histological grading and analysis (figure 
2.1). Paracetamol was found to cause a time-dependent increase in necrosis in the PC region, 
with peak necrosis occurring at 4 h post-dose (Grade 5). The columnar pattern of necrosis 
caused by paracetamol affected cells differentially within the PC region, with some 
succumbing to necrosis and others not. After 4 h the injury appeared to resolve, suggesting 
the occurrence of regeneration and recovery. FS similarly caused a time-dependent increase 
in PC necrosis, with the peak level arriving at 24 h post-dose (Grade 6) with no-resolve within 
this time-course, suggesting the peak of toxicity may yet be anticipated. The pattern of 
necrosis caused by FS-injury presented as a wave radiating outwards from the PC region as 
time-progressed, affecting all cells within this region similarly.  
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2.3.2 Toxic doses of paracetamol and FS cause elevations in serum transaminase levels in 
a time-dependent manner 
To examine the utility of ALT, the gold-standard biomarker of DILI in both FS- and 
paracetamol- DILI, we measured the serum ALT activity in our CD-1 mouse models of DILI 
(figure 2.2). Paracetamol caused a time-dependent increase in serum ALT activity to 8 h post-
dose, peaking at 2334.3 U/L, compared to 22.7 U/L for saline treated controls at 8 h (8 h 
paracetamol vs 8 h Saline P<0.01). Serum ALT activity in FS-DILI was marginally elevated 
from 8 h post-dose (8 h FS: 384 U/L vs 8 h PBS: 17.250 U/L), however by 24 h it had risen 
to 6836.3 U/L (average), compared to 21.8 U/L for the PBS-dosed control group (p<0.0001).  
	  	  
  
Figure 2.2 A, Serum ALT activity in CD-1 mice following 530 mg/kg paracetamol or 0.9% saline for up 
to 8 h. Serum ALT is significantly elevated at 8 h following paracetamol (*p<0.01) B, Serum ALT 
activity in mice following 400 mg/kg FS or 0.9% saline for up to 24 h. ALT is significantly elevated in 
the serum of mice administered 400 mg/kg FS for 24 h (***p<0.0001). 
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2.3.4 Hepatic GSH is depleted early in paracetamol-DILI, but is not depleted significantly 
in FS-DILI in CD-1 mice 
To determine whether depletion of GSH is necessary to elicit necrosis within the liver, we 
aimed to determine whether hepatic GSH was significantly depleted during both paracetamol- 
and FS-DILI (figure 2.3). Baseline hepatic GSH levels were found to vary in both studies with 
peak GSH falling at 0 h and the lowest level of GSH being found at 8h in both studies which 
was due to the previously studied circadian expression of GSH in the liver (Beaver et al. 2012). 
After 1 h paracetamol mean hepatic GSH levels were significantly depleted (1 h paracetamol: 
5.3 nmol/mg vs 1 h saline: 40.4 nmol/mg; p<0.0001, n=4). Mean hepatic GSH levels 
continued to remain low (2 h: 3.9nmol/mg, p<0.001; 4 h 5.0 nmol/mg, p<0.0001, n=4) until 8 
h post-dose, at which point hepatic GSH levels rebound to match GSH levels in saline-treated 
controls (8 h paracetamol: 26.2 nmol/mg vs 8 h Saline: 24.5 nmol/mg). In FS-DILI, hepatic 
GSH did not differ significantly at any time-point from hepatic GSH levels in PBS-treated 
controls. In this study, the baseline level of hepatic GSH in both PBS-treated controls and FS-
treated animals varied throughout the time-course, with the trough occurring at 8 h (FS: 123.6 
nmol/mg; PBS: 134.2 nmol/mg) and the peak occurring at 4 h (FS: 209.3 nmol/mg; PBS: 
211.0 nmol/mg; n = 5). This can be explained by the circadian expression cycle of GSH, in 
which GSH expression is at its highest in the morning and at its lowest in the evening 
(Matsunaga et al. 2004). 
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Figure 2.3 A, Total hepatic GSH levels in CD-1 mice following 530 mg/kg paracetamol or 0.9% saline for up 
to 8H. Paracetamol caused a significant GSH depletion at 1 h (***p<0.0001), 2 h (**P<0.001) and 4 h 
(***p<0.0001). GSH levels had rebounded by 8 h and matched those of the vehicle group. B, Total hepatic 
GSH following 400 mg/kg FS or 0.9% saline for up to 24 h. FS did not lead to a significant level of GSH 
depletion at any time during the time-course suggesting that FS causes toxicity independent of GSH-depletion. 
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**
***
Chapter 2 – 3-nitrotyrosine formation is present in both paracetamol- and FS-DILI 
	  
65	  
	  
2.3.5 Serum GLDH is significantly elevated following a toxic dose of paracetamol, but not 
after a toxic dose of FS 
In order to determine the ability of serum GLDH to predict different forms of DILI, we aimed 
to determine whether this marker could predict injury in both paracetamol- and FS-DILI 
(figure 2.4).  Paracetamol administration caused a time-dependent increase in serum GLDH 
levels from 2 h to 8 h (2 h: 46.5U/L; 4 h: 332.5 U/L; 8 h: 1707.5 U/L, p<0.01), when compared 
to saline dosed animals, which remained at baseline (22.75-51.75 U/L). At 1h after 
paracetamol, there was a small non-statistically significant difference between paracetamol-
dose and Saline-dosed animals (Saline: 51.75 U/L vs paracetamol: 146.5 U/L). In FS-DILI, 
serum GLDH levels remained at baseline until 24h, at which point a highly-variable non-
significant elevation was witnessed in FS-treated animals compared to PBS-treated (FS: 
282.75 U/L vs PBS: 3.67 U/L). Comparison of peak serum GLDH levels between 
paracetamol- and FS-injury, demonstrates that paracetamol leads to a ~6-fold greater elevation 
in serum GLDH levels than FS at their peak. Correlation analysis of GLDH and ALT in both 
paracetamol- and FS-injury, demonstrates that GLDH and ALT have a strong positive 
correlation in paracetamol-injury (Pearson R = 0.9359; p<0.0001), whereas the two markers 
correlate weakly in FS-injury (Pearson R = 0.039; p<0.01). 
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Figure 2.4 A, Serum GLDH activity in CD-1 mice following 530 mg/kg paracetamol or 0.9% saline for up 
to 8 h. B, Serum GLDH activity following 400 mg/kg FS or PBS for up to 24 h. C, Correlation analysis of 
serum ALT and serum GLDH in CD-1 mice following 530 mg/kg paracetamol or 0.9% saline for up to 8 h. 
D, Correlation analysis of serum ALT and serum GLDH in CD-1 mice following 400 mg/kg FS or PBS for 
up to 24 h. (*p <0.01, ***p < 0.0001). 
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2.3.6 Peroxynitrite mediated PTN of bovine serum albumin is reduced by the addition of a 
physiological concentration of GSH 
In order to develop a western blot assay to detect PTN a positive control was developed 
through incubating a range of peroxynitrite concentrations (10 mM-1 pM) with bovine serum 
albumin (BSA; 1 mg/ml) to create nitro-BSA (figure 2.5). Using an anti-nitrotyrosine antibody 
(1:400 overnight incubations; Merck Millipore), we were able to detect 3-nitrotyrosine 
adducts in a peroxynitrite-concentration dependent manner, down to 1 µM peroxynitrite using 
a western blot. To examine the role of GSH in PTN-formation, we co-incubated peroxynitrite 
and BSA, with a physiological concentration of GSH (5 mM). The addition of GSH to the 
reaction abolished PTN formation up to 1mM peroxynitrite. 
Figure 2.5 PTN western blot assay method development. A, 3-nitrotyrosine is detectable in a 
peroxynitrite concentration dependent manner in BSA. B, A physiological concentration of GSH (5 
mM) is able to abolish nitration in a BSA up to a concentration of 10 mM peroxynitrite. 
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2.3.7 Cellular GSH is protective against PTN in a mouse hepatoma cell-line  
To examine the role of cellular GSH in protection against PTN, we incubated hepa1c1c cells 
(mouse hepatoma cells) with 500 µM BSO (optimal dose calculated using standard curve and 
GSH micro titre assay – figure 2.6) for 24 h to deplete cellular GSH levels, before incubation 
with peroxynitrite to induce PTN (figure 2.7C). 24 h of 500 µM BSO led to a 70% reduction 
in cellular GSH levels (figure 2.6, p<0.005), but did not increase the susceptibility of cells to 
peroxynitrite mediated PTN formation over non-GSG depleted cells with or without serum-
containing media (figure 2.7A+B). PTN was only detectable at 1 mM peroxynitrite in the – 
BSO group (serum-free, figure 2.7B and serum-containing, figure 2.7A), and 100 µM in the 
+BSO group (figure 2.7C). This experiment was then repeated, but instead using serum-free 
culture medium (serum removed immediately prior to peroxynitrite administration) and BSO 
depletion of GSH. BSO depletion in the absence of serum led to the detectability of PTN 
adducts down to 1nM peroxynitrite (compared to 1 mM without BSO, figure 2.7D).	   
   
Figure 2.6. Depletion of glutathione in hepa1c1c cells using BSO. Cells were incubated with up to 
500µM of BSO for 24 h and were then harvested for GSH quantification using the GSH recycling 
assay. Concentrations of greater than 100µM BSO led to significant levels of depletion of GSH 
(*100µM, 200µM, 300µM: p<0.05, **400µM: p<0.01, ***500µM: p<0.005). 
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2.3.8 PTN is present in both paracetamol- and FS-DILI 
In order to establish whether mitochondrial damage was required for the formation of PTN, 
we examined whether PTN adducts are detectable in a CD-1 mouse model of paracetamol-
DILI, a mitochondrial toxin, and a model of FS-DILI, a compound thought not to target the 
mitochondria (figure 2.8). Western blotting for 3-nitrotyrosine in liver tissue from mice treated 
with paracetamol, or vehicle for up to 8 h, demonstrates that there is a time-dependent increase	  
in the formation of PTN up until 4 h, after which there is a marginal decrease in PTN. 
Similarly, when a 24 h time-course examining the effects of FS-DILI on PTN was examined, 
a time-dependent increase in nitration can be seen until 4 h post-dose, after which there is a 
brief fall in PTN levels, until 24 h, where PTN levels again increase. Interestingly, levels of 
PTN also appear to increase in the vehicle-dosed animals in the FS-study, possibly as a by-
product of a pH change in the circulation driven by the alkaline vehicle. 
  
Figure 2.8 PTN is present in both paracetamol- and FS- DILI. Each time point displayed on the 
western blot represents a pool of either 4 mice (paracetamol) or 5 mice (furosemide). A, PTN increases 
in a time-dependent manner up to 4 h following 530 mg/kg paracetamol in CD-1 mice. B, PTN 
increases in a time-dependent manner up to 4 h, before declining at 8 h, followed by a further increase 
up to 24 h in CD-1 mice, after a 400 mg/kg dose of FS. 
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2.3.9 Quantification of PTN levels in paracetamol- and FS-DILI  
To establish whether PTN was more prolific in either paracetamol- or FS-DILI, due to 
differential mechanisms of toxicity, we quantified PTN levels through titration of protein 
loading on a western blot, to establish PTN levels per µg of protein loaded at peak PTN in 
both types of injury (both at 4 h post-dose) (figure 2.9). After quantification through 
densitometry analysis of all bands present in each individual well of the blot, using Licor 
Biosciences densitometry software, peak PTN levels in each injury type were not statistically 
different, suggesting equivalent occurrence of PTN in each injury type (Average intensity 
value: paracetamol = 0.235 vs FS = 0.287). 
	    
Figure 2.9 PTN is present at equivalent levels in both paracetamol- and FS-DILI in CD-1 mice. A, 
protein loading titration of CD-1 mouse liver tissue administered with either 530 mg/kg paracetamol or 
400 mg/kg FS for 4 h, probing for 3-nitrotyrosine. B, Quantification of 3-nitrotyrosine levels at peak 
PTN in paracetamol- and FS- DILI in CD-1 mice using densitometry. 
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2.3.10 Immunohistochemical detection of hepatic PTN adducts under basal conditions and 
in injury models 
 In order to localise the formation of PTN adducts in DILI, we aimed to establish an IHC assay 
to detect PTN in slices of fixed liver tissue (figure 2.10-14). To test the success of this method 
we produced a positive PTN control, by directly administering (37 mM) peroxynitrite to a 
fixed slice of healthy (non-dosed) liver tissue from a CD-1 mouse. PTN is clearly observable 
in regions in which the peroxynitrite was placed on the slide (brown stain), and absent in areas 
not incubated with peroxynitrite. However, it was observed that under basal (non-dosed mice) 
conditions PTN is present surrounding the portal vein (dark brown stain). Examination of PTN 
formation in paracetamol-DILI, demonstrated that PTN increases in a time-dependent manner 
until 4 h post-dose (Grade 5), after which it begins to decrease. PTN was visibly present in its 
highest levels in the cells surrounding the area of necrosis in the PC region. In FS-DILI, PTN 
increased in a time-dependent manner until 24h. PTN was similarly present in its highest levels 
on the periphery of the necrotic region (PC). 
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Figure 2.10 Detection of hepatic PTN (3-nitrotyrosine) using immunohistochemistry. A, 
Development of a positive control for nitration through direct application of peroxynitrite to 
liver tissue (Brown stain = 3-nitrotyrosine). B, IHC staining for 3-nitrotyrosine in liver tissue 
taken from healthy CD-1 mice demonstrates that high levels of PTN are present surrounding 
the portal vein under normal conditions.  
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Figure 2.12 Detection of hepatic PTN (3-nitrotyrosine) using immunohistochemistry 
following 530 mg/kg paracetamol demonstrates the formation of PTN in cells 
surrounding the area of injury at 4 h post-dose.  
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Figure 2.14 Detection of hepatic PTN (3-nitrotyrosine) using IHC in mice administered with 
400 mg/kg FS for 24 h demonstrates that PTN is present in high levels on the periphery of the 
injured region. 
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2.4 DISCUSSION 
PTN is a post-translational modification of protein tyrosine residues that is caused by the 
nitrating agent peroxynitrite. Peroxynitrite is usually formed in large amounts under oxidative 
stress conditions through the spontaneous reaction between nitric oxide and superoxide. PTN 
has previously been shown to be present in paracetamol-DILI early in the course of toxicity 
(Hinson et al. 1998), but there is no consensus on the cellular events which lead to its 
occurrence. Previous work in primary mouse hepatocytes has suggested that the MPT and thus 
mitochondrial injury plays a role in the formation of PTN in DILI (Burke et al. 2010). To 
examine this, we compared and contrasted DILI due to paracetamol and FS. Paracetamol is 
known to be a pericentral hepatotoxin which causes hepatotoxicity through damaging the 
mitochondria, leading to hepatocellular necrosis (McGill et al. 2012). In contrast, FS, also a 
pericentral hepatotoxin (Williams et al. 2007), is thought to cause necrosis through a pathway 
independent of the mitochondria, possibly through targeting the endoplasmic reticulum 
(Antoine et al. 2008; Qu et al. 2014). In utilising these compounds, we hypothesised that 
mitochondrial injury in paracetamol-DILI would lead to PTN, whereas FS, which is thought 
to leave the mitochondria intact should not cause PTN.  
In order to test our hypothesis, we performed two time-course studies, in which CD-1 mice 
were either administered with a toxic dose of paracetamol (530 mg/kg) or FS (400 mg/kg), or 
vehicle. To confirm that each compound was hepatotoxic in our model, we carried out 
histological grading of the liver tissue, and measurement of serum ALT levels, the gold-
standard circulating marker for assessment of hepatotoxicity. Histological assessment found 
that paracetamol-injury caused pericentral necrosis with increasing severity until 4 h post-
dose, before beginning to resolve at 8 h post-dose. This is a contrast to previous studies 
examining paracetamol-DILI in mice, which found that the severity of injury continued to 
increase until 24 h post-dose (McGill et al. 2012). However, this may be caused by the 
previous models utilising fasted mice, whereas our model used fed mice, which may suggest 
that increased feeding aids the response to injury. Assessment of the FS dosed animals 
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similarly demonstrated necrosis in pericentral areas, which continued to worsen in severity 
until 24 h post-dose.  Interestingly, although paracetamol and FS both target the pericentral 
region, they both cause distinctly different types of damage. Paracetamol cause an almost 
columnar pattern of injury radiating out from the central vein, affecting cells differentially. 
On the other hand, FS caused a wave of injury radiating outwards from the central vein which 
increased in size throughout the time-course, affecting all cells within the region. Both 
hepatotoxins were found to cause ALT elevations, in line with the previous literature 
(Jaeschke et al. 2012; McGill et al. 2012; Williams et al. 2007). Peak ALT levels in 
paracetamol-DILI were detected at 8 h post-dose, 4 h after peak injury was detectable in the 
liver tissue. Similarly, a significant ALT elevation was only detectable 24 h post FS dose, 20 
h later than toxicity was detected using histology. This suggests that ALT has little use as a 
prognostic marker for DILI in experimental models, and that peak ALT levels should not be 
used to direct the selection of tissue samples for analysis.  
A study previously examining FS-DILI in rodents suggested that FS did not cause depletion 
of cellular GSH in vivo (Wong et al. 2000), but did cause hepatotoxicity. GSH depletion is a 
critical cellular event in paracetamol-toxicity which allows the progression of toxicity (McGill 
et al. 2012), and it has been demonstrated that boosting GSH levels using N-acetylcysteine 
(NAC) or i.v. GSH provided protection from paracetamol-DILI (Whitehouse et al. 1985). 
However, a limitation of the study examining FS depletion of GSH was that the time-course 
only stretched to 5 h post-dose, whereas our study suggests that the toxicity is only beginning 
at 5 h post-dose. Therefore, to confirm that FS is able to cause toxicity without GSH depletion 
we assessed hepatic GSH content throughout our time-course, and compared this to 
paracetamol, a compound known to cause GSH depletion early in the course of injury. 
Assessment of cellular GSH levels following a toxic dose of paracetamol demonstrated that 
GSH was almost fully depleted by 1 h post-dose, a trend which continued until 8 h post-dose 
at which point GSH rebounded. This is expected, as paracetamol has been shown to induce 
the Nrf2 pathway, which regulates several of the enzymes involved in the biosynthesis of GSH 
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(Randle et al. 2008). Analysis of cellular GSH levels following a toxic dose of FS 
demonstrated that levels were not significantly different from the vehicle-dosed mice 
throughout the time-course until 24 h post-dose. At 24 h cellular GSH levels displayed a non-
significant decrease, which may be explained by an overall decrease in the number of 
hepatocytes left within the liver due to the ongoing necrosis. Importantly, there was no early 
depletion of GSH, suggesting that GSH depletion does not play a role in the mechanism of 
FS-toxicity. Interestingly, in both models, GSH levels were decreased at 8 h post-dose in the 
vehicle treated animals. This can be explained by the fact that GSH is expressed in a cyclic 
manner under the control of the circadian clock (Tunon et al. 1992), in which GSH levels are 
lowest in the evening (matching our study; 8 h post-dose = 7 pm). This highlights the 
importance of using time-matched vehicle control animals in time-course studies.  
Plasma GLDH is a mitochondrial membrane-associated protein involved in urea synthesis, 
and has previously been suggested to be a novel biomarker of DILI (Aubrecht et al. 2013; 
Schomaker et al. 2013a). However, this has been debated with one group suggesting that this 
marker is not a general marker of DILI, and is a marker of mitochondrial injury (Jaeschke and 
McGill 2013). In the Jaeschke group’s study they were able to demonstrate that plasma GLDH 
was elevated after a toxic dose of paracetamol, but not after a toxic dose of FS (McGill et al. 
2013). This was suggested to be due to mitochondrial damage in the case of paracetamol, and 
a lack of this following FS. Previous work within our group examining sub-cellular patterns 
of drug-protein covalent binding in different forms of DILI has also provided evidence to 
suggest this. It was found that paracetamol administration in mice led to a high level of 
covalent binding within the mitochondria of hepatocytes, whereas a toxic dose of FS had little 
effect on the mitochondria, but did cause covalent binding within the endoplasmic reticulum 
(Antoine et al. 2008). This led to our choice of paracetamol and FS as compounds to examine 
the role of the mitochondria in the formation of PTN. To confirm the previous work, in which 
GLDH was only measured at a single time-point in FS-injury, we profiled serum GLDH levels 
throughout the time-course of injury in both models. Similar to the previous study, we found 
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that paracetamol administration led to a time-dependent increase in serum GLDH levels, 
peaking at 8 h post-dose. Conversely, FS administration had little effect on serum GLDH 
levels until 24 h post-dose. At 24 h a highly variable increase in expression was documented, 
which was less marked than in comparison to that of paracetamol, suggesting either than some 
level of mitochondrial injury is occurring with FS or that there was some contamination of our 
serum samples with intact mitochondria which had been leaked out of the plasma membrane 
during necrosis. It has been previously suggested that this is a possibility and that this could 
be mitigated in future through the use of a high speed centrifugation step during the processing 
of serum in order to remove these intact mitochondria (McGill et al. 2013). Interestingly this 
may suggest that GLDH may have two utilities as a biomarker depending on the processing 
method chosen, one as a general injury marker and another as a mitochondrial injury marker, 
suggesting the importance of sample preparation method selection. Importantly serum GLDH 
did not strongly correlated to serum ALT, the gold-standard of liver injury suggesting either 
that it is not as sensitive as a marker of liver injury or that mitochondrial injury is more limited 
in FS-injury when compared to paracetamol-injury. 
To build towards our goal of assessing PTN levels in paracetamol- and FS-DILI we first had 
to establish a method to detect PTN. We first sought to develop a positive control for PTN 
through the incubation of peroxynitrite with BSA, based on work performed in a previous 
study (Hinson et al. 2000). We then chose to develop a western blot method for detection of 
PTN, in the hope that this would also validate an antibody for immunohistochemistry. 
Analysis of a nitro-BSA standard curve (10 mM-1 pM) using an anti-3-nitrotyrosine antibody 
demonstrated that we were successful in detecting PTN by western blot. We then examined 
the role of GSH in the formation of PTN, through incubating a physiological concentration of 
GSH in the peroxynitrite/BSA reaction mix. Interestingly, we found that GSH was able to 
completely abolish the nitration of BSA up to concentrations of 1 mM peroxynitrite, 
suggesting that cellular GSH depletion may be necessary in order to see PTN formation, 
providing further evidence to support our hypothesis that FS may not lead to PTN, due to a 
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lack of GSH depletion. To build on this, we aimed to examine the role of cellular GSH in 
protection against peroxynitrite-mediated PTN in a hepatoma cell line (hepa1c1c), utilising 
BSO, an inhibitor of γ-GCL, an enzyme involved in biosynthesis, to deplete cellular GSH. 
Initially we found that depletion of GSH has little or no effect on the levels PTN after 
incubation with a range of peroxynitrite concentrations. However, upon removal of serum 
from the culture medium, we found that depletion of GSH using BSO increased PTN levels 
down to 1 pM (from 10 µM without GSH depletion). This provided further evidence that GSH 
depletion is necessary for the initiation of PTN. 
In order to test our hypothesis that PTN will occur in paracetamol-DILI, due to GSH depletion 
and mitochondrial injury, and not in FS-DILI, due to a lack of both of these factors, we aimed 
to assess levels of PTN across our time-course models of DILI. Interestingly, we found that 
both paracetamol and FS lead to PTN in a time-dependent manner in our rodent models of 
DILI, disproving our hypothesis that this would not be found in FS-DILI. Furthermore, 
quantification of PTN levels in both types of DILI suggest that both produced equivalent levels 
of PTN, disproving our thoughts that levels in paracetamol-DILI would be higher due to 
increased ROS production during mitochondrial damage. We then assessed PTN in both 
models using IHC and found that the pattern of PTN closely followed the periphery of the 
area of injury, suggesting that PTN occurs before the cell undergoes necrosis.  
To summarise, we have confirmed in mice that FS is able to cause hepatotoxicity without 
depleting GSH and without causing elevations in serum GLDH, whereas these both occur in 
paracetamol-DILI. We were also able to demonstrate that GSH is protective from PTN 
formation in both a simple chemical system, and in a cell-line model. Finally, we demonstrated 
that PTN occurs in both paracetamol- and FS-DILI despite their divergent pathways to 
toxicity, suggesting that PTN formation may not depend on the formation of ROS through 
mitochondrial damage, or on the depletion of GSH. Further work should be performed to 
identify the patterns of PTN in each model to assess whether both target similar proteins, or 
whether PTN can be related back to the organelles through which the drugs instigate toxicity.  
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This work could take the form of a similar study to Abdelmegeed et al. (2010), in which a 
proteomic approach was utilised to isolate nitrated proteins after paracetamol injury in mice.  
However, in this study, a 2D gel approach was used which limited the number of proteins 
available for analysis. Therefore a further study could use an affinity mass spectrometry 
approach, similar to the one used in  Zhan et al. (2006) to isolate a large number of nitrated 
proteins for analysis using tandem mass spectrometry in order to compare the patterns of PTN 
in furosemide and paracetamol DILI.
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CHAPTER 3 
 
 
 
 
EXOSOME-BOUND AND PROTEIN-BOUND PROFILES OF LIVER-
SPECIFIC MICRORNAS DURING DRUG-INDUCED LIVER INJURY IN 
HUMANS AND RATS 
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3.1 INTRODUCTION 
Drug-induced liver injury (DILI) is the most prevalent form of adverse drug reaction seen 
within the clinic in the western world and is a major impediment to the development of new 
drugs. Because of this, sensitive and specific circulating biomarkers of DILI are required in 
the clinic to diagnose DILI, and also in the pharmaceutical industry to assess potential liver 
toxicity early in the development of new drugs. MicroRNAs hold many of the properties 
desired of biomarker candidates; they are organ-specific, species-conserved, stable in 
biofluids, and are easily quantifiable. Wang et al (2009) identified that two liver-enriched 
miRNAs, miR-122 and miR-192, were raised in the circulation in response to paracetamol-
DILI, in both a time, and dose-dependent manner. Importantly, circulating miR-122 levels 
were elevated earlier in the course of DILI than plasma ALT. This provided the first evidence 
that miRNAs could be early markers of DILI, possibly providing prognostic value within the 
clinic. Work within our group has since demonstrated that both miR-122 and miR-192 are 
significantly raised in the plasma of patients suffering from acute paracetamol-induced liver 
injury and other forms of DILI (Starkey Lewis et al. 2011). Importantly, these microRNAs 
remained unchanged in patients undergoing chronic kidney injury, supporting the specificity 
of these markers. Further work has since suggested that miR-122 has prognostic value in 
patients admitted to hospital with suspected DILI due to paracetamol. miR-122 readings taken 
upon hospital admittance were able to predict peak toxicity ALT values, whereas admission 
ALT levels remained at baseline levels in all patients (Antoine et al. 2013a).  
Although there is a great amount of evidence now available to suggest that miR-122 is an early 
marker of paracetamol-related DILI, there is little evidence to explain how miR-122 levels are 
raised in the circulation before other markers of DILI, such as ALT. Because of this, we aimed 
to examine in what form miR-122 was contained in within the circulation in order to shed 
further light on the release mechanism of this marker during DILI, in an attempt to explain its 
early elevation. Evidence now suggests that microRNAs can be held in several forms in the 
circulation, in extracellular vesicles, protein-complexes or lipid-complexes (Arroyo et al. 
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2011; Turchinovich et al. 2011; Vickers et al. 2011). Extracellular vesicles can be further sub-
divided into apoptotic bodies, microvesicles (shedding vesicles) and exosomes (Extracellular 
vesicles are reviewed in: (Andaloussi et al. 2013). The work in this chapter focusses on the 
release of microRNAs within exosomes. Exosomes are nanovesicles (30-100 nm in diameter), 
which have been shown to be involved in immune regulation, and cell-cell signalling (Bianco 
et al. 2007; Valadi et al. 2007). Exosomes are actively released from the cell through the 
endosomal/multivesicular body pathway, through exocytosis. It has been demonstrated that 
their contents are not solely a reflection of the content of their parent cells contents, but that 
they are selectively packaged, and importantly they are able to laterally transfer their contents 
to other cells, which can then modulate the function of the recipient cell (Royo et al. 2013). 
We hypothesise that miR-122 is actively secreted from hepatocytes in exosomes early in the 
course of DILI, as an early biological response to paracetamol overdose. To examine this, we 
optimised a method to extract exosomes from the plasma/serum and profiled the content of 
miR-122 in both the exosomal fraction and the remaining serum/plasma throughout the course 
of DILI, in both rodent models of DILI, and human clinical samples from cases of DILI due 
to a variety of different drugs.  
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3.2 METHODS 
3.2.1 Materials 
All reagents unless otherwise stated were bought from Sigma Aldrich (St Louis, MO, USA). 
miRNeasy and RNeasy minElute kits were purchased from Qiagen (Venlo, Netherlands). 
Stem-loop reverse transcription primers and Taqman stem-loop reverse transcription 
primers/report (miRNA assays) were purchased from Life Technologies (Foster City, CA, 
USA). Thermo Infinity ALT Liquid Stable Reagent was purchased from Thermo (Waltham, 
MA, USA).   
3.2.2 Experimental Animals 
Rat studies were performed at Almirall, Barcelona under the following protocol. Male Wistar 
Han rats (6-8 weeks of age) were obtained from Charles River Laboratories (Lyon, France) 
and allowed 1 week to acclimate prior to the study. Six animals were housed per cage, on a 
12 h light/dark cycle, temperature of 22 ± 2ºC and humidity of 55% ± 15%.  Standard food 
and water were provided ad libitum. Care of animals was undertaken in compliance with the 
European Community Directive 86/609/CEE for the use of laboratory animals and with the 
Autonomous Catalan law (Decret 214/1997). All experimental procedures were approved by 
the Almirall Ethics Committee before initiation of the study. Rats were administered 
paracetamol (500, 1000, 1500 mg/kg) in 0.1% methylcellulose by oral gavage, at 0 h, 24 h, 48 
h, 72 h and 96 h, followed by humane culling at 0 h, 2 h, 4 h, 6 h, 24 h, 48 h, 72 h, 96 h and 
14 days following the first dose of paracetamol. Animals administered with paracetamol, 
which were immediately culled following dosing (0 h group) were used as the control group. 
Processed plasma samples were then shipped on dry ice to the Centre for Drug Safety Science 
(Liverpool, UK) for analysis. 
3.2.3 Clinical Samples 
NB: work performed on the Spanish DILI cohort was performed jointly with Joanna Clarke 
(MRC CDSS, PhD Student) 
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Plasma samples were obtained from ten individuals suffering from hepatocellular, mixed and 
cholestatic DILI by the Spanish DILI registry (Malaga, Spain) as part of the larger Spanish 
DILI cohort (Details available in Andrade et al 2005). Patients had been prescribed (or had 
ingested non-prescribed dietary supplements) a variety of different drugs and substances, 
including levofloxacin, methotrexate, co-amoxyclav, ciprofloxacin, methoxy-isoflavone, 
paracetamol, fenofibrate, simvastatin/co-amoxyclav, cocaine, erythromycin, sertraline, which 
led to DILI (Table 3.1). Plasma samples were taken at time of first admission to hospital 
(‘baseline’), followed by a number of follow-up samples until recovery. The criteria for 
inclusion of subjects were: an increase in alanine transaminase (ALT) ≥3 times the upper limit 
of normal (xULN) or ≥2 xULN of alkaline phosphatase (ALP). However, 93% of the cases 
also fulfilled the more recent DILI criteria established by a recent study: ALT ≥5 xULN or 
ALT ≥3 xULN + total bilirubin (TBL) ≥2 xULN or ALP ≥2 xULN (Aithal et al. 2011). The 
pattern of liver injury was classified based on R value calculations as previously described 
(Benichou et al. 1990). A detailed description of the operational structure of the registry, data 
recording and case ascertainment has been reported elsewhere (Andrade et al. 2005).  
Details of the healthy subjects in the therapeutic dose paracetamol trial can be found within 
(Watkins et al. 2006). Briefly, healthy volunteers were administered a therapeutic dose of 
paracetamol or a paracetamol-containing OTC analgesic daily for 14 days. Plasma ALT values 
were assessed daily, and in a later prospective study, miR-122 levels were also assessed in 
these samples. Subjects were then characterised as responders or non-responders based on 
ALT values. The criteria to be classed as a responder was displaying ALT values above the 
upper limit of normal, 40 U/L. Readings classed as above the upper the limit of normal are 
highlighted in red on table 3.2. 15 subjects were classed as responders in the study with marked 
elevations in ALT levels occurring at day 9 of the study, and miR-122 elevations occurring at 
day 8 (Thulin et al. 2013). Subjects 19, 33, 37 and 45 displayed values above the ULN, but 
were not classed as responders due to them either displaying these values consistently from 
day 1 of the study, suggesting a higher than normal basal level of ALT expression or that ALT 
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levels were raised by less than 10% throughout the study. Based on this, we assessed exosome-
bound and exosome-free miR-122 at day 8 of this study in all subjects displayed on table 3.2. 
Ethical approval was obtained for all human studies. 
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Table 3.1 Details of Spanish DILI cohort samples used in our study. Patients were prescribed or 
ingested compounds and then displayed signs of liver injury related to these drugs. Liver injury types 
were catagorised into hepatocellular, mixed and cholestatic based on displayed biomarker levels. ALT 
expression was assessed in available samples and expressed as a times the upper limit of normal value. 
Values listed as a hyphen were classed as normal and in some cases samples were not available for 
analysis, and so no data was available. 
Patient ID Visit ALT (x ULN) Drug Type of injury
678 Baseline - Co-amoxyclav Cholestatic
1 -
687 1 7 Simvastatin/Coamoxy -
714 Baseline - Co-amoxyclav Hepatocellular
1 5
753 1 4 Paracetamol Hepatocellular
758 1 12 Levofloxacin Hepatocellular
2 3
759 1 60 Dietary supplement (Camelia sinensis) Hepatocellular
762 Baseline - Methotrexate Hepatocellular
1 73
2 No data
3 10.5
4 No data
764 Baseline - Ciprofloxacin Hepatocellular
1 19
2 12
3 7.7
4 No data
768 Baseline - Co-amoxyclav Mixed
1 4
769 Baseline - Cocaine Hepatocellular
1 25
806 Baseline - Co-amoxyclav Mixed
1 2
2 1.8
839 1 - Co-amoxyclav Cholestatic
2 -
860 1 6.8 Ciprofloxacin Mixed
2 8.5
3 5.3
4 2
5 -
861 Baseline - Dietery supplement (methoxy-isoflavone) Hepatocellular
1 8
909 Baseline - Fenofibrate Cholestatic
1 1.5
945 1 - Sertraline Cholestatic
990 1 5 Erythromycin Hepatocellular
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3.2.4 Serum ALT activity determination 
Serum ALT activity was performed as in Chapter 2. 
3.2.5 Exosome extraction from serum 
 Exosomes were extracted from serum, plasma and other biofluids using Exoquick (SBI, 
Cambridge, UK), Total Exosome Isolation Solution (Life Technologies, Foster City, USA), 
Exospin (Cell Guidance Systems, Stevenage, UK) or through ultracentrifugation (see 
(Pisitkun et al. 2004). Briefly, serum was centrifuged to remove dead cells and then incubated 
with a volume of the exosome isolation solution for the manufacturers indicated time. This 
solution was then centrifuged at the manufacturers indicated speed and time until the exosome 
fraction of the serum formed a pellet. The supernatant was then aspirated by pipette and saved 
for analysis. The exosome pellet was then suspended in a volume of nuclease-free water, equal 
to the starting volume of bio-fluid (for detailed work-flow see figure 3.1). Exosomes and 
supernatant were then characterised through western blotting for exosome markers (CD63 and 
TSG101). Additionally, exosomes were characterised through transmission electron 
microscopy using a negative staining protocol developed by Dr Alison Beckett (Department 
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of Physiology, University of Liverpool) and Dr Marion Pope (Department of Veterinary 
Pathology, University of Liverpool).	  
3.2.6 miRNA extraction from serum 
miRNA was extracted from serum using a miRNeasy kit (Qiagen, Venlo, Netherlands), 
following the manufacturer’s instructions with minor modifications. In brief, 40 µL of sample 
was diluted to 200 µL with nuclease-free water, and was then combined with 700 µL of 
QIAzol. The sample was then left to incubate for 5min to ensure complete nucleo-protein 
dissociation, before addition of 10 µL of (5 fM) Cel-lin-4 (Integrated DNA Techologies, 
Cambridge, USA) as a ‘spike-in’ technical control. 140 µL of chloroform was then added and 
the samples were centrifuged at 12,000 g for 15 minutes at 4 ºC. 350 µL of the upper aqueous 
Figure 3.1. Work-flow of exosome-isolation methods, including ultracentrifugation and exosome 
isolation kits.  
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phase was the removed and mixed with an equal volume of 70% ethanol, before being added 
to a miRNeasy minispin column. The column was spun for 15s at >8,000 g at room 
temperature and the flow-through, containing the small-RNA fraction was kept.  
3.2.7 miRNA Purification   
The small-RNA fraction was removed and added to a fresh 2 mL Eppendorf tube, to which 
450 µL 100% ethanol was also added. This solution was then added 700 µL at a time to a 
Qiagen MinElute column, in which the small-RNA fraction was immobilised. The column 
was then washed with RWT (700 µL) and RPE buffer (500 µL), before the final wash with 
500 µL 80% ethanol. The column was then dried thoroughly in the centrifuge (column lids 
open, >8,000 g, 5 min, RT) and then was transferred to a new 1.5 mL collection tube. The 
small RNA fraction was then eluted in 14 µL of nuclease-free water and stored at -80 ºC until 
reverse transcription.  
3.2.8 Quantitative Polymerase Chain Reaction Analysis  
miRNA and snRNA levels were measured using Taqman-based quantitative polymerase chain 
reaction (qPCR). The small RNA elute obtained from miRNA Purification step was reverse 
transcribed to cDNA using specific stem-loop reverse transcription primers (Life 
Technologies, Foster City, CA) for each miRNA species, following the manufacturer’s 
instructions. 1.33 µL of cDNA was used in the PCR mixture with specific stem-loop PCR 
primers (Life Technologies, Foster City, CA) in a total volume of 20 µL. Levels of miRNA 
were measured by the fluorescent signal produced from the Taqman probes on an Applied 
Biosystems Viia-7 (Life Technologies, Foster City, CA). miRNA levels were then normalised 
to either Cel-lin-4 (a technical normaliser) or various endogenous normalisers, such as snRNA 
U6 or hsa-Let-7d, as described elsewhere (Zhang et al. 2010). Alternatively, where no 
appropriate miRNA normalisation method was available miRNA levels were expressed as 40 
minus the cycle threshold (Ct) reading for each sample. As a reference, work performed 
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previously by the author has suggested that miR-122 is usually detectable at negligible levels 
in non-DILI human serum samples (40-Ct level of <1). 
3.2.9 Determination of Total Protein Concentration of Samples 
Total protein concentration was determined using the method described by (Lowry et al. 
1951). 
3.2.10 Immunoblotting 
Immunoblotting was performed as described in Chapter 2 using primary antibodies raised 
against TSG101 (Abcam ab83; 1:3000 overnight) and CD63 (Abcam ab134045; 1:10,000 
overnight), followed by incubation for one hour with 1:10,000 anti-rabbit (Sigma A0545). 
3.2.11 Statistical analysis 
Statistical analysis was performed as described in Chapter 2. 
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3.3 RESULTS 
3.3.1 Isolation and characterisation of exosomes from biofluids 
In order to understand the role of exosomes in the release of miR-122 during paracetamol-
DILI, we first sought to develop a robust and repeatable method for their isolation. Initially 
we chose human urine as a source to isolate exosomes from for convenience. Using an 
ultracentrifugation approach, we isolated exosomes from 66 ml of urine, and then confirmed 
their presence through TEM imaging, under a negative stain (Figure 3.2A). Measurement of 
the imaged vesicles confirmed the homogeneity of the solution for vesicles under 150 nm in 
diameter, suggesting that this was a pure population of exosomes. To further build towards 
our goal of analysing blood-bound miR-122, we aimed to extract exosomes from human 
plasma, due to the large volumes of substrate available. Analysis of the human plasma 
exosome fraction using TEM imaging confirmed the successful isolation of a pure population 
of <150 nm diameter nanovesicles using ultracentrifugation from >33 ml plasma. Due to the 
large volumes of starting solution required for the ultracentrifugation method, and because our 
aim was to examine miR-122 profiles in rodents, we looked to develop a method for exosome 
isolation requiring smaller volumes of biofluid. Three kits were initially identified, Exospin 
(Cell Targeting Systems, Cambridge, UK), Exoquick (Exiqon, Cambridge, UK) and Total 
exosome isolation solution (Life Technologies, Foster City, USA). Each kit was shown to be 
successful in isolating exosomes from a starting volume as low as 50 µL of human plasma, by 
TEM imaging (Figure 3.2B). Exosomes were then isolated from 50 uL rat plasma using each 
kit for characterisation. TEM imaging using a negative staining protocol was able to 
demonstrate that each kit had isolated a homogenous population of nanovesicles, (<150 nm in 
diameter) (Figure 3.2C; representative image of all three kits). To further enhance our 
confidence that we had isolated a pure population of exosomes, we assessed the expression of 
exosome markers in both the ‘exosome-fraction’ (the isolated exosomes) and the ‘protein-
rich’ fraction (the remainder of the plasma), using immuno-blotting. Both CD63, and TSG101 
(Figure 3.3) were found to be enriched in the exosome-fraction of the serum.  
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To examine the yield of exosomes produced from equal volumes of the same plasma sample 
by each different exosome-isolation kit, the protein expression in the exosome-fraction was 
measured using a protein assay (Lowry assay). The Exospin and Total exosome isolation 
solution on average produced a 5 µg/µL exosome solution, whereas the Exoquick kit was able 
to produce a ~8 µg/µL solution from an equal starting volume (Figure 3.4A).  
To assess whether miR-122 was detectable in exosomes, and also to assess the distribution of 
exosome-bound and exosome-free miR-122 in the plasma of rats under basal conditions, we 
profiled miR-122 across both fractions in 35 healthy rats (Figure 3.4B). Analysis of baseline 
miR-122 content in all control animals demonstrated that the protein-rich fraction content of 
miR-122 is on average ~14-fold higher than in the exosome fraction (p<0.01) (Figure 3.4B), 
with the differences between the two fractions being highly variable between animals. 
However, in all animals, the protein-rich fraction contained more miR-122 than the exosome-
fraction.	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hU Exosomes hP Exosomes Rat Exosomes A B C 
Figure 3.2 Transmission electron microscope images of exosomes extracted from human urine (A), human plasma 
(B) and rat plasma (C). 
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Exospin 
Life Tech 
Exoquick 
Exosome Supernatant 
CD63 
Exo-spin 
Life Tech 
Exoquick 
TSG101 
Exosome Supernatant 
Figure 3.3 Analysis of the exosome markers CD63 and TSG101 in exosomes isolated from rat plasma 
using three different commercially available exosome-isolation kits, and in the retrospective plasma 
supernatant (Each lane displays exosomes or plasma-supernatant from a different individual rat). 
Figure 3.4 A, analysis of the total exosomal protein yields generated by each commercially available 
exosome-isolation kit from an equal starting volume of serum. B, Exosome-bound and exosome-free 
basal expression levels of miR-122 in 35 healthy non-dosed rats. MiR-122 is expressed at significantly 
higher levels in the protein-rich fraction when compared to the exosome fraction using a two-way t-test. 
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3.3.2 miR-122 and ALT are significantly elevated in the plasma of rats after 1500mg/kg 
paracetamol 
In order to qualify miR-122 as an alternative marker of drug-induced hepatotoxicity, groups 
of rats (n = 6) were treated with a single dose of paracetamol (500, 1000 or 1500 mg/kg) and 
then sacrificed at 2, 4, 6 or 24 hours post administration. Other animals received a daily 
administration of paracetamol for 2, 3 or 4 days and were sacrificed 24 hours after the last 
administration. Body weight was monitored during the study and there was no difference in 
rats treated at 500 mg/kg compared to each corresponding vehicle group, whereas the body 
weight of the rats treated with 1000 and 1500 mg/kg was significantly reduced after 3 and 4 
days of paracetamol administration (data not shown). The rats in the recovery group 
progressively gained weight from treatment day 4 until the fourteenth post-dosing day. No 
mortality was observed in the rats at any dose tested.  
Conventional liver biomarkers were investigated in the plasma of all animals and the values 
were compared to the respective vehicle control groups for each treatment. Both aspartate 
aminotransferase (AST) (Table 3.3) and ALT levels began to increase after 24 hours after a 
single administration of 1500 mg/kg (AST: 1.8-fold, p<0.05; ALT: 2.0 fold, p<0.001) (figure 
3.5). The levels of AST and ALT peaked to the same extent after 2 days daily administration 
of 1500 mg/kg (AST: 43.8-fold, p>0.001; ALT 44.3-fold, p>0.001) and then remained mildly 
elevated until day 3 and 4, respectively. Other biomarker measurements can be found in Table 
3.3.  
Analysis of alternative DILI biomarkers GLDH (figure 3.6) and miR-122 (Figure 3.7) 
revealed large dose-dependent changes from 24 hours: GLDH increased by 5-fold at 24 hours 
and peaked at day 2 in the 1500 mg/kg dose-group (24 h: 5.2-fold, p>0.001; day 2: 475.4-fold, 
p>0.001). GLDH-levels remained elevated until day 4 for the two highest dose-groups (day 
3: 1000 mg/kg: 10.4-fold, P>0.001; 1500 mg/kg: 44.9-fold, p>0.001; day 4: 1000 mg/kg: 3.8-
fold, p>0.001; 1500 mg/kg: 14.4-fold, p>0.001). Significant increases of miR-122 were 
observed after 24hrs treatment (1000 mg/kg: 7.0-fold, p>0.01; 1500 mg/kg: 17.7-fold, 
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p>0.001) and similarly, peaked at day 2 (1500 mg/kg: 79.9-fold, p>0.001) (figure 3.7). In 
contrast to the other liver markers, the levels of miR-122 had returned to baseline for all 
treatment groups by day 3.  
   
Figure 3.5 Plasma ALT is elevated after a toxic dose of paracetamol in a rat model of paracetamol-
DILI. Plasma ALT levels are significantly elevated at 48 h post-dose in the 1500 mg/kg group, before 
returning to baseline levels by 96 h post-dose. 
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Figure 3.6 Fold-change in plasma GLDH relative to the 2 h vehicle mean. 
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Figure 3.7 Total plasma miR-122 is elevated in rats administered with a toxic dose (1500 mg/kg) of 
paracetamol at 24 h post-dose, peaking at 48 h. 
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Table 3.3 Clinical chemistry values (expressed as fold-change to 2 h vehicle) for all biomarkers 
measured in the rat paracetamol-DILI study. Significance values were assessed based on the 
mean fold-difference between the treatment group and the 2 h vehicle group (*p < 0.05). 
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3.3.3 miR-122 is released in both exosome-bound and non-exosome bound forms under 
basal-conditions and in DILI 
To establish whether miR-122 is present in a specific compartment of the plasma in DILI, and 
moreover, whether fractionation of the plasma into exosomes and the ‘protein-rich’ fraction 
(remainder of plasma) increased the sensitivity of miR-122 as a biomarker, we isolated 
exosomes from the plasma of all rats in the 1500 mg/kg group of the rat paracetamol-DILI 
study for microRNA profiling analysis. Both fractions were subject to analysis of their miR-
122 content, and it was found that both exhibited an almost matching profile (when expressed 
as fold-change to control average), with both peaking at 48 h post-dose, at ~130-fold times 
control values (exosome-bound 48 h vs control: p<0.001, exosome-free 48 h vs control: 
P<0.001) (Figure 3.8A). Expression profiles throughout the course of injury in both fractions 
are highly correlative (R2 = 0.781; p <0.0001) (Figure 3.8B). On average the exosome-bound 
miR-122 content was 13.1% of the total plasma miR-122, with the remainder being present in 
the protein-rich fraction. The exosome-bound miR-122 content increased at the later time-
points (72, 96 and 96 h + recovery) to represent 22.2% (SD = 38.42%), 27.1% (SD = 21.96%) 
and 38.5% (SD = 35.42%) of the total plasma miR-122, however due to a high level of 
variation between animals, these values are not statistically significant (ANOVA). The 
average exosome miR-122 content in the earlier time-points (2-48 h) was ~5% (SD = 3.1%) 
of the total plasma miR-122 (Figure 3.8C). 
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Figure 3.8 A, Profile of exosome-bound and exosome-free miR-122 throughout the course of paracetamol 
injury in rats. Exosome-bound and exosome-free miR-122 are expressed in the plasma of rats in similar profiles 
throughout the course of paracetamol-DILI when expressed as fold-change to control samples (animals 
administered paracetamol and immediately culled). B, Correlation analysis of exosome-bound and exosome-
free miR-122 expressed as fold-change to the mean of the normalised control group samples. Exosome-bound 
and exosome-free miR-122 are strongly correlated throughout the course of paracetamol-DILI. C, Analysis of the 
percentage of the total serum miR-122 contained within exosomes. The percentage miR-122 contained within 
the exosome-bound fraction remains at ~13% throughout the course of DILI. However, from 72 h onwards a small 
highly variable, but marginally significant elevation of the proportion of miR-122 contained within the exosome 
fraction can be seen. 
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3.3.4 miR-192 is raised in both the exosome-fraction and plasma-supernatant fraction in 
paracetamol-DILI in rats 
To examine the release of another liver-enriched miRNA, miR-192 which has previously been 
shown to be released into the circulation during paracetamol DILI in rodents and humans 
(Wang et al. 2009; Starkey Lewis et al. 2011), we profiled this marker in both the exosome-
rich and protein-rich fractions of plasma taken from the 1500 mg/kg dose group (figure 3.9). 
Similarly, to miR-122, miR-192 was detectable in both fractions of the plasma and 
significantly elevated in both fractions at 48 h following a toxic dose of paracetamol 
(exosome-bound miR-192: p < 0.01, exosome-free miR-192: p < 0.01). Both the exosome and 
exosome-free fraction displayed similar expression profiles of miR-192 throughout the course 
of injury (Pearson R = 1.00, p<0.0001), with no significant differences being found at any 
time point between the exosome-bound and exosome-free fraction of miR-122 (time exosome-
bound miR-192 vs time exosome-free miR-192, n = 6). Analysis of the relative quantities of 
miR-192 contained within exosomes and free-from exosomes (from equal starting volumes) 
illustrated that exosome-bound miR-192 accounts for 4.9% of the total plasma miR-192 on 
average, with little difference between time-points in the study (Average = 4.9%, S.D. = 4.2%; 
Range = 0.7-18.5%).  
  
Figure 3.9 A, Exosome-bound and exosome-free miR-192 profiles follow a similar expression 
trend throughout DILI. B, The percentage of the total miR-192 in the plasma contained within 
exosomes remains constant throughout paracetamol-DILI. 
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3.3.5 Exosomal release of miR-122 is not the cause of early transient elevations of this 
biomarker in a human study examining biomarker elevations after therapeutic doses of 
paracetamol 
A study was previously undertaken in which healthy subjects were administered with a 
therapeutic (4 g/day) dose of paracetamol for 14 days. Blood samples were taken daily to 
examine for elevations in conventional liver biomarkers, such as ALT. Subjects were then 
grouped into responders (those with ALT elevations), and non-responders (those-without) 
(Watkins et al. 2006). Responders were defined as those individuals who displayed plasma 
ALT levels of above 3 times the upper limit of normal (40 U/L) during the study period (Table 
3.2). These samples were then subject to miR-122 analysis in another study (Thulin et al. 
2014) and elevations of miR-122 were seen in responders as early as 8 days after paracetamol, 
one day in advance of ALT elevations. To examine the possibility of differential forms of 
miR-122 release in this model, exosomes were extracted from the plasma of healthy volunteers 
administered 8 days of paracetamol (figure 3.10). Successful exosome isolation was 
confirmed through western blotting for exosome markers and visualisation of exosomes using 
TEM (Data not shown).  Profiling of miR-122 in the exosome and protein-rich fractions in 
both responders and non-responders, demonstrated a lack of correlation between the two 
fractions (Pearson R = 0.025, N.S.). Comparison of the exosome-bound (Mean: 17.69, S.D.: 
49.60) and exosome-free miR-122 (Mean: 2.96, S.D.: 4.66) levels in the responsive subjects 
similarly demonstrated that the fractions were not correlative (Pearson R = -0.1; N.S.), but 
neither was shown to be statistically significantly different from the other (p = 0.3).  
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Figure 3.10 A, miR-122 expression in the exosome-fraction and the protein-rich fraction of subjects 
administered with a therapeutic dose of paracetamol (4 g/day) for 8 days. B, Correlation analysis of the 
exosome-bound and exosome-free expression levels of miR-122. C, Expression analysis of exosome-
bound and exosome-free miR-122 in responders (those with ALT rises after paracetamol) and non-
responders (those with no ALT response). D, Correlation analysis of exosome-bound and exosome-free 
miR-122 levels in patients with displayed an ALT response after therapeutic doses of paracetamol. 
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3.3.6 Different forms of liver injury do not cause any differentiation between the exosomal 
and protein-rich content of miR-122 in human patients after exposure to different 
hepatotoxic drugs 
As our initial hypothesis was not supported by our study examining forms of miR-122 release 
during acute injury in rats, we aimed to examine the mechanisms behind miR-122 release in 
non-acute forms of DILI and under sub-toxic conditions in order to fully establish the role of 
exosomes in miR-122 release. To examine whether miR-122 is preferentially released from 
the liver in exosomes during different forms of DILI, 31 human plasma samples from patients 
(See table 3.1 for details of samples assessed) suffering hepatocellular, mixed or cholestatic 
DILI were obtained from the Spanish DILI registry (Malaga, Spain). Exosomes were then 
isolated and characterised as previously described, then miR-122 was profiled in each fraction 
to assess whether either fraction was better able to predict the type of injury. Correlation 
analysis of all samples from all injury types and drugs indicated that the exosome-bound and 
exosome-free profiles of miR-122 strongly correlated (Pearson R = 0.612, p < 0.0005) (Fig 
3.11A). Similarly, correlation analysis of only the samples taken from each patient at peak 
exosome-free miR-122 levels, demonstrated that the exosome-bound and exosome-free 
fractions of miR-122 are strongly correlated (Pearson R = 0.637, p < 0.005) (Figure 3.11D). 
Analysis of first presentation samples (listed as ‘baseline’ on table 3.1) demonstrated that there 
was a weak negative correlation between exosome-bound and exosome-free miR-122 
(Pearson R = -0.252, p = 0.3 N.S.) (Figure 3.11B). However, samples analysed in this category 
were highly clustered, with a low overall difference in expression between the highest and 
lowest readings making it difficult to assess any possible relationships or differences between 
the exosome-bound and exosome-free miR-122. To examine whether different injury types 
(cholestatic, mixed and hepatocellular) caused different profiles of miR-122 release, the 
results were categorised based on the aetiology. Exosome-bound and exosome-free miR-122 
profiles in hepatocullar injury patients were correlative (Pearson R = 0.636, p < 0.01) (Figure 
3.11B+C). Mixed injury samples displayed a non-significant trend towards correlation 
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(Pearson R = 0.556, N.S., n = 8) and those with cholestatic injury showed little correlation 
between the exosome-bound and exosome-free fractions (Pearson R = 0.042, N.S.) (Fig 
3.12A). Individual patient profiles of exosome-bound and exosome-free miR-122 (expressed 
as 40-Ct) were then subject to comparison to each other, and also to ALT (xULN) values 
measured previously (figure 3.13). In 4 out of 6 cases of hepatocellular DILI both the 
exosome-bound and exosome-free profiles of miR-122 were closely matched. In 1 out of the 
6, specifically patient 769, exosome-bound and exosome-free miR-122 displayed an opposite 
trend, with exosome-bound increasing and exosome-free decreasing. However, the dynamic 
change in this sample was small in both assessments. In the case of patient 764, there is a clear 
fall in exosome-free miR-122 expression in sample 2, in comparison to the smooth increase 
in exosome-bound miR-122. Due to the limited number of ALT samples in the hepatocellular 
group, meaningful comparisons could only be obtained from patients 758,762 and 764. In all 
cases, peak ALT was matched in time by peak exosome-free miR-122 and in two out of three 
cases, was also matched by peak exosome-bound miR-122. Similarly, the overall direction of 
expression change was similar between ALT, exosome-bound miR-122 and exosome-free 
miR-122 in two out of three cases, and in three out of three cases for the comparison of 
exosome-free miR-122 to ALT. In all mixed injury cases exosome-bound miR-122 and 
exosome-free miR-122 followed similar expression trends (patient 768, 806, 860), and in the 
case of 860, ALT also followed a similar expression trend. Interestingly, in patient 806, ALT 
expression was seen to fall between sample 1 and 2 (ALT: 2.0 vs 1.8 xULN), whereas miR-
122 levels remained consistent in both fractions. In the patients displaying cholestatic injury 
little trend could be seen between the exosome-bound and exosome-free miR-122 fractions, 
with two patients (839, 678) displaying opposite expression trends and one patient (909) 
displaying a stable expression levels of exosome-bound miR-122, with increasing levels of 
exosome-free miR-122. In all cases, cholestatic patients did not show ALT elevations and 
therefore it was not possible to obtain this comparison. 
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Figure 3.12 A, Correlation analysis of exosome-bound and exosome-free miR-122 expression in 
cholestatic injury patients. B, Correlation analysis of exosome-bound and exosome-free miR-122 
expression in mixed injury patients. C, Correlation analysis of exosome-bound and exosome-free miR-
122 in hepatocellular injury patients. 
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 3.4 DISCUSSION 
To investigate our hypothesis that early detection of circulating miR-122 in DILI is possible 
due to its active release in exosomes, it was first necessary to develop a method to separate 
exosomes from the remainder of the plasma/serum. Through testing several commercially 
available kits for exosome extraction, alongside well established non-kit based methods, we 
identified that three commercially available kits produced an equivalent quantity, and purity 
of exosomes from a smaller volume of serum than was possible to use with the centrifugation 
method. Based on this, we selected Life Technologies Total Exosome Isolation Solution for 
the remainder of the studies within the chapter.  
In order to assess whether miR-122 is raised early in the circulation within exosomes, we first 
had to select an appropriate experimental model, taking into account the current literature 
examining miR-122 as a marker of DILI, and also encompassing the necessary longitudinal 
capability to detect its early release. Initially, our chosen model was a rat model of 
paracetamol-induced liver injury, in which non-fasted rats were administered by oral gavage 
in order to elongate the time-course of paracetamol injury. This is demonstrated by peak miR-
122 and ALT levels only being achieved by 48 h post-dose, whereas in an equivalent fasted, 
I.P. dosing study in mice, this would be expected as early as 8 h, as seen in chapter 2 of this 
thesis.  Importantly, total plasma miR-122 was elevated to a significantly greater level in the 
plasma at 24 h after paracetamol (17.7-fold), when compared to ALT (2-fold), adding further 
evidence to the previous literature which suggests that miR-122 is an early marker of DILI.  
To test our hypothesis that miR-122 is released early within exosomes, we then examined the 
profiles of miR-122 expression in both exosomes and the remainder of the plasma. Analysis 
of the basal expression of miR-122, and miR-192, another liver-enriched microRNA, suggests 
that the majority of these microRNAs are contained in an exosome-free form. This is not 
unexpected, and it has previously been shown in a study examining basal levels of a number 
of microRNAs that the majority are free from vesicles under normal conditions (Turchinovich 
et al. 2011). Our analysis of the profiles of both fractions throughout the time-course of 
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paracetamol-DILI demonstrates for the first time that miR-122 is released in equivalent 
profiles both bound to exosomes, and un-bound throughout the course of DILI. However, the 
exosomal quantity of miR-122 was ~13% on average of the total plasma miR-122 content 
throughout the time-course. This suggests that in paracetamol-DILI, miR-122 is being 
released in multiple forms, which may suggest that this is a product of necrotic cellular 
membrane damage, which leads to a non-selective release of this marker into the circulation. 
This complements work performed in a previous study (Bala et al. 2012) in mice, which 
suggested that the majority of miR-122 is released in the exosome-free fraction after a toxic 
I.P. dose of paracetamol. This together suggests that measurement of exosomal miR-122 in 
this rodent model does not add any further prognostic use in DILI, over measuring whole 
plasma/serum miR-122. However, interestingly the percentage of the total plasma miR-122 
contained within the exosome-fraction increased from 72 h onwards, peaking at an average of 
38%, three times the average baseline level. Although this result was not statistically 
significant due to high levels of variation between the rats, several hypotheses could be 
generated from this. First, miR-122 packaged in exosomes may be more stable than exosome-
free miR-122, allowing the packaged miR-122 to remain in the plasma after injury resolves.	  
This is supported by studies examining the stability of exosome-bound miRNAs, which have 
now suggested that these miRNAs remain stable in the circulation for much longer than ones 
un-bound (Ge et al. 2014). However, the finding that exosome-bound miR-192 levels 
remained constant throughout the time-course, may suggest that both forms of miRNA 
packaging are equally stable in the circulation. Second, could be the reverse of our initial 
hypothesis, that the liver actively secretes exosome-bound miR-122 in the regenerative stages 
of injury to increase the proliferative response of the remaining hepatocytes. Both however 
would need to be experimentally verified.  
As our rat model provided evidence against our initial hypothesis, we developed a new 
hypothesis that miR-122 is not selectively released in exosomes following a toxic dose of 
paracetamol, due to the severity of the injury involved, but this marker may be released in 
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exosomes following a low, non-toxic dose of paracetamol. There is evidence to support the 
release of both miR-122 and other miRNAs in exosomes during alcohol-induced liver injury, 
which is a much slower form of injury than paracetamol, in which cellular energy and transport 
functions are still active (Bala et al. 2012). To examine this hypothesis, we obtained plasma 
samples from healthy individuals who were administered with a therapeutic dose of 
paracetamol daily for 14 days (Watkins et al. 2006). Previously, these samples have shown 
that some individuals within this trial displayed transient ALT elevations at as early as 9 days 
after paracetamol. A study following this then demonstrated that miR-122 was also elevated 
in these responders at around one day earlier than ALT (on average) (Thulin et al. 2014). Once 
again, we tested whether this early release, with no signs of toxicity, is due to an active release 
of miR-122 through the exosome pathway. In our analysis miR-122 was elevated in both 
fractions, and similarly to the rat model, no statistically significant difference could be seen 
between exosome and non-exosome bound miR-122 in the plasma of the patients which 
responded to paracetamol. This once again suggests that after sub-toxic doses of paracetamol, 
miR-122 is not selectively released in exosomes over other pathways of miRNA release. The 
lack of correlation between the two plasma fractions may explained by the small dynamic 
range of miR-122 expression in this study, and also the expected levels of inter-individual 
variations that are seen in human trials.  
Finally, we aimed to test the hypothesis that miR-122 may be released in different 
compartments during different types of DILI. To examine this, we obtained human plasma 
samples from the Malaga DILI registry, which comprises individuals who have been 
prescribed a variety of hepatotoxic drugs and have displayed mixed, hepatocellular or 
cholestatic injury. To account for the different number of blood samples taken from each 
patient, direct comparisons between patients were taken at peak ALT values, and individual 
longitudinal plasma miR-122 profiles were compared separately. Similarly to both of the 
previous studies, our analysis demonstrated that exosome and non-exosome miR-122 profiles 
are highly correlative when all samples taken from hepatocellular injury patients were 
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compared. In contrast, mixed injury displayed a weaker relationship, and in cholestatic injury 
the correlation between the two different fractions was low. However, it is likely this that can 
be attributed to the low dynamic range of the change in miR-122 in cholestatic injury, due to 
miR-122 largely being associated with hepatocyte injury, and not injury of the bile ducts. 
Interestingly, when individual patient profiles were analysed and compared with each other, 
and also ALT, there was little overriding trend amongst patients suffering each individual type 
of injury, and no distinguishing factor in exosome-bound or exosome-free profiles of miR-
122 could be found to clearly separate the different types of injury. Similarly, when ALT 
profiles were compared to the profiles of each miR-122 fraction, no distinguishing trend could 
be found, with peak ALT measurements matching those of both miR-122 fractions in the 
majority of samples involving hepatocyte injury, supporting our previous conclusions drawn 
from our rat study. In fact, the only distinguishing factor found was that ALT was not elevated 
in patients undergoing cholestatic injury and that elevations in miR-122 in both fractions were 
minimal in comparison to mixed and hepatocellular injury. This however is of no surprised as 
it has been suggested that miR-122 expression is highly enriched in hepatocytes (Lagos-
Quintana et al. 2002; Kia et al. 2015) and therefore in cholestatic injury, where hepatocyte 
injury will initially be considerably less than in the other forms of injury, it is no surprise that 
a hepatocyte-injury marker would not be elevated (Padda et al. 2011).  
Another interesting finding in our study examining forms of human liver injury, was that 
exosome-bound miR-122 expression actually decreased in two out of the three patients 
undergoing cholestatic injury and levels were maintained in the third, in comparison to 
exosome-free miR-122 expression which actually increased. An explanation for this could be 
the slow progressive nature of cholestatic injury in which hepatocyte injury is usually 
secondary to bile duct injury (Padda et al. 2011), meaning that cell-signalling may play more 
of a role than in more acute forms of injury. Therefore, it is possible that hepatocytes are 
actively slowing the release of exosomes which contain miR-122 as an adaptive response to 
the oncoming injury. This finding is a contrast to much of the previous literature which is 
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examining the release of exosomes as signalling or shuttling vehicles which are able to 
transport intracellular molecules to recipient cells to elicit a response (Herrera et al. 2010; 
Mittelbrun et al. 2011), and is therefore relatively unexplored.   
In summary, we have examined whether the exosomal pathway is implicated in the early 
release of miR-122 during DILI in both rats and humans. Although miR-122 levels are raised 
in exosomes during DILI, exosome-free miR-122 levels also are raised similarly, suggesting 
that there is not one specific pathway for miR-122 release. This suggests that there is little 
prognostic value added through the fractionation of plasma to exosomes, over what is gained 
from miR-122 measurement in the whole plasma. Despite our findings which suggest a limited 
prognostic use for exosome-bound miR-122, studies examining slower, more progressive 
forms of liver injury, such as alcohol-induced liver injury (ALD), have produced different 
findings. In one example, it was found that exosome-bound miR-122, and miR-155, a miRNA 
associated with inflammation were elevated in the exosome-bound fraction over the protein-
rich fraction during ALD (Bala et al. 2012). This result supports our previous suggestion that 
that exosomal release of miRNAs may be more of a factor in progressive forms of liver injury, 
in which cell-cell signalling and inflammation is a more predominant factor. 
Future work could look to further examine the pathways of miR-122 release, through further 
fractionation of the exosome-free fraction into microvesicles, protein complexes and lipid 
complexes in order to assess whether miR-122 is associated with all of these release pathways, 
or whether it is selectively associated to any one of these. Additionally, work could be 
undertaken to manipulate the levels of exosome release in DILI using exosome release 
blockers (Mittelbrun et al. 2011) to fully understand the functional effects of these molecules.  
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4.1 INTRODUCTION 
The liver by mass is almost 60% hepatocytes, which are responsible for the production of 
albumin, and the metabolism of endogenous compounds, and drugs. Hepatocytes are a 
heterogeneous species, with their phenotype being dependent on their proximity to a portal or 
central vein (Reviewed by (Colnot and Perret 2011). Zone I hepatocytes (periportal) are rich 
in glutathione, express low levels of cytochrome P450 enzymes, and contain high levels of 
phase II metabolism enzymes. In contrast, zone III hepatocytes, located in the oxygen-poor 
pericentral regions, express a low levels of glutathione, but high levels of cytochrome P450 
enzymes. Because of this zone III hepatocytes are particularly susceptible to toxicity caused 
by certain drugs, such as paracetamol, due to increased bioactivation of the compound, but 
reduced excretion (Anundi et al. 1993). Some zonated processes, such as glycolysis and 
gluconeogenesis are subject to environmental regulation, by factors such as differential 
oxygen content between the hepatic zones, and because of this are reversible through changes 
in the local blood content (Berkowitz et al. 1995; Braeuning et al. 2006; Gebhardt 1992; 
Häussinger et al. 1991). Other zonated processes, such as ammonia detoxification are also 
subject to transcriptional regulation, which is not reversible through changing external 
environmental conditions (Tygstrup et al. 1962). Studies since utilising knock-out models 
have now attributed this master zonal regulation to the Wnt/Beta-Catenin pathway 
(Benhamouche et al. 2006b; Cadoret et al. 2002).   
microRNAs (miRNAs) are small non-coding RNAs (20-22nt) that are able to regulate gene 
expression through translational repression or mRNA degradation. miRNAs regulate various 
biological processes, such as lipid metabolism (Esau et al. 2006), apoptosis (Cimmino et al. 
2005), and carcinogenesis (Lu et al. 2005). It is not currently understood whether gene-
regulation at a miRNA level plays a role in zonation within the liver. Yamaura et al, examined 
hepatic zonal miRNA profiles basally, and in different forms of DILI in rats, demonstrating 
that 49 miRNAs are differentially expressed between zone I and zone III regions of the liver 
(27 up-regulated in PV, 22 down-regulated) (Yamaura et al. 2014), however no analysis of 
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the downstream function of this expression was undertaken. Therefore, this chapter aims to 
identify and characterise miRNAs which are significantly differentially expressed between 
different regions of the liver, and importantly, link this expression to possible downstream 
targets within the liver to establish the role of miRNA gene regulation in hepatic zonation. An 
additional aim is to address contrasting results within the literature examining whether miR-
122, a biomarker of DILI is lost from the liver during liver injury. To address this, we aimed 
to profile miR-122 and other miRNAs in both zone I and III after paracetamol treatment in 
rats, in order to establish both whether miR-122 is lost from injured areas, and whether other 
miRNA expression changes occur during injury within either region. The rat was chosen as 
our species of investigation in order to allow sufficient zonal tissue collection for the study 
discussed within this chapter and a recently published partner study (Holman et al. 2016).  
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4.2 METHODS 
4.2.1 Animal use 
Sprague Dawley rats were chosen for use in this study based on their previous use by the 
Hamner Institutes for Health Sciences in similar studies. 6-8 week old Sprague Dawley rats 
(200-250 g) were obtained from Charles River (Raleigh, NC), housed in pairs, and left to 
acclimatise for 1 week prior to use. Food and water was available ad libumtum, and animals 
were kept in a 12 h light-dark cycle.  All animal work was approved by the Institutional Animal 
Care and Use Committee, and was carried out under Hamner Institutes for Health Sciences 
regulations. 
4.2.2 Study Design 
This study was performed at the Hamner Institutes for Health Sciences (Raleigh-Durham, NC, 
USA) as a collaborative effort between the MRC Centre for Drug Safety Sciences and the 
Hamner Institute for Drug Safety Sciences. Food was removed from the housing of 120x 
Sprague Dawley rats prior to the study commencing. After 16 h, rats were administered with 
either vehicle (0.5% methylcellulose in water), 500 mg/kg paracetamol in vehicle, or 1400 
mg/kg paracetamol in vehicle by oral gavage. Rats were then culled at 1, 2, 4, 8, and 24 h 
post-dosing, in groups of 5 per treatment. Blood was then collected and stored in EDTA-
plasma tubes for subsequent plasma separation. Liver tissue was also collected and the lobes 
were separated. The left and median lobes were then processed for histology, including H&E 
and immunohistochemistry.   
4.2.3 Clinical Chemistry 
Approximately 250 µl of plasma was used for clinical chemistry analysis. Plasma was selected 
to maximize the spectrum of analytes that can be measured in this study. Chemistries were 
assessed using standard assays on a CLC 720 clinical chemistry analyzer (Carolina Liquid 
Chemistries, Winston Salem, NC). Analysis includes ALT, aspartate aminotransferase (AST), 
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alkaline phosphatase (ALP), glutamate dehydrogenase (GLDH), albumin (ALB), blood urea 
nitrogen (BUN), creatinine (CR) and total and direct bilirubin.  
4.2.4 Laser Capture Microdissection 
Slices from both the left and median liver lobes of each animal were frozen in OCT medium 
within a cryomold by gradual submersion in liquid nitrogen. Cryomolds were then placed onto 
dry ice until they can be stored at approximately at ≤ -70 °C. For sectioning, tissue blocks 
were mounted onto a brass chuck and sectioned into 12 µM sections using a cryostat set at 
approximately -12 ̊C. Approximately 2-5 sections from the interior portion of the liver slices 
were immediately affixed to membrane slides (Molecular Machines & Industries, Haslett, 
MI), followed by fixation in EtOH and staining with hemotoxylin. LCM was conducted 
utilizing an Olympus 1X81 microscope and MMI Cell Cut Plus software (Molecular Machines 
& Industries, Haslett, MI). Within median liver sections, periportal (zone 1) and pericentral 
(zone 3) hepatic cells were isolated separately and the area of tissue collected was recorded 
for the purpose of data normalization. A zone of four hepatocytes depth was collected 
surrounding the portal and central veins in order to ensure the specificity of zones collected. 
Sections were collected on diffuser caps (Molecular Machines & Industries) and subsequently 
immersed into RLT buffer (Qiagen, Valencia, CA), a guanidine isothiocycanate-containing 
lysis buffer, and stored at ≤ -70°C. 
 
4.2.5 Taqman microRNA profiling 
Total RNA was isolated from select tissue sections using the miRNeasy Micro Kit (Qiagen, 
Valencia, CA) in accordance with manufacture’s recommended protocol. Isolated RNA was 
reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit and the 
Megaplex Reverse Transcription Rodent Pools Set V. 3.0 (Life Technologies, Foster City, 
CA). The resulting cDNA was pre-amplified using TaqMan PreAmp Master Mix and 
MegaPlex Preamp Rodent Pools Set V. 3.0 (Life Technologies, Foster City, CA) following 
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the manufacturer’s instructions. MiRNA profiling was then conducted using TaqMan Rodent 
miRNA Set A and B V. 3.0 Arrays and Taqman Universal Master Mix II, No UNG (Life 
Technologies) following the manufacturer’s specifications. Quantitative real time PCR (qRT-
PCR) of these arrays was then performed using a Viia-7 Real-Time PCR System (Applied 
Biosystems).  
 
4.2.6 Taqman microRNA qPCR 
Pre-amplified and reverse transcribed microRNA samples (See above) were subject to qPCR 
validation. Briefly, equal quantities of cDNA were analysed examining individual microRNAs 
using Taqman microRNA assays (Life Technologies, Foster City, CA) and universal Taqman 
master mix (Life Technologies), on a Viia-7 qPCR platform.  
 
4.2.7 Total RNA extraction and analysis 
Total RNA extraction was performed as described above. Pre-amplification of the total RNA 
content was performed using a MiScript Preamp PCR kit (Qiagen, Venlo, Netherlands) under 
the manufacturer’s protocol. Total RNA was then quantified using a Nanodrop (Thermo 
Scientific) and loaded in equal quantity onto a 384-well qPCR plate. Specific primers 
(Eurofins) then combined with universal SYBR master-mix reagent (Sigma), and added to the 
cDNA. The content of the specific genes was then quantified using a Viia-7 qPCR platform 
(Applied Biosystems). 
 
4.2.8 In situ hybridization of miR-122 
MiR-122 was localised using double-DIG labelled miRCURY LNA microRNA detection 
probes (Exiqon A/S, Vedbaek, Denmark). The in situ hybridization procedure was performed 
on a fully-automated Ventana Discovery Ultra (Roche diagnostics AG, Rotkreuz, 
Switzerland). All reagents were provided by Roche Diagnostics. Briefly, whole liver sections 
were de-paraffinized at 62 °C for 12 minutes before proteinase K digestion step (Exiqon A/S, 
Vedbaek, Denmark) treatment (37 °C, 24 min). The antimiR-122 probe (25 pmoles) was then 
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incubated at 54 °C for 3 h with de-paraffinized sections. Sections were then washed with 3 × 
8 mins cycles of saline sodium citrate, an acidic salt buffer solution at increasing stringency 
per cycle (2.0×, 1.0×, 0.5×) to control acidity. A negative scramble control was also used in 
place of the antimiR-122 probe, which is an antimiR probe targeted against a sequence non-
existent miRNA sequence. The secondary antibody (alkaline phosphatase-linked Sheep anti-
DIG, dilution 1:500 in antibody diluent) was then incubated at 37 °C for 32 mins. 
Chromogenic detection was performed using the BlueMap® kit as per the manufacturer’s 
instructions. The substrate was allowed to develop for 6 h before counterstaining with Red 
Stain II for 4 mins. Slides were manually washed before mounting on laboratory-grade 
glycerol gelatin (Sigma-Aldrich, Buchs, Switzerland). Slides were scanned using a 
Nanozoomer 2.0-HT digital slide scanner (Hamamatsu photonics, Hamamatsu, Japan). 
Images were captured using NDP.view2 software (Hamamatsu photonics, Hamamatsu, 
Japan). 
 
4.2.9 Expression analysis, statistical analysis and pathway mapping 
Initial data processing was carried out using Expression Suite Software (Life Technologies, 
Foster City, USA) and Graph Pad Prism for statistical analysis, in which groups were 
compared using multiple t-tests followed by a Holm-Sidak correction for multiple 
comparisons. P values below 0.05 were considered as statistically significant. Data is 
expressed as mean fold change (FC) which denotes the mean fold difference of the score of 
the test group versus the control group. Pathway mapping was then carried out using Ingenuity 
Pathway Analysis Software (Qiagen, Venlo, Netherlands) in order to identify downstream 
targets of miRNAs in order to suggest functional outcomes of differentially expressed 
miRNAs. P values were developed in IPA from previous study data and mathematically 
predicated targets. RQ values denotes the log-transformed fold-difference to control. 
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4.3 RESULTS 
4.3.1 CPS1, GS, CYP2E1 and PCK are expressed differentially in periportal and pericentral 
regions  
Zone I and Zone III hepatic tissue was dissected using LCM from four healthy Sprague 
Dawley rats in order to assess differential RNA expression profiles between the two regions. 
The tissue was initially subject to analysis of mRNA expression through qPCR to examine the 
profiles of previously established zonally expressed genes, including cyp2e1, glycogen 
synthase (gs), phosphoenolpyruvate carboxyinase (pck) and carbamoyl-synthase 1 (cps1) 
(figure 4.1). As has previously been shown, pck and cps1, zone I markers, had their highest 
expression levels in zone I tissue (Bartels et al. 1993). Conversely, cyp2e1 and gs were 
expressed at their highest in zone III.     
  
Figure 4.1 mRNA expression of zonally expressed genes from four individual 
animals 
Zone	  I	  
Zone	  III	  
Zone	  I	  
Zone	  III	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4.3.2 45 microRNAs are differentially expressed between pericentral and periportal regions 
of the liver in healthy Sprague Dawley rats 
After confirmation of the correct expression profiles of previously characterised zonally 
expressed genes, thus confirming the correct dissection of zone I and III tissue, a global 
miRNA expression analysis was performed on both regions of the liver from four healthy 
(non-dosed) rats. Our miRNA analysis was able to detect 421 individual miRNA species 
detected in three or more rats from a specific region. Comparison of the profiles of both 
regions using a correlation analysis demonstrates that the miRNA profiles of either region 
highly correlate (Pearson R = 0.923; p<0.001). Importantly, several outliers can be seen on 
the correlation plot, suggesting the differential expression of some miRNAs (figure 4.2A). 
Volcano plot analysis confirms the significant differential expression of 45 microRNAs when 
zone III is compared to zone I (figure 4.2B). Analysis of the individual microRNAs which 
were found to be differentially expressed demonstrates that eight miRNAs are up-regulated in 
zone III, when compared to zone I, and 41 miRNAs are down-regulated (Figure 3). miR-671-
3p is the most statistically significant up-regulated miRNA in Zone III (p = 0.009), whereas 
miR-203 is the most statistically significant down-regulated (p = 0.0009) (table 4.1). Three 
randomly selected miRNAs, miR-138, miR-16 and let-7f were then quantified using RT-
qPCR in the same samples as those used in the above study in order to validate the results 
generated using miRNA arrays (figure 4.4). As was the case in the array data, miR-138 was 
expressed at higher levels in zone III, whereas miR-16 and let-7f were expressed at higher 
levels in zone I.  
  
Chapter 4 – Analysis of zonal miRNA expression profiles 
	  
127	  
	  
   
Pearson	  R	  =	  0.923 
-­ 5 0 5
0
1
2
3
4
L o g 2  P V /PP
-­L
o
g
2  
P
  V
a
lu
e
Zone	  I-­‐enriched Zone	  III-­‐enriched 
P=	  0.05 
A 
B 
Figure 4.2 Comparison of hepatic microRNA expression between zone I, and zone III. A, 
Correlation of zone I and zone III microRNAs shows that the two profiles strongly correlate. B, 
Volcano plot analysis of zone I and zone III microRNA expression (zone III vs I) comparing negative 
log 2 p-value to log 2 fold-change to zone I, demonstrates that 45 miRNAs are significantly 
differentially expressed between the two regions (p < 0.05). Cut off lines denote a two-fold difference 
in expression level (vertical) and a negative log 2 p-value of 1.3 (p = 0.05, horizontal). Significantly 
different miRNAs fall above the horizontal cut-off line. 
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Table 4.1. Statistically significant differentially expressed microRNAs identified by a global comparison of 
microRNA profiles in hepatic zone I and III. Expressed as fold-difference between miRNA expression zone III versus 
zone I. Red = highly expressed in specific zone, Orange = marginally overexpressed in specific zone compared to comparator 
zone, Green = under-expressed in zone compared to comparator zone. 
Target'Name Mean'fold0change P'value
mmu#miR#671#3p 1.9 0.009
mmu#miR#375 1.8 0.01
mmu#miR#139#3p 2.4 0.02
mmu#miR#1195 3.4 0.02
mmu#miR#1935 11.8 0.03
mmu#miR#211 990.9 0.05
Target'Name Mean'fold0change P'value
mmu#miR#203 0.2 0.0009
mmu#miR#218 0.2 0.004
mmu#let#7b 0.6 0.004
rno#miR#547 0.2 0.005
mmu#miR#31* 0.2 0.006
mmu#miR#184 0.2 0.006
rno#miR#146B 0.5 0.006
mmu#miR#99b 0.6 0.007
mmu#miR#16 0.6 0.007
snoRNA135 0.6 0.01
mmu#miR#335#3p 0.4 0.01
mmu#miR#30d 0.6 0.02
mmu#miR#129#3p 0.2 0.02
mmu#miR#183 0.2 0.02
mmu#miR#31 0.004 0.02
mmu#miR#215 0.3 0.02
mmu#miR#200c 0.1 0.02
mmu#let#7c 0.7 0.02
mmu#miR#15a 0.5 0.02
mmu#let#7d 0.7 0.02
mmu#miR#130a 0.5 0.03
mmu#miR#32 0.4 0.03
mmu#let#7a 0.6 0.03
mmu#miR#301b 0.7 0.03
mmu#miR#15b 0.7 0.03
mmu#let#7f 0.4 0.03
mmu#miR#802 0.3 0.03
mmu#miR#125b#5p 0.7 0.03
hsa#miR#9* 0.004 0.03
mmu#miR#207 0.2 0.03
mmu#miR#23a 0.001 0.03
mmu#let#7e 0.7 0.03
mmu#miR#450a#5p 0.1 0.04
mmu#miR#101a 0.8 0.04
mmu#let#7i 0.7 0.04
mmu#miR#322 0.6 0.04
mmu#let#7g 0.7 0.04
mmu#miR#29a 0.5 0.04
mmu#miR#434#3p 0.4 0.05
Zone%III>Zone% I
Zone%I>Zone%III
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4.3.3 Two microRNAs are present exclusively within zone I or zone III 
Global miRNA analysis in zone I and zone III liver tissue from healthy rats was able to identify 
two miRNAs and one pre-cursor miRNA present exclusively within one zone of the liver 
(negligible level of detection in the other) (table 4.2). miR-211 (p = 0.05) was only detectable 
in zone III, whereas miR-23a (p = 0.03) and the precursor miRNA miR-9* (p = 0.03) were 
only detectable in zone I. 
 
4.3.4 Six microRNAs target the mRNAs of well-characterised zonally expressed proteins 
Differentially expressed miRNAs were subject to a target analysis using Ingenuity Pathway 
Analysis (IPA) and target scan to identify mRNA transcripts of known zonally expressed 
genes targeted by differentially expressed miRNAs from our analysis (table 4.3). A single up-
regulated miRNA and five down-regulated miRNAs were found to be predicted to target six 
characterised zonally expressed genes. The genes were found to have roles in arginine 
degradation, xenobiotic metabolism signalling, the pentose phosphate pathway, glycerol 
degradation I and the TCA cycle II. 
  
Table 4.2 MicroRNAs detected significantly in only one hepatic region 
Zone%III Specific
Target%Name Mean%FC P%value
mmu#miR#211 990.9372 0.05
Zone%I%Specific
Target%Name Mean%FC P%value
hsa$miR$9* 0.004054132 0.03
mmu#miR#23a 0.001067765 0.03
*opposing(strand(of(precursor1microRNA
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4.3.5 Pathway analysis identifies the top canonical pathways regulated by differentially 
expressed microRNAs 
Up-regulated and down-regulated microRNAs were then individually subject to a global 
mRNA target screen, followed by an analysis of their involvement in biological function and 
canonical pathways using Ingenuity Pathway Analysis (IPA, Qiagen, Venlo, Netherlands). In 
both of the individual analyses, the top statistically significant canonical pathway was shown 
to be the molecular mechanisms of cancer (table 4.4). The Wnt/β-Catenin pathway was found 
to be in the top ten canonical pathways perturbed by up- and down-regulated miRNAs (Zone 
I > Zone III = 8th; Zone III > Zone I = 5th). Other significantly perturbed pathways of interest 
include HGF signalling, STAT3, ERM/MAPK, TGF-B, PI3K/AKT (all I > III), PKA (Both I 
and III). 
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Table 4.5 Top 50 canonical pathways associated with differentially expressed microRNAs 
PP>PV$miRNA$target pathways$ in$PV
Rank Ingenuity$Canonical$Pathways <log(p<value)
1 Molecular*Mechanisms*of*Cancer 16.8
2 Axonal*Guidance*Signaling 14.7
3 HGF* Signaling 11.0
4 STAT3*Pathway 10.5
5 Cardiac*Hypertrophy* Signaling 9.82
6 Glioblastoma*Multiforme*Signaling 9.75
7 Protein*Kinase*A*Signaling 9.72
8 Wnt/βOcatenin*Signaling 9.34
9 ERK/MAPK*Signaling 9.15
10 B*Cell*Receptor*Signaling 8.96
11 PTEN*Signaling 8.56
12 Glioma*Signaling 8.35
13 Breast* Cancer*Regulation*by*Stathmin1 8.33
14 p53*Signaling 8.23
15 ErbB Signaling 8.04
16 IGFO1*Signaling 8.03
17 ILO8*Signaling 7.99
18 TGFOβ* Signaling 7.83
19 Mouse*Embryonic*Stem*Cell*Pluripotency 7.79
20 Chronic*Myeloid*Leukemia*Signaling 7.66
21 Role*of*NFAT*in*Cardiac*Hypertrophy 7.5
22 HERO2*Signaling*in*Breast*Cancer 7.45
23 NGF*Signaling 7.42
24 Regulation*of*the*EpithelialOMesenchymal*Transition*Pathway 7.38
25 Pancreatic* Adenocarcinoma*Signaling 7.35
26 SAPK/JNK*Signaling 7.28
27 Signaling*by*Rho*Family*GTPases 7.21
28 Insulin*Receptor*Signaling 7.1
29 Colorectal*Cancer*Metastasis* Signaling 7.01
30 Regulation*of*ILO2*Expression*in*Activated*and*Anergic*T*Lymphocytes 6.93
31 ILO6*Signaling 6.92
32 UVAOInduced*MAPK*Signaling 6.91
33 Prolactin*Signaling 6.89
34 GDNF*Family*LigandOReceptor*Interactions 6.87
35 PEDF*Signaling 6.87
36 Ephrin*Receptor*Signaling 6.79
37 EGF* Signaling 6.5
38 Ovarian*Cancer*Signaling 6.48
39 LPSOstimulated*MAPK*Signaling 6.44
40 Protein*Ubiquitination*Pathway 6.44
41 RANK*Signaling*in*Osteoclasts 6.41
42 FGF* Signaling 6.41
43 p70S6K*Signaling 6.4
44 UVBOInduced*MAPK*Signaling 6.4
45 PI3K/AKT*Signaling 6.38
46 HIPPO*signaling 6.29
47 FLT3*Signaling*in*Hematopoietic*Progenitor*Cells 6.24
48 Role*of*Osteoblasts,*Osteoclasts*and*Chondrocytes*in*Rheumatoid*Arthritis 6.14
49 Role*of*Macrophages,*Fibroblasts*and*Endothelial*Cells*in*Rheumatoid*Arthritis 6.06
50 T*Cell*Receptor*Signaling 6.06
PV>PP$miRNA$target pathways$ in$PV
Rank Ingenuity$Canonical$Pathways <log(p<value)
1 Molecular*Mechanisms*of*Cancer 9.29
2 Ephrin*Receptor*Signaling 7.29
3 Axonal*Guidance*Signaling 7.22
4 Signaling*by*Rho*Family*GTPases 5.45
5 Wnt/βOcatenin*Signaling 4.97
6 Protein*Kinase*A*Signaling 4.65
7 Regulation*of*the*EpithelialOMesenchymal*Transition*Pathway 4.44
8 RhoGDI Signaling 4.4
9 cAMPOmediated*signaling 4.23
10 Ephrin*B*Signaling 4.04
11 GOProtein*Coupled*Receptor*Signaling 4
12 Notch*Signaling 3.92
13 Adipogenesis*pathway 3.67
14 CXCR4*Signaling 3.48
15 p53*Signaling 3.44
16 RAR*Activation 3.42
17 Phospholipase*C*Signaling 3.38
18 Colorectal*Cancer*Metastasis* Signaling 3.37
19 Glioblastoma*Multiforme*Signaling 3.33
20 Semaphorin*Signaling*in*Neurons 3.25
21 Cardiac*Hypertrophy* Signaling 3.22
22 Role*of*Macrophages,*Fibroblasts*and*Endothelial*Cells*in*Rheumatoid*Arthritis 3.14
23 Thrombin*Signaling 3.13
24 ILO8*Signaling 2.98
25 ILO1*Signaling 2.94
26 SphingosineO1Ophosphate*Signaling 2.83
27 Melanocyte* Development*and*Pigmentation*Signaling 2.73
28 TR/RXR*Activation 2.7
29 Chronic*Myeloid*Leukemia*Signaling 2.64
30 Cellular*Effects*of*Sildenafil*(Viagra) 2.55
31 Circadian*Rhythm*Signaling 2.55
32 Basal*Cell*Carcinoma*Signaling 2.47
33 GABA*Receptor*Signaling 2.47
34 Cell*Cycle:*G1/S*Checkpoint*Regulation 2.31
35 Agrin*Interactions*at*Neuromuscular*Junction 2.29
36 Calcium*Signaling 2.27
37 Role*of*Osteoblasts,*Osteoclasts*and*Chondrocytes*in*Rheumatoid*Arthritis 2.26
38 Acute*Myeloid*Leukemia*Signaling 2.25
39 RhoA*Signaling 2.24
40 Leptin*Signaling*in*Obesity 2.14
41 Relaxin*Signaling 2.14
42 Ovarian*Cancer*Signaling 2.11
43 Reelin*Signaling*in*Neurons 2.08
44 DNA*Methylation*and*Transcriptional*Repression*Signaling 2.07
45 Angiopoietin*Signaling 2.05
46 Role*of*NFAT*in*Cardiac*Hypertrophy 2.03
47 GNRH*Signaling 2.03
48 VEGF* Signaling 2.02
49 Death* Receptor*Signaling 2.02
50 Neuroprotective* Role*of*THOP1*in*Alzheimer's*Disease 2.01
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4.3.6 The master zonation regulating pathway, the Wnt/β-Catenin pathway is targeted by 
nine differentially expressed microRNAs 
Analysis of the top canonical pathways perturbed by up- and down-regulated miRNAs 
identified the Wnt/β-Catenin pathway as a top 10 significantly perturbed pathway in both of 
the individual analyses (table 4.4). Up-regulated miRNAs are defined as miRNAs with a 
significantly higher expression level in zone III when compared to zone I, conversely, down-
regulated miRNAs are defined as those with a significantly lower expression in zone III when 
compared to zone I. To further examine the role of miRNAs in the Wnt/β-Catenin pathway, 
an mRNA target filter analysis was performed in order to identify individual mRNAs targeted 
(predicted or observed) by the differentially expressed miRNAs. Three up-regulated miRNAs 
(miR-138-5p, miR-1913 and miR-671-3p) were found to target 45 mRNAs (predicted) 
associated with the Wnt/β-Catenin Pathway, including WNT isoforms, SOX isoforms and 
CD44 (table 4.5 and figure 4.5). Six down-regulated miRNAs were found to target 109 
mRNAs (13 experimentally observed, 96 predicted) associated with the Wnt/β-Catenin 
signalling pathway (table 4.6 and figure 4.6).  
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Table 4.6 Up-regulated miRNAs in zone III known or predicted to target genes associated 
with the Wnt/β-Catenin signalling pathway 
ID Mean FC Symbol Evidence
miR$138$5p* 1.624 ACVR2A High* (predicted)
ACVR2B High* (predicted)
AKT3 Moderate* (predicted)
CD44 Moderate* (predicted)
DVL2 Moderate* (predicted)
DVL3 Moderate* (predicted)
EP300 Moderate* (predicted)
GNAO1 Moderate* (predicted)
MARK2 High* (predicted)
MDM2 High* (predicted)
PPARD High* (predicted)
RARA High* (predicted)
SOX12 High* (predicted)
SOX13 High* (predicted)
SOX4 High* (predicted)
SOX5 High* (predicted)
SOX7 Moderate* (predicted)
SOX8 Moderate* (predicted)
SOX9 High* (predicted)
TCF3 High* (predicted)
TCF4 High* (predicted)
WNT2B Moderate* (predicted)
miR$1913 2.000 ACVR1C Moderate* (predicted)
AKT2 High* (predicted)
APC2 Moderate* (predicted)
CDH5 High* (predicted)
CSNK1D Moderate* (predicted)
EP300 Moderate* (predicted)
FRZB High* (predicted)
FZD9 Moderate* (predicted)
HNF1A Moderate* (predicted)
KREMEN2 Moderate* (predicted)
LEF1 Moderate* (predicted)
RARA Moderate* (predicted)
RARG High* (predicted)
SMO Moderate* (predicted)
SOX6 Moderate* (predicted)
SRC Moderate* (predicted)
TAB1 High* (predicted),Moderate* (predicted)
WNT3A High* (predicted)
WNT4 Moderate* (predicted)
WNT8B Moderate* (predicted)
WNT9B Moderate* (predicted)
miR$671$3p 1.910 WNT3A Moderate* (predicted)
WNT5A Moderate* (predicted)
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Figure 4.5. mRNA members of the Wnt/β-Catenin Pathway (highlighted in purple) targeted by miRNAs which 
were expressed at higher levels in zone III (in comparison to zone I) in healthy rats  
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Table 4.7 Down-regulated miRNAs in zone III known or predicted to target genes associated with the 
Wnt/β-Catenin signalling pathway 
ID Mean'FC Symbol Evidence ID Mean'FC Symbol Evidence
mmu#let#7f #2.280 ACVR1B High7(predicted) miR#16#5p #1.778 ACVR2A High7(predicted)
ACVR1C High7(predicted) ACVR2B High7(predicted)
ACVR2A High7(predicted) AKT3 High7(predicted)
ACVR2B High7(predicted) AXIN2 High7(predicted)
AKT2 High7(predicted) BTRC High7(predicted)
APC2 High7(predicted) CCND1
Experimentally7Observed,High7
(predicted)
CCND1 Experimentally7Observed,7High7(predicted) DVL1 Moderate7 (predicted)
CDH1 Moderate7 (predicted) FRZB Moderate7 (predicted)
CSNK1D Experimentally7Observed FZD10 High7(predicted)
DKK3 High7(predicted) FZD4 High7(predicted)
DVL3 High7(predicted) FZD6 High7(predicted)
FZD3 High7(predicted) JUN Experimentally7Observed
FZD4 High7(predicted) LRP6 High7(predicted)
KREMEN1 High7(predicted) PPM1L Moderate7 (predicted)
MYC Experimentally7Observed PPP2R1AHigh7(predicted)
NLK High7(predicted) PPP2R1BModerate7 (predicted)
PPP2R2A High7(predicted) PPP2R5C
Experimentally7Observed,High7
(predicted)
SOX13 High7(predicted) RARB High7(predicted)
SOX6 High7(predicted) SOX5 High7(predicted)
TGFBR1 Experimentally7Observed,High7(predicted) SOX6 High7(predicted)
TGFBR3 High7(predicted) TCF3 High7(predicted)
TP53 High7(predicted) TGFBR3 High7(predicted)
WNT1 Experimentally7Observed,7High7(predicted) TLE4 High7(predicted)
mmu#miR#
125b#5p #1.521 ACVR1C High7(predicted) WIF1 Moderate7 (predicted)
APC High7(predicted) WNT3A
Experimentally7Observed,High7
(predicted)
APPL1 Moderate7 (predicted) WNT4 High7(predicted)
BMPR2 High7(predicted) WNT5B High7(predicted)
CDH12 Moderate7 (predicted) WNT7A High7(predicted)
CDH5 Experimentally7Observed,High7(predicted) miR#218#5p #5.951 BCL9 High7(predicted)
CDKN2A Experimentally7Observed CDH2 High7(predicted)
CSNK1G1 High7(predicted) CSNK1E High7(predicted)
CSNK2A1 High7(predicted) DKK2 High7(predicted)
DVL3 High7(predicted) FZD4 High7(predicted)
MARK2 High7(predicted) GNAO1 High7(predicted)
PPP2CA High7(predicted) GSK3B High7(predicted)
PPP2R1B Moderate7 (predicted) MARK2 High7(predicted)
PPP2R4 High7(predicted) PPP2R2AHigh7(predicted)
PPP2R5C High7(predicted) PPP2R2C High7(predicted)
SFRP5 Moderate7 (predicted) PPP2R4 High7(predicted)
SMO Experimentally7Observed PPP2R5AHigh7(predicted)
SOX11 High7(predicted) RARA High7(predicted)
TLE3 High7(predicted) SFRP2 High7(predicted)
TP53 Experimentally7Observed,Moderate7 (predicted) SOX11 High7(predicted)
miR#129#1#
3p7 #4.551 BMPR2 Moderate7 (predicted) SOX5 High7(predicted)
DKK2 Moderate7 (predicted) SOX6 High7(predicted)
FZD10 Moderate7 (predicted) TCF4 High7(predicted)
GJA1 Moderate7 (predicted) TGFB2 Moderate7 (predicted)
MAP3K7 Moderate7 (predicted) WNT2B High7(predicted)
SOX10 Moderate7 (predicted) miR#329#3p #2.783 AKT2 High7(predicted)
TGFBR3 Moderate7 (predicted) AKT3 Moderate7 (predicted)
BCL9 Moderate7 (predicted)
BMPR2 High7(predicted)
BTRC Moderate7 (predicted)
CSNK1G3 High7(predicted)
CSNK2A1 High7(predicted)
H2BFM Moderate7 (predicted)
NLK Moderate7 (predicted)
PPP2R2C High7(predicted)
SOX17 High7(predicted)
TCF7L1 High7(predicted)
WNT1 High7(predicted)
WNT3 High7(predicted)
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Figure 4.6. mRNA members of the Wnt/β-Catenin Pathway (highlighted in purple) targeted by under-
expressed miRNAs in zone III (in comparison to zone I) in healthy rats  
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4.3.7 miR-122 is expressed at lower levels in zone III regions of the liver following 
paracetamol administration in rats 
In order to assess whether previously seen elevations in circulating miR-122 during 
paracetamol-injury are a product of miR-122 loss from the liver, we profiled miR-122 
individually using qPCR in zone I and zone III LCM-dissected liver tissue samples from rats 
administered with a toxic dose of paracetamol (1400 mg/kg), a sub-toxic dose (500 mg/kg) 
and vehicle for 24H (figure 4.7). MiR-122 expression was found to be significantly lower than 
control (vehicle zone III) in zone III of rats administered a high dose of paracetamol for 24 h 
(Control zone III vs 1400 mg/kg paracetamol zone III: p<0.05), with two out of the 5 rats 
measured displaying a lower response to paracetamol. Although not significant, zone I in the 
1400 mg/kg dose rats, and both zone I and III in the low dose rats also displayed a varied level 
of response to paracetamol. In situ hybridisation of miR-122 in the livers of rats administered 
with 1500 mg/kg paracetamol for 48 h displays a marked loss of miR-122 from hepatocytes 
in zone III regions when compared to vehicle control, with little or no change in zone I miR-
122 content (figure 4.8B).  
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Figure 4.7 Zonal analysis of miR-122 expression basally, and after mild or toxic dose of paracetamol, 
expressed as ΔCt normalised to the total RNA loaded. Rats were administered either a low-dose (500 mg/kg) or 
a high-dose (1500 mg/kg) of paracetamol for 24 h, after which their livers were subject to LCM to excise zone I 
and zone III of the liver for analysis. MiR-122 levels were then measured in each zone and compared back to vehicle 
control animals. It was found that all paracetamol groups displayed a varied response to APAP, but only the high-
dose zone III group showed a significant response to paracetamol (p < 0.05). 
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4.3.8 Differential changes in microRNA expression between zone I and III 24H after a toxic 
dose (1400mg/kg) of paracetamol 
In order to assess whether paracetamol causes changes in the tissue expression of miRNAs 
other than miR-122, we performed a separate global miRNA analysis of hepatic zone I, and 
zone III (n = 4), 24 h after administration of 1400 mg/kg paracetamol. ALT levels were seen 
to significantly elevated at 24 h post-dose similar to the findings in chapter 3 (figure 4.9). 
Correlation analysis of all detected miRNAs (421) between zone I and zone III suggested that 
there was a lack of correlation between the miRNA profiles of the two zones after 24 h 
paracetamol (Pearson R = 0.005; p = 0.918) (figure 4.10A). MiRNA profiles in each region 
from paracetamol-dosed rats were then compared to profiles from the same region in healthy 
non-dosed rats. Analysis of changes in the miRNA profile caused by paracetamol in zone I, 
demonstrated that miRNAs were both up and down regulated after paracetamol, with a greater 
number being significantly up-regulated (figure 4.10B and C, figure 4.11A and B). Analysis 
of significantly changed (p < 0.05) miRNAs in zone I demonstrated that the expression of 43 
miRNAs was changed, with 32 being up-regulated, and 11 being down-regulated. The same 
analysis of zone III demonstrates an even distribution of up- and down-regulated miRNAs 
when compared using a volcano plot. Expression analysis of significantly changed miRNAs 
demonstrates that the expression of 42 miRNAs was changed by paracetamol, with 22 being 
up-regulated, and 20 being down-regulated. 
To gain a greater understanding of the consequences of the dysregulation of these miRNAs, 
we performed a pathway analysis using IPA (Qiagen, Venlo, Netherlands) on the significantly 
changed miRNAs from each zone (analysis was performed separately for each zone). miRNA 
target filter analysis suggested that the significantly deregulated miRNAs from zone I, and 
zone III targeted 1874 and 3562 mRNAs, respectively. Analysis of these mRNAs using the 
IPA tox functions analysis was then performed. miRNAs changed in zone I were found to 
target mRNAs involved in both liver proliferation (6 out of top 20 significant pathways), and 
liver damage (14 out of top 20). Those changed in zone III were found to target mRNAs 
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involved in liver damage/necrosis (15 out of top 20) and liver proliferation/hyperproliferation 
(5 out of top 20) (table 4.9).   
Figure 4.9. Plasma ALT activity in rats administered with vehicle, 500 mg/kg paracetamol or 1400 mg/kg 
paracetamol for up to 24 h  
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Figure 4.11 Global analysis of microRNA expression changes (expressed as log fold-change) in zone I (N=4) 
and III (N=5) after paracetamol administration demonstrates that 43, and 42 miRNAs are significantly 
changes in zone I and III, respectively. 
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Table 4.8 Global analysis of microRNA expression changes in zone I and III after paracetamol 
administration demonstrates that 43, and 42 miRNAs are significantly changes in zone I and III, 
respectively. MicroRNAs are ranked based on significance following a t-test with a multiple comparison 
correction. The colour scheme is representative of the log fold change value, with red denoting higher values 
and green denoting lower value.  
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Table 4.9 Significantly changed microRNAs in zone I and III are associated with toxicological functions 
identified by IPA, such as liver proliferation (highlighted green) and liver damage (highlighted red). 
Significantly perturbed miRNAs following APAP were analysed using a miRNA targetscan followed by a downstream 
Ingenuity Tox Functions analysis in order to identify toxicological pathways predicted to be affected by these miRNAs. 
Significance was based on the number of downstream molecules predicted to be targeted and the concentration of 
molecules in specific pathways associated with these toxicological functions. The Tox Functions analysis suggested 
in the case of both zone I and zone III that the most predicted toxicological functions to be occurring were liver 
hyperplasia, hyperproliferation, proliferation, necrosis and cell death.  
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4.4 DISCUSSION 
MiRNAs have been shown to be potential circulating markers of drug-induced liver injury, 
however, little is known about changes in the tissue content of miRNAs in the liver during 
injury. Therefore, we undertook a study to identify zonal miRNA changes in pericentral (zone 
3) and periportal (zone 1) hepatocytes during paracetamol-induced injury in rats.  
Initially, we aimed to establish baseline zonal miRNA expression profiles through performing 
a global miRNA expression analysis in four healthy non-dosed rats. Although, Yamaura et al 
(2014) had previously carried out a similar analysis, we felt their use of a single array for each 
group in the analysis limited the robustness of their study and created difficulties in our 
identification of statistically significant differentially expressed miRNAs between the liver 
regions. Therefore, we looked to repeat this analysis with adequate numbers for appropriate 
statistical analysis, to ensure robustness in our identification of zone-specific miRNAs. 
Our global zonal miRNA analysis was able to detect 421 miRNAs which were identified in 
three or more rats in a single zone. Of these miRNAs we assessed that 45 were significantly 
differentially expressed between zone I and zone III, with 8 being up-regulated in zone III, 
and 41 being down-regulated. Similarly to Yamaura et al, we detected over 40 differentially 
expressed miRNAs, importantly however, only 9 of these miRNAs overlapped, and three of 
these had the opposite expression trend (miR-200c, miR-31*, miR-184). A possible 
explanation for this could be due to differences in study design, due to our study having 
multiple replicates allowing for statistical analysis and elimination of non-significant changes 
in miRNA expression. Another possible cause could be our choice of using fasted rats, 
whereas the previous study utilised fed rats. It has previously been established that blood 
content is a driver of many zonated processes, including gluconeogenesis and glycolysis; 
therefore, it is possible that miRNA expression is also affected by this. To account for this, we 
compared our differentially expressed miRNAs to a list of miRNAs generated in Yamaura’s 
study which were altered in their comparison of fed and fasted rats. We found that 14 of our 
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45 differentially expressed miRNAs were altered in the previous study by fasting, suggesting 
that fasting may partially explain the discrepancies in results between the two studies (Table 
4.10). Interestingly, this suggests that miRNA expression may be under the control of both 
environmental factors, such as food consumption, but could also be under the control of 
transcriptional mechanisms independent of external factors. It has previously been 
demonstrated that the zonal expression pattern of some proteins remains, even in conditions 
were the blood content was reversed between zone I and zone III, supporting that this may be 
also the case with miRNA expression (Tygstrup et al. 1962).   
 
Another aim of our study was to identify zone-specific miRNAs that could provide use as 
biomarkers of zone-specific liver damage, as well as providing possible candidates for miRNA 
regulators of zonation. We were able to identify 3 molecules expressed in only one zone, miR-
211, miR-23a and the precursor miRNA miR-9*. Although further validation is required in 
injury models of zone-specific injury, possibly comparing the zone III toxin paracetamol to 
the zone I toxin methapyrilene, these miRNAs offer potential use as mechanistic biomarkers 
of liver injury.  
 In order to assess the relevance of differential miRNA expression in the liver, we undertook 
pathway analysis of the significantly differentially expressed miRNAs in order to identify 
Table 4.10 Comparison of Yamaura et al (2014) to our study. MiRNAs detected in our study have been 
demonstrated to be regulated by feeding/fasting 
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possible biological pathways perturbed by these molecules, as well as specific mRNA targets. 
In our canonical analysis, ‘the molecular mechanisms of cancer’ was identified as the most 
significantly perturbed pathway. Although this is seemingly unrelated, this is not surprising 
as many miRNAs are commonly deregulated in cancer and therefore it is common for this 
type of analysis to identify this pathway as the most significant result, largely due to it being 
a heavily studied area. Importantly, the Wnt/β-Catenin pathway was identified in both our 
analysis of down-regulated microRNAs (in zone III) and up-regulated miRNAs in the top ten 
most perturbed pathways. The Wnt/β-Catenin pathway has previously been implicated as 
being the master transcriptional regulator of zonation within the liver in studies utilising beta-
catenin and APC KO models to remove zonation from the liver (Benhamouche et al. 2006). 
This provided the first evidence that miRNAs may be implicated in the regulation of zonation, 
however it is also possible that their zonated expression is a product of this transcriptional 
pathway. In order to further elucidate the role of miRNAs in the Wnt/β-Catenin pathway 
within the liver, we performed a target filter search to identify potential downstream mRNA 
targets of the differentially expressed miRNAs in our study. This analysis identified 109 
mRNA targets of 9 of the differentially expressed miRNAs, further suggesting that miRNAs 
may be involved in the regulation of this pathway. However, to fully understand the role of 
miRNAs in this pathway, studies must be undertaken to manipulate the levels of these 
miRNAs in order to establish a cause and effect relationship between these molecules and the 
potential mRNA targets. 
Studies examining hepatic miR-122 concentrations following paracetamol-administration 
have thus far produced mixed results, with one suggesting that hepatic miR-122 content is 
decreased in paracetamol-injury (Wang et al. 2009), and one suggesting that this is not the 
case (Bala et al. 2012). One possible explanation for the findings in Bala et al (2012) is that 
total hepatic miR-122 was measured, however it is probable that miR-122 is only lost from 
hepatocytes in the area surrounding zone III, the area undergoing damage in paracetamol-
injury. Therefore, measurement of total hepatic miR-122 may mask the magnitude of the 
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change in miR-122 levels within the liver. In order to resolve this, we aimed to both quantify 
and visualise hepatic miR-122 during paracetamol-DILI in specific regions of the liver, using 
both LCM followed by qPCR and in situ hybridisation of miR-122. Quantification of hepatic 
miR-122 levels in zone I and III demonstrates that there is a reduction of miR-122 in hepatic 
zone III of rats administered a toxic dose of paracetamol for 24 h. Interestingly, we also 
detected variable non-significant reduction of hepatic miR-122 after a high dose of 
paracetamol in zone I, and a low-dose of paracetamol in both zone I and III. This mixed 
response could be explained by inter-individual variation in the rats used and possible 
differences in the re-feeding patterns of the rats after fasting. To further confirm this reduction 
in zone III miR-122 levels, in situ hybridisation was performed on the livers of rats 
administered with a toxic dose of paracetamol (48 h). Even more clearly than our zonal qPCR 
analysis, we saw a marked loss of miR-122 from zone III areas after paracetamol, with no 
obvious loss of miR-122 in zone I regions. Therefore, through two different methods we have 
demonstrated that hepatic miR-122 is reduced during paracetamol-injury.      
After establishing that miR-122 levels change within the liver following paracetamol in a 
zonal manner, we aimed to examine whether the expression of other miRNAs were also altered 
following a toxic dose of paracetamol. We hypothesised that miRNAs would be lost 
indiscriminately from zone III due to the ongoing necrosis and breakdown of cells, whereas 
miRNA levels in zone I would be altered as a possible adaptive response to the ongoing 
damage in zone III. In order to do this, we performed a global microRNA profiling experiment 
on hepatic zone I and III of rats administered 1400 mg/kg paracetamol, and then compared 
these expression profiles back to those found in healthy non-dosed controls. Comparison of 
the miRNA profiles in zone I and zone III from rats administered with paracetamol suggested 
that there was little correlation between the two global profiles, in contrast to that of healthy 
controls, in which both were found to be highly correlative. This suggested that, as expected 
the zones were responding differently to paracetamol-treatment. When a comparative analysis 
was carried out between zones in paracetamol-dosed and healthy rats, we found that 43 and 
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42 miRNAs were changed significantly in zone I, and zone III respectively. It is interesting 
that an almost equivalent number of miRNAs were changed in zone I, as in zone III, despite 
no injury occurring in this area, suggesting that living cells in this region are responding to the 
damage ongoing in zone III. We found that the majority of miRNAs in zone I were up-
regulated (32 out of 43), further confirming that these expression changes were not due to 
necrotic damage and were due to an active response from the cells. When a downstream 
analysis was performed using IPA, examining the mRNA targets of these miRNAs, we found 
that the top three functions associated with targets were liver hyperplasia/hyperproliferation, 
liver proliferation and liver necrosis. This suggests that although there are functions associated 
with toxicity occurring, the most significant functions occurring in zone I at this point are 
proliferative, suggesting that this region may be adapting to paracetamol. Analysis of zone III 
miRNA expression changes after paracetamol demonstrated that 22 out of 42 miRNAs were 
down-regulated, which fits with the hypothesis that large-scale necrosis would cause a loss of 
miRNA from this region of the liver. However, the finding that 20 miRNAs were up-regulated 
was less expected, which suggests that there is some form of transcriptional response to the 
injury in this region. This is reflected when IPA was used to examine the top Tox Functions 
occurring in this region. The most significant function occurring in this region was found to 
be liver proliferation, with the second and third being cell death, and necrosis, suggesting that 
although widespread damage is occurring, so is an adaptive response to this. 
This suggests that a form of adaptation is occurring in unaffected regions of the liver, which 
may be as a response to compensate for the loss of zone III hepatocytes. These findings from 
both our study and the Yamaura study led us to generate two hypotheses for further 
investigation. First, that damaged hepatocytes in zone III have elicited this response in zone I 
hepatocytes through cell-cell signalling. Studies previously mentioned in chapter 3 have 
highlighted the complexity of cell-cell signalling through exosomal transport, which is just a 
single form of cell-cell communication. This was further highlighted by a study which 
demonstrated that hepatocyte-derived exosomes were able to longitudinally transfer RNA to 
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hepatic stellate cells, eliciting increased expression of nitric oxide synthase 2 (Royo et al. 
2013), and another which suggested that mice undergoing ischemia/reperfusion treated with 
hepatocyte-derived extracellular vesicles, demonstrated a higher level of hepatocyte 
proliferation (Nojima et al. 2014). Therefore, it is possible that stressed hepatocytes in zone 
III may use this form of cell-cell communication in order to produce an adaptive response in 
other cells in zone I. Further work could be performed utilising exosome release-blocking 
agents, such as manumycin-A (Mittelbrunn et al. 2011) in order to assess the role of exosomal 
cell-cell signalling on microRNA expression in zone  I, to fully understand whether this is part 
of an adaptive response in the liver. Our second hypothesis was that these changes in miRNA 
expression are driven directly by paracetamol in zone I hepatocytes, but due to zonal gene 
expression, zone I hepatocytes are not damaged, while zone III hepatocytes are. In 
paracetamol injury, hepatocytes in zone I will be similarly exposed to the same dose of 
paracetamol, as those hepatocytes in zone III. However, they are not susceptible to injury due 
to decreased CYP2E1 expression, and increased GSH expression. However, it may be possible 
that the parent-drug may elicit a form of active response. The role of the parent compound 
may be established using analogues of paracetamol, such as AMAP, which have previously 
been used to examine the role of covalent binding in paracetamol-toxicity (Qiu et al. 2001).    
In summary we have evaluated zonal profiles of miRNAs within the liver, identifying potential 
candidates for use as zonal biomarkers, we have established that miR-122 is lost from the liver 
during paracetamol-DILI, and we have found global miRNA profiles also change 
differentially between the zones after paracetamol. Further work should aim to validate these 
findings using simpler qPCR-based methods, followed by functional work to examine the role 
of these identified microRNAs in the regulation of zonation. Also, in order to validate the use 
of potential zone-specific miRNA biomarkers, work should now be performed using models 
of zonal injury, such as the comparison of paracetamol and methapyrilene toxicity in order to 
assess whether the expression of these markers is changed in the circulation in the correct 
pattern following injury. It will also be critical for these markers to undergo assessment in 
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human liver tissue in order to establish, first, that these miRNAs are present in humans and 
second, that they are expressed in a similar zonal manner. 
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5.1 INTRODUCTION 
The biliary system is responsible for the production of bile components, and the transport of 
bile into the duodenum. Biliary epithelial cells (BEC), which comprise of 3-5% of the total 
hepatic cell count, form the three-dimensional structure of the bile ducts which span from 
small intrahepatic bile ducts, through to the large extra-hepatic bile duct network (Sherlock 
1998). BEC are a heterogeneous species which range from small-BEC, which line the 
intrahepatic bile ducts, to large BEC which form the extra-hepatic bile duct network (Kanno 
et al. 2000). BEC are susceptible to injury caused by a number of toxins, including 
flucloxacillin (Lakehal et al. 2001), 5-fluorodeoxyuridine (Hohn et al. 1985) and fenofibrate 
(Hajdu et al. 2009). BEC are differentially susceptible to drug-induced liver injury (DILI), 
with small BEC being prone to ‘vanishing bile duct syndrome’ (VBD) (Desmet 1997; 
Strazzabosco et al. 2000), and large BEC being prone to direct drug-induced damage leading 
to cholestasis (Alpini et al. 1996; Lazaridis et al. 2004; Strazzabosco et al. 2000). VBD is 
characterised by the progressive, permanent loss of the intrahepatic bile duct structure, leading 
to long-term cholestasis (Desmet 1997). Small BEC also possess a high level of plasticity and 
are able to transdifferentiate into periportal (zone 1) hepatocytes, suggesting their importance 
in hepatocyte regeneration after injury (Limaye et al. 2008; Watanabe et al. 2008).  
Current circulating biomarkers of bile duct injury and cholestasis include alkaline phosphatase 
(ALP), γ-glutamyl transferase (GGT), and total bilirubin (T-BIL) (Dufour et al. 2000; Nishio 
et al. 2000; Ramaiah 2007). Each of these markers suffers from either a lack of specificity, 
possibility of false positives, or a lack of prognostic value. Therefore, new candidate 
biomarkers which are specific to BEC, and can be demonstrated to have prognostic value 
would be of great use in the diagnosis of bile duct injury and cholestasis, both in the clinic, 
and in drug development. MicroRNAs have previously demonstrated potential as biomarkers 
drug-induced liver injury, with miR-122 specifically being shown to be a prognostic, specific 
and sensitive marker of hepatocellular necrosis in paracetamol-, heparin- and alcohol-induced 
liver injury (Antoine et al. 2013b; Starkey Lewis et al. 2011). Other work has demonstrated 
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that miR-122 is not the only organ-enriched miRNA, with others such as miR-1 (heart), let-7i 
(brain) and miR-194 (kidney) being enriched in other organs (Ai et al. 2010; Balakathiresan 
et al. 2012; Sharkey et al. 2012). Therefore, we hypothesised that BEC may be enriched in 
specific miRNAs, which may have potential as circulating biomarkers of bile duct injury. To 
examine the potential of miRNAs as biomarkers of BEC/bile duct injury, and also whether 
miRNA profiles in both hepatocytes, and BEC can be linked to the overall function of these 
cell types, we isolated each cell type and performed a global microRNA profiling analysis in 
order to elucidate the basal microRNA profiles of these cell types. We then sought to identify 
miRNAs which were enriched in BEC over hepatocytes for future validation as potential bile 
duct injury biomarkers.   
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5.2 METHODS 
5.2.1 Animals 
The protocols described within this thesis were performed by personal licence holders 
according to the regulations defined within the project licence granted under the Animals 
(Scientific Procedures) Act 1986 and approved by the University of Liverpool ethics 
committee. CD-1 mice were purchased from Charles River (Manston, UK) or Harlan and 
housed at a constant temperature and humidity with free access to food and water. Mice were 
allowed to acclimatise for at least 7 days before any experimental procedure and were kept in 
a 12-hour light/dark cycle (Lights on: 08:00/Lights off: 20:00).  
5.2.2 Isolation of hepatocytes from mouse liver  
Hepatocytes were isolated by a modified two-step collagenase perfusion method, as 
previously described in Li et al. (2010). Briefly, mice were anaesthetised using pentobarbital 
(1 µL/g), after which a V-shaped transverse incision was made on the abdomen to reveal the 
intestinal cavity. The intestines were then moved to the left to reveal the hepatic portal vein 
and vena cava. A small clamp was then used to close the hepatic artery and the hepatic portal 
vein was cannulised using an 18 G winged catheter. The liver was then perfused for 9 minutes 
using a wash buffer (10x Ca2+ -free Hanks Balanced Salt Solution, 5.8 mM HEPES, 4.5 mM 
NaHCO3) to remove circulating blood before being digested by digestion buffer (wash buffer, 
0.05% w/v collagenase, 0.068% w/v trypsin inhibitor, 5 mM CaCl2) for 5 minutes. Following 
the digestion, the liver was excised into a petri dish, washed with wash buffer and the liver 
capsule was disrupted using blunt forceps to release the digested cells. The cell suspension 
was then filtered through a 100 µm cell strainer to remove the vasculature resulting in a 
mixture of parenchymal and non-parenchymal cells.  
The cell suspension was centrifuged to pellet hepatocytes (30 g for 2 minutes at 4 °C). The 
hepatocyte pellet was then re-suspended in wash buffer and the centrifugation step was 
repeated to pellet the hepatocytes. This step was twice repeated before cells were counted and 
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viability was assessed using a trypan blue exclusion method (20 µL trypan blue: 100 µL cells). 
Only isolations with a viability of above 85% were used for experiments. Hepatocytes were 
then pelleted (30 g for 2 minutes at 4 °C) and re-suspended in 700 uL of Qiazol for RNA 
analysis. 
5.2.3 Isolation of mouse biliary epithelial cells 
A mouse hepatocyte isolation was first performed (see above). The remaining liver capsule 
and vascular bed (minus hepatocytes) was retained, and finely diced using a scalpel. The diced 
tissue was then suspended in a collagenase solution (1 g/L collagenase type A, Roche, 
Switzerland in RPMI medium, Sigma Aldrich) for 1 h. The digested tissue was then pelleted 
by centrifugation (500 g for 5 min), and re-suspended in a cell dissociation medium (800 mg/L 
Trypsin in 1x PBS) for 20 min. The dissociated cell solution was then passed through a 22 G 
needle three times and incubated with a monoclonal antibody targeted at epithelial cell 
adhesion marker (EPCAM, 1 µL/mL, Abcam, Cambridge, UK) for 1 h (37 °C). The cell 
solution was then incubated with Dynabeads (Life Technologies, CA, USA) coated with sheep 
anti-rabbit monoclonal secondary antibodies (1 h, 4 °C). The solution containing BEC bound 
to Dynabeads was then subject to a magnetic field to remove contaminants, followed by 
washing with 1x PBS (repeat 5x). The purified BEC bound to Dynabeads were then suspended 
in 700 µL Qiazol (Qiagen, Venlo, Netherlands) or 1x PBS.  
5.2.4 Determination of Total Protein Concentration of Samples 
Total protein concentration was determined as described in previous chapters. 
5.2.5 Immunoblotting and immunohistochemistry 
Immunoblotting and immunohistochemistry was performed as described in chapter 2 using 
antibodies targeted against epithelial cell adhesion marker (EPCAM; Abcam ab32392; 1 h at 
1:5000), keratin-19 (K-19; Abcam ab52625; 1 h at 1:10,000), γ-glutamylcysteine ligase 
catalytic subunit (GCLC; Abcam ab41463; 1 h at 1:10,000), albumin and cytochrome P450 
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2E1 (cyp2e1; Abcam ab28146; overnight at 1:5000). Antibodies were then incubated with 
their corresponding species of horseradish peroxidase conjugated secondary antibody for 1 h 
at a dilution of 1:10,000. 
5.2.6 miRNA extraction and purification 
miRNA was extracted and purified using the method described in Chapter 3.  
5.2.8 Global microRNA quantification in BEC and Hepatocytes 
A global microRNA analysis was performed on isolated BEC and hepatocytes using the 
Agilent microRNA hybridisation array platform, as per the manufacturer’s guidelines (Agilent 
Biosystems, CA, USA). 
5.2.9 Expression analysis, statistical analysis and pathway mapping 
Initial data processing was carried out using GeneSpring (Agilent), or using the R2-based 
AgiMicroRna software (Bioconductor) and Graph Pad Prism for statistical analysis. Groups 
were compared using multiple t-tests followed by a Bonferroni multiple comparisons 
correction, with significance being set at p < 0.05. Pathway mapping was carried out using the 
Ingenuity Pathway Analysis Software (Qiagen, Venlo, Netherlands) miRNA targetscan 
method.   
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5.3 RESULTS 
5.3.1 A modified to two-step perfusion method, followed by antibody purification is able to 
produce a pure population of BEC and hepatocytes 
To validate the anti-Epcam antibody selected for BEC immunoprecipitation (IP), 
immunohistochemistry was performed on sections of healthy mouse liver tissue using this 
antibody (figure 5.1A). The sections clearly display areas of staining (brown stain) 
surrounding the large bile ducts in the portal region of the liver, and also staining within the 
tissue surrounding hepatocytes, suggesting the detection of intrahepatic BEC. Upon successful 
validation of the IP antibody, BEC and hepatocytes were isolated from CD-1 mice using a 
modified two-step collagenase perfusion method, followed by characterisation. Analysis of 
the BEC markers, Epcam and keratin-19 (k-19) demonstrated that these markers were enriched 
in isolated BEC lysates, and not detectable in hepatocyte lysates (figure 5.1B). Conversely, 
the hepatocyte markers, albumin and glutamate-cysteine ligase, catalytic-subunit (Gclc), were 
enriched in hepatocytes over BEC. Analysis of cyp2e1, a member of the cytochrome P450 
family demonstrated that this marker was expressed at higher levels in hepatocytes, with a 
low-level of expression in BEC (figure 5.1B). 
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  A 
B 
Figure 5.1 IP antibody validation and characterisation of BEC. A, Immunohistochemical staining of 
healthy mouse liver sections using an anti-EPCAM antibody to target Epcam (brown-stain), a cell-surface 
marker present on the cell-membrane of BEC. B, Western blot analysis of the BEC markers, K-19 and 
Epcam, and the hepatocyte markers albumin and Gclc, as well as Cyp2e1.  
Gclc
Cyp2e1
Albumin
Epcam
K.19
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5.3.2 Global microRNA analysis of BEC and hepatocytes identifies differential rank 
expression profiles between the cell types 
In order to identify possible microRNA biomarkers of BEC injury, we performed a global 
miRNA profiling analysis in both BEC, and hepatocytes in order to establish rank expression 
profiles of miRNAs, and possible differentially expressed miRNAs. Global miRNA 
expression analysis in healthy BEC identified 111 individual miRNA species, with the top 
three ranked miRNA being miR-5109 (Mean intensity/MI: 503267.4, S.D.: 133149.2), miR-
6243 (MI: 278441.5, S.D.: 162571.1), and miR-1224-5p (MI: 78147.22, S.D.: 65911.07) 
(Figure 2). Global miRNA expression analysis in healthy hepatocytes identified 33 individual 
miRNA species, with the top three ranked miRNA being miR-122-5p (MI: 15340.3, S.D.: 
1308.3), miR-5109 (MI: 13548.3, S.D.: 1139.3), and miR-6243 (MI: 9871.2, S.D.: 1105.2) 
(figure 5.3).   
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Figure 5.2 Rank expression profile of primary mouse BEC microRNAs. Normalised intensity values represent the 
mean of normalised intensity values generated off n = 5 individual array plates. Normalised values are generated using 
multiple incorporated standard miRNAs on each array plate and Agilent GeneSpring pre-processing software 
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Figure 5.3 Primary mouse hepatocyte rank microRNA expression profile. Normalised intensity values represent 
the mean of normalised intensity values generated off n = 5 individual array plates. Normalised values are generated 
using multiple incorporated standard miRNAs on each array plate and Agilent GeneSpring pre-processing software 
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5.3.3 BEC and hepatocyte enriched miRNAs 
To identify miRNAs which were differentially expressed between BEC and hepatocytes, the 
global miRNA profiles of each cell type were subject to comparison, and statistical analysis 
using multiple t-tests, followed by a multiple comparisons correction to identify significantly 
enriched miRNAs in either cell type. Comparison of the two profiles revealed that 92 miRNAs 
were significantly up-regulated in BEC over hepatocytes and of these miRNAs 85 were only 
detectable at a negligible level within hepatocytes, suggesting relative enrichment in BEC 
(figure 5.4 and table 5.1). Conversely, 25 miRNAs were upregulated in hepatocytes over BEC, 
of which 8 miRNAs were detected in hepatocytes, which were not detected in BEC (miR-194-
5p, miR-378b, miR-365-3p, miR-455-3p, miR-378d, miR-107-3p,	  miR-130a-3p,	  miR-192-
5p). Several miRNAs were found to be significantly enriched in BEC over hepatocytes, 
including miR-574-5p (Fold-change: 7416.2, p < 0.05), miR-721 (FC: 5734.4; p < 0.05), and 
miR-1187 (FC: 3310.9, p < 0.05) (figure 5.5). MicroRNAs were also detected that were 
significantly enriched in hepatocytes over BEC, including miR-107-3p (FC: 93.3, p < 0.05), 
miR-194-5p (FC: 72.9, p < 0.05) and miR-378b (FC: 61.7, p < 0.05) (figure 5.6). The 
previously examined hepatocyte-enriched miRNA, miR-122 was found to be present in both 
cell types, but enriched in hepatocytes over BEC (FC: 5.4, p < 0.05). Another characterised 
hepatocyte-enriched miRNA, miR-192 was only detectable in hepatocytes and not in BEC 
(MI: 172.84; S.D.: 163.3).    
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Table 5.1 MicroRNAs detectable in BEC, but not in hepatocytes. Average values represent the mean 
normalised intensity reading obtained from the analysis of n = 5 mice per group (individual array plates 
per mouse) 
Name Average S.D. Name Average S.D.
mmu-miR-574-5p 7416.2 5880.9 mmu-miR-6418-5p 404.6 311.4
mmu-miR-721 5734.4 4680.5 mmu-miR-652-5p 395.3 301.5
mmu-miR-1187 3310.9 2586.8 mmu-miR-6392-3p 391.3 350.4
mmu-miR-3470a 2880.6 2296.7 mmu-miR-466q 373.3 142.1
mmu-miR-3082-5p 2412.9 1795.8 mmu-miR-1892 328.6 183.8
mmu-miR-714 1864.9 1125.5 mmu-miR-125a-3p 322.4 262.6
mmu-miR-1895 1763.8 460.4 mmu-miR-483-5p 315.8 166.3
mmu-miR-3072-5p 1524.3 375.4 mmu-miR-690 292.0 117.0
mmu-miR-328-5p 1446.8 851.6 mmu-miR-32-3p 247.9 236.3
mmu-miR-1306-3p 1335.7 761.0 mmu-miR-5113 243.2 184.4
mmu-miR-5112 1265.0 844.7 mmu-miR-706 237.4 126.3
mmu-miR-3102-5p.2-5p 1222.3 257.9 mmu-miR-468-3p 227.7 220.5
mmu-miR-5107-5p 1214.7 379.9 mmu-miR-5131 211.2 159.0
mmu-miR-1904 1077.0 355.4 mmu-miR-3572-5p 211.0 131.5
mmu-miR-6368 1075.2 450.7 mmu-miR-681 205.8 123.3
mmu-miR-3472 1011.1 705.7 mmu-miR-691 193.3 157.7
mmu-miR-3095-3p 909.2 461.4 mmu-miR-3067-3p 191.2 99.9
mmu-miR-467f 811.7 281.7 mmu-miR-6352 190.9 115.9
mmu-miR-1982-5p 780.3 629.8 mmu-miR-450a-2-3p 176.0 81.1
mmu-miR-466h-3p 772.1 228.0 mmu-miR-1967 163.1 92.7
mmu-miR-5128 755.7 403.0 mmu-miR-6240 162.6 110.4
mmu-miR-1897-5p 750.1 266.3 mmu-miR-466f-3p 160.7 64.2
mmu-miR-3099-3p 723.8 384.6 mmu-miR-1940 157.6 102.2
mmu-miR-712-5p 636.8 368.9 mmu-miR-466i-3p 153.3 75.0
mmu-miR-5119 617.7 143.4 mmu-miR-3110-3p 149.3 102.0
mmu-miR-760-3p 585.9 417.0 mmu-miR-669c-3p 139.4 74.6
mmu-miR-1196-5p 579.0 210.8 mmu-miR-6370 139.0 122.6
mmu-miR-669p-3p 565.8 214.5 mmu-miR-423-5p 126.0 96.8
mmu-miR-669n 540.8 493.2 mmu-miR-6354 123.6 66.5
mmu-miR-3473a 537.8 178.0 mmu-miR-6349 120.5 73.5
mmu-miR-1894-3p 533.8 248.9 mmu-miR-6343 111.6 61.9
mmu-miR-149-3p 532.3 236.9 mmu-miR-3473e 102.7 63.0
mmu-miR-6385 521.6 330.2 mmu-miR-1971 98.8 64.6
mmu-miR-5130 517.4 320.9 mmu-miR-6351 90.3 49.5
mmu-miR-705 491.9 105.0 mmu-miR-5132-5p 86.8 49.3
mmu-miR-3077-5p 473.5 273.1 mmu-miR-5103 74.1 43.9
mmu-miR-370-3p 463.5 172.2 mmu-miR-3075-5p 68.8 66.2
mmu-miR-1934-3p 461.5 62.4 mmu-miR-195a-3p 62.4 59.7
mmu-miR-1231-5p 433.2 101.2 mmu-miR-5118 43.4 32.6
mmu-miR-680 428.9 156.3 mmu-miR-6394 38.9 35.7
mmu-miR-1906 423.7 172.6 mmu-miR-327 28.9 18.9
mmu-miR-1896 418.3 82.6 mmu-miR-30c-1-3p 27.6 15.0
mmu-miR-6405 409.0 141.2
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Figure 5.4 Volcano plot comparison of the global microRNA profile of BEC, compared to hepatocytes. 
Comparison of negative log2 P-value versus log2 fold-change of mean values taken from n = 5 mice per group. 
Each individual data point represents an individual miRNA species. Significance is set at p<0.05 (-log2 p<1.3). 
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Figure 5.5 BEC microRNA profile in comparison to the microRNA profile of hepatocytes. Mean fold-
change (FC) values represent the mean calculated intensity value derived from n = 5 array plates (n = 5 mice 
per group) for the group (BEC), divided by the same value derived from the other group (hepatocytes). The 
three most significantly enriched miRNAs in BEC over hepatocytes were found to be miR-574-5p, miR-721 
and miR-1187. The miRNAs highlighted in red, miR-467f and miR-712-5p have been identified in a recent 
study examining markers of cholestatic injury as being elevated (miR-467f: 5-fold elevated, miR-712: 3-fold) 
in the circulation during ANIT injury (Church et al. 2015) 
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Figure 5.6 Hepatocyte microRNA profile compared to the microRNA profile of BEC. Mean fold-change 
(FC) values represent the mean calculated intensity value derived from n = 5 array plates (n = 5 mice per 
group) for the group (hepatocytes), divided by the same value derived from the other group (BEC) 
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5.4. DISCUSSION 
The current biomarkers of BEC/bile duct injury are prone to false positive readings, are not 
specific to BEC, and have little prognostic value. Therefore, new biomarkers with better 
characteristics would be useful within the clinic and industry in order to diagnose bile duct 
injury early in its course. MicroRNAs have previously been shown to be useful prognostic 
markers in several forms of DILI, due to their organ specificity, stability, and ability to be 
detected in the circulation earlier in the course of injury than the current gold-standard markers 
of DILI. This phenomenon is not solely restricted to the liver, with other studies demonstrating 
that miRNAs are enriched within other organs, such as the heart and kidneys. Because of this, 
we hypothesised that a miRNA species may be enriched, or even be specific to BEC cells, 
offering the possibility that it may be used as a circulating biomarker of BEC injury.  
In order to identify possible miRNA biomarkers of BEC injury we performed a global 
microRNA profiling analysis of primary isolated BEC and hepatocytes, in order to determine 
whether each cell type displays a differential miRNA expression profile, and also whether any 
miRNAs are enriched in BEC. Our global microRNA analysis indicated that miR-5109, miR-
6243, miR-5105 were highly expressed in both cell types, however post-analysis, it has now 
been demonstrated that these miRNA are derived from a fragments of large sub-unit ribosomal 
RNA (Castellano and Stebbing 2013), therefore they cannot be considered for further analysis. 
This highlights the speed at which the field of miRNAs is developing, and also the importance 
of validating the existence of miRNAs detected when using global profiling studies. After 
removal of these miRNA from the analysis, we found that the top three ranked miRNAs in 
BEC were miR-1224-5p, miR-5126 and miR-494-3p, and in hepatocytes were miR-122-5p, 
miR-3963 and miR-6366.  
The detection of miR-122-5p as the most enriched miRNA in hepatocytes was expected, as it 
has previously been suggested that this species makes up ~70% of the miRNA content of the 
liver (Lagos-Quintana et al. 2002), and has previously been shown to be the most enriched 
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miRNA in primary human hepatocytes (Kia et al. 2014). Both miR-3963 and miR-6366 are 
recently discovered miRNAs which have yet to be fully investigated in context to the liver. It 
has previously been demonstrated that miR-3963 has a role in myogenic differentiation in a 
myoblast cell line (Katase et al. 2015).  
Interestingly, each of these miRNAs was also detected within BEC cells, with miR-122-5p, 
miR-3963 and miR-6366 being the 19th, 14th, and 11th most enriched miRNAs in BEC. This 
suggests that none of these markers can be classed as truly hepatocyte specific, and that miR-
122 is a liver-tissue-specific biomarker, as it is present in at least two liver cell types. 
Therefore, we have generated the following hypotheses to explain this, first, although the 
method for BEC extraction contains several purification steps, there may be some residual 
hepatocyte carry-over, due to the sheer abundance of both hepatocytes in the liver, and miR-
122 in the hepatocytes (Wang et al. 2009). Therefore, only a small number of hepatocytes left 
within the sample could produce this result. Second, miR-122 may be present within BEC, as 
previously much of the work examining miR-122 expression has only focussed on whole liver 
tissue (Lagos-Quintana et al. 2001); making the assumption that miR-122 is only present 
within hepatocytes without validation. Our hypothesis is not without reason, as it has been 
shown that small BEC are able to transdifferentiate to become zone I hepatocytes, 
demonstrating that these cells share the same lineage (Limaye et al. 2008). And finally, it may 
be possible that our extraction method may also have isolated oval cells (liver progenitor 
cells), which may express a low-level of miR-122, due to them representing the cells which 
are able to differentiate to form hepatocytes (LeCluyse et al. 2012). 
Similarly, the three most enriched miRNAs in BEC were also detectable within the 
hepatocytes, with miR-1224-5p, miR-5126, and miR-494-3p being the 7th, 10th and 11th most 
enriched miRNAs in hepatocytes in our analysis, suggesting that they will not offer value as 
a BEC-specific miRNA.  Additionally, miR-1224-5p has previously been suggested to be a 
circulating biomarker several forms of cancer, including primary colon cancer (Ogata-Kawata 
et al. 2014), miR-5126 has been detected in adipose and brain tissue (Tao et al. 2015; Zhao et 
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al. 2015), and miR-494-3p has been implicated in prostate cancer (Shen et al. 2014), 
suggesting a lack of organ/cell-specificity.  
To eliminate miRNAs which were present in both hepatocytes and BEC, we performed a 
comparison analysis of the two global microRNA profiles, in order to identify miRNAs 
enriched, or only detected in one cell type, in order to increase the possibility of discovering 
a cell-specific miRNA. In this analysis we were able to identify 106 miRNAs which were 
enriched in BEC over hepatocytes, and 11 miRNAs which were enriched in hepatocytes over 
BEC. Of these miRNAs, 85 were only detected in BEC, and 8 others were only detected in 
hepatocytes. The three most enriched miRNAs detected only in BEC were miR-574-5p, miR-
721, and miR-1187. Examination of the literature surrounding these molecules suggests that 
miR-574 has been implicated in non-small cell lung cancer (Foss et al. 2011), and miR-721 in 
stimulation of iPS cell generation (Pfaff et al. 2011), suggesting that neither is specific for 
BEC. Investigation of the literature examining miR-1187 suggests this microRNA is down 
regulated in the liver in acute liver failure, and that use of a miR-1187 mimic is able to inhibit 
caspase-8 activation and apoptosis in hepatocytes in acute liver failure, however there is little 
knowledge presented of whether this miRNA is present within hepatocytes in the liver or 
within non-parenchymal cells (Yu et al. 2012). In fact, of the 85 miRNAs detected only in 
BEC, all were found to be implicated in pathologies or processes elsewhere in the body, 
suggesting that our analysis was unable to find a completely BEC-specific miRNA. However, 
future studies will evaluate whether there is sufficient enrichment in BEC that may make these 
miRNAs sufficiently BEC-selective to be useful cell markers. Interestingly, in a recent study 
which aimed to examine hepatobiliary injury and biliary hyperplasia, two miRNAs which 
were identified as BEC-enriched in our study, namely miR-467f (5-fold increase) and miR-
721 (3-fold) were demonstrated to be elevated in the plasma of rats administered the model 
hepatotoxin alpha-napthylisothiocynate (ANIT), and FB004BA, a proprietary compound 
synthesised by Bayer (Bayer Pharmaceuticals, Germany) known to cause hepatobiliary injury 
(Church et al. 2015). ANIT is of particular interest because it is understood to initially cause 
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BEC injury, leading to secondary development of hepatocellular injury, followed by a 
recovery phase which entails cellular regeneration and compensatory biliary hyperplasia 
(Kossor et al. 1993), making it an ideal compound to investigate potential biomarkers of 
biliary cell injury. Unfortunately, due to methodological difference between our study and the 
study performed by Church et al. (2015), a number of the miRNAs we identified as BEC-
enriched were not investigated in their study. Therefore, if a study was performed using a 
wider range of miRNA species similar to the study performed using ANIT, more potential 
biomarkers may be identified from the work performed within our study.  
A limitation of our study was that we isolated BEC as a single species, however as previously 
discussed in this thesis, BEC are a heterogeneous species which differ depending on their 
location along the biliary tract (Glaser et al. 2006). Due to this heterogeneity, BEC are 
differentially affected by DILI-causing compounds. Therefore, to build on this relatively 
simplistic experiment, counter-flow elutriation could be utilised in order to separate different 
BEC species, based on their size, in order to identify differential expression of microRNAs 
between different BEC species. This could then be used to identify markers of different types 
of biliary tract injury. An additional limitation may be a product of the use of the microRNA 
array platform, limiting our analysis to only previously known miRNAs, and not potentially 
new species, which may have been identified with sequencing approach. Therefore, a possible 
direction for the future would be to build on the global microRNA profile of this cell type 
using an approach which would allow the identification of novel miRNA sequences. 
In summary, we were able to identify different global miRNA profiles of BEC and hepatocytes 
in CD-1 mice. Further future work, after the limitations of this study were addressed could 
aim to examine the utility of BEC-enriched miRNAs, which were not detectable in 
hepatocytes as biomarkers of BEC injury in complex cell culture systems which have 
incorporated this cell type to mimic the overall structure of the liver. 
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6. GENERAL DISCUSSION 
As described throughout this thesis, our aim to identify, examine and validate novel 
biomarkers of DILI was driven by the current lack of sensitive and specific biomarkers to 
diagnose this pathology (Reviewed by Hornby et al. (2014)). In this chapter we briefly outline 
the major findings of this thesis, the implications of our findings, possible future work and 
finally, we discuss future perspectives on the wider field as a whole.  
6.1 MAJOR FINDINGS  
We approached our major goal from several perspectives, first, we investigated mechanisms 
behind the early release of miR-122 in DILI (Antoine et al. 2013a; Harrill et al. 2012; Starkey 
Lewis et al. 2011; Wang et al. 2009). In our study we aimed to understand whether miR-122 
was released actively in exosomes early in DILI, however in our study we found no evidence 
to suggest that this was the case, but we did find that the percentage of this marker in exosomes 
began to rise in the recovery phase of DILI, which suggests possible implications in hepatic 
regeneration. Our results are in line with current research which suggested that miR-122 is 
mainly contained free-from exosomes which no specific exosome-bound release in acute 
forms of DILI (Bala et al. 2012). 
Our second aim was to identify new miRNA biomarkers of DILI through examination of cell-
specific, and hepatic zonal miRNA profiles. To do this we sought to develop methods for the 
isolation of hepatic non-parenchymal cells, and also specific areas of the hepatic architecture. 
Our study examining zonation in hepatic miRNA expression demonstrated that certain 
miRNAs are expressed in a zonal pattern, with several being highly enriched in either zone I 
or zone III. This suggests the potential for miRNAs to not only predict hepatic injury, but also 
to provide an insight into in which zone injury is occurring. Our study also suggested a 
possible role for microRNAs in the regulation of zonation, through modulation of the Wnt/β-
catenin pathway, the molecular driver of zonation (Burke et al. 2009), hinting at the possible 
mechanistic role of miRNAs in liver zonation. Then in chapter 5, we provided the first view 
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of the global microRNA expression profile of BEC, and compared this to that of hepatocytes, 
in order to identify cell-specific enriched miRNAs. Despite the preliminary stages of this 
work, we were able to identify several miRNAs which were enriched in BEC over 
hepatocytes, and even more interestingly several more of these have recently been shown to 
be elevated in the circulation in an ANIT model of biliary tract injury (Church et al. 2015).  
Finally, we aimed to gain a greater understanding of the mechanisms behind the formation of 
3-NT adducts in DILI through utilising paracetamol and FS rodent models of DILI. The major 
finding of our study was that although the two hepatotoxins cause injury through separate 
pathways, they both lead to 3-NT formation suggesting that there are multiple mechanisms 
for the occurrence of this adduct, both through and independent of the mitochondria.  
6.2 IMPLICATIONS OF FINDINGS AND FUTURE DIRECTIONS 
Aside from our main hypotheses which have been discussed in depth in each chapter and 
briefly above, there is the possibility that our findings will have implications for the wider 
fields of DILI and DILI biomarkers, which will now be outlined in the following section.  
Our finding that exosome-bound miR-122 is elevated in the recovery phase of DILI may 
suggest that these molecules may have a use in drug-development for the prediction of 
mechanisms surrounding DILI, or moreover as therapeutic molecules in their own right 
(Reviewed in Suntres et al. (2013), with studies now demonstrating that exosomes derived 
from stem-cells or perturbed cells may be able to modulate an adaptive or proliferative 
response in recipient cells (Herrera et al. 2010; Tan et al. 2014). There is already some 
evidence to suggest that extracellular vesicles may accelerate a proliferative response. In a 
study examining the hepatectomy model in rats, the authors were able to show that 
administration of human liver stem cell-derived microvesicles accelerated hepatic 
regeneration following hepatectomy (Herrera et al. 2010). Another study demonstrated that 
exosomes sourced from hepatocytes treated with alcohol are able to directly transfer miR-122 
to monocytes, inhibiting the HO-1 pathway and sensitising the cells to LPS (Momen-Heravi 
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et al. 2015). This, in contrast to the first study mentioned, may suggest that miR-122 is actively 
being shed in DILI to active the hepato-protective HO-1 pathway in perturbed hepatocytes. 
However, further work examining the effects of blocking exosome release, using molecules 
such as manumycin (Mittelbrun et al. 2011), during the recovery phase of injury should be 
undertaken in order to fully establish a cause-and-effect role of circulating exosomes in an 
adaptive response to injury. If it was possible to establish this link, miR-122 could have an 
important therapeutic role as a promoter of liver regeneration. Interestingly, the targeting of 
miR-122 is not novel however, as pharmaceutical companies are currently developing an 
antagonist of miR-122 in order to block the replication of the Hepatitis C virus (Bhat et al. 
2013; Regulus Therapeutics: http://www.regulusrx.com/therapeutic-areas/rg-101/), in which 
miR-122 has previously been shown to play a role (Fukuhara et al. 2012). Similarly, a number 
of studies are now studying the potential of exosomes as therapeutic targets and as a method 
of drug delivery (Reviewed by Johnsen et al. 2014). Therefore, this taken as a whole, suggests 
that exosome-bound miRNA research in the future may be better directed towards examining 
mechanisms of injury, and the modulatory effects of these molecules, rather than seeking out 
exosome-bound miRNAs as biomarkers of acute injury. 
A current major focus of the DILI field is the development of complex cell culture models in 
order to reduce the use of animal models and also to improve on the relative lack of availability 
of cell culture models which accurately predict DILI. Current model systems such as HepG2, 
a human hepatoma cell line and Hepa1c, a mouse hepatoma cell line which are still commonly 
used in toxicity studies, have long lives in culture, but lack in the expression of many important 
drug metabolism enzymes, such as CYP2E1 (cyp2e1), limiting their true predictive ability 
(Wu and Cederbaum 2008). Conversely, primary human hepatocytes, the current gold 
standard cell culture model for the examination of DILI are the closest match to human 
hepatocytes in situ, but they de-differentiate quickly which limits their useful life (Rowe et al. 
2010; Heslop et al. 2016). Because of this, groups are now focussed on producing cell culture 
systems which contain multiple cell-types in organ-like systems in the hope that if conditions 
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are more closely matched to those in vivo then cells will maintain their phenotype and 
metabolic activity for longer period (Maschmeyer et al. 2015). Examples of which are the 
LiverChip which incorporates Kupffer cells, endothelial cells, stellate cells and hepatocytes 
on a single microfluidic chip arranged similarly to the liver acinus (Bushan et al. 2013), and 
bioprinted human liver tissue developed by Organovo, a California-based biotechnology 
company which involves 3D printing of multiple liver cell types in a normal liver like structure 
(Murphy et al. 2015). Our work in developing a method for BEC isolation may offer its use 
for the production of these liver models, in order for them to contain bile duct-like structures 
in order to more closely match the phenotype of the parent liver, if it is found that our method 
is transferable to human liver tissue. Additionally, if it can be established that a miRNA, or a 
group of miRNAs are involved in driving the zonal phenotype, possibly through the Wnt//β-
Catenin pathway, it is possible that our work may have wider long-term implications in the 
development of in vitro models for the examination of DILI. If this was the case, it may be 
possible to generate zone I-like, or zone III-like hepatocytes using miRNA knock-down, or 
transfection approaches to manipulate miRNA levels within these cells, it would be of great 
use in the assessment of new compounds. Inhibitors of miRNAs, such as Antagomirs, have 
been used previously to silence the function of miR-16, miR-122, miR-192 and miR-194 in 
vivo in order to gain a greater understanding of the roles of these molecules, demonstrating 
the feasibility of this approach (Krutzfelt et al. 2005). 
A further outcome of our work may be that zonal- and cell-enriched miRNAs may have the 
potential to identify zone-specific or cell-specific injury in pre-clinical models, in clinical 
trials and also in the complex cell-culture systems mentioned previously. However, limitations 
of these markers may become apparent because of their lack of liver-specificity, due to their 
expression in other cell-types and organs (Chitnis et al. 2012; Packer et al. 2008). However, 
this issue could be mitigated through the use of a panel of miRNAs, encompassing miR-122, 
in order to diagnose general hepatocyte injury, and then zone-specific markers in order to 
identify the localisation of the injury. This could be progressed further through the use of cell-
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specific biomarkers, such as the miRNAs identified in our study examining BEC, to develop 
a full miRNA panel capable of identifying general injury, the zone in which injury is taking 
place and any other cell types undergoing injury. This approach is not novel and has previously 
been suggested for the identification of types of cancer (Wang et al. 2015; Zheng et al. 2014; 
Tan et al. 2014a) and has been used as a standard approach in DILI for a number of years in 
which ALT, AST and bilirubin were used in combination (Kaplowitz et al. 2006). 
6.2 FUTURE PERSPECTIVES ON PROGRESSING MICRORNAS AS DILI 
BIOMARKERS 
6.2.1 Barriers to the progress of miRNA biomarkers towards use in the clinic 
Much of the work within this thesis has focussed on the development of miRNAs as 
biomarkers of DILI, however before these markers can truly become challengers to the current 
gold standard biomarker of DILI, ALT, several points must be addressed. 
Despite the work in this thesis and in the wider literature, the greatest hindrance towards the 
development of miRNAs as clinical biomarkers are the assays which are used to quantify 
them. The most common technique for miRNA quantification is reverse transcription-
quantitative PCR (RT-qPCR), which despite having a high level of sensitivity, is inappropriate 
for clinical use as it can take up to 8 hours to perform the assay (Kramer et al. 2011). In the 
case of paracetamol acute liver injury, the onset of toxicity may be rapid and therefore this 
test would be too slow to provide prognostic value (Starkey Lewis et al. 2011). In comparison, 
the assay to detect ALT is relatively simple requiring little sample preparation and extremely 
quick, with the time between sampling and results being as little as 90 minutes (Reviewed by 
Huang et al. 2006). Another consideration is cost, analysis of a single miRNA sample can 
currently cost as much as £20, whereas this cost can be as little as £1 for analysis of serum 
ALT, creating another barrier to the progression of miR-122 towards becoming a mainstream 
biomarker. To facilitate the transition of miRNAs from a proof-of concept biomarker to a true 
clinical bedside test, a fast, robust, simple and sensitive new clinical assay must be developed 
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for the rapid quantification of miRNAs in accessible biofluids. Several novel assays are 
currently in development for the detection of miRNAs that would be more suitable in a clinical 
setting, however none have yet undergone the rigorous testing required for use. Recently, a 
group developed a label-free method to quantify miRNAs through the use of gold nanoparticle 
networks and a duplex-specific nuclease (DSN) which allowed detection of miRNAs at sub-
femtomolar levels, with almost no sample preparation required (Shen et al. 2013). Another 
group, Cissel et al, have developed a microtiter plate assay to quantify miRNAs, using Renilla-
luciferase labelled microRNA as a competitor to free microRNA for binding to a 
complementary microRNA probe. An assay which takes a total of 1.5 hours, requires no PCR 
amplification step and is sensitive down to a femtomolar level (Cissel et al. 2008). In addition 
to those examples, many other novel methods for microRNA quantification have emerged, in 
which silicon nanowire biosensors (Zhang et al. 2009), universal tagged probes and time-
resolved fluorescence technology (Jiang et al. 2012), and solution-phase detection of miRNAs 
(Broyles et al. 2012) are all used to detect miRNAs with high levels of sensitivity. However, 
until one of these methods is fully validated and accepted, miRNAs as biomarkers will remain 
a concept within the clinic and not a reality.  
Another consideration for progressing miR-122 to becoming a mainstream biomarker, is the 
establishment of a baseline level of miR-122 within humans, much like the ULN value used 
for ALT, as little is currently know about inter-individual variability in this biomarker. Inter-
individual variation of miRNAs was first documented in a study using significance analysis, 
in which 4 miRNAs were identified that were 63-95% higher in females, compared to males 
(Duttagupta et al. 2011). In another study, Wang et al demonstrated differences in miRNA 
content of human male serum samples; specifically, miR-130b and miR-18b were slightly 
higher in males compared to females (Wang et al. 2010). The significance of this in DILI is 
still unknown and will require further study. This however, highlights the need for studies 
which assess baseline levels across different population groups and patient groups for 
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individual miRNAs. This information would then allow clinicians to set an upper limit of 
normal for each of these biomarkers across a population. 
6.3 FINAL THOUGHTS AND CONCLUSION 
To conclude, our overall aim was to investigate novel biomarkers of DILI, which we addressed 
through examining release forms of miR-122, zonal and cellular hepatic miRNA profiles, and 
cellular patterns of 3-NT formation in DILI, with our findings suggesting that future work 
should be focussed on understanding the regulatory roles of these potential biomarkers, as 
well as their combined use alongside other current biomarkers.  
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6.3 FINAL COMMENTS 
Finally, the hypotheses addressed in this thesis will be commented on individually:  
Hypothesis 1 
Paracetamol and FS both produce necrosis in centrilobular regions of the liver, but both 
compounds cause this toxicity through distinct routes. We hypothesise that formation of 3-
nitrotyrosine adducts, a marker of oxidative stress, will occur during paracetamol injury, but 
will not occur during FS injury, due to lack of mitochondrial damage in FS injury. 
Comment: We were able to successfully develop a western blot and IHC method for the 
detection of 3-nitrotyrosine adducts. However, in contrast to our hypothesis we found that 3-
NT adducts were detectable in both paracetamol-, and FS-DILI despite the divergent routes 
of toxicity. In order to further understand the cause of this, a proteomic assessment of the 3-
NT adductome should be performed to assess whether any localisation of 3-NT adducts is 
present within the cell, in order to assess the causative factor of the nitration.  
Hypothesis 2 
miR-122 is detectable earlier in the course of DILI than conventional DILI markers due to its 
mechanism of release. We hypothesise that miR-122 is released actively from the liver in 
exosomes upon receiving a toxic insult in order to adapt to circumvent DILI. 
Comment: Analysis of the profiles of exosome-bound and exosome-free miR-122 throughout 
the course of a rat model of paracetamol-DILI, suggested that miR-122 is in fact released in 
similar profiles in both fractions. This suggests that our initial hypothesis was incorrect and 
that miR-122 release is likely to be due to non-specific release after loss of plasma membrane 
integrity. Further work must be done in less severe models of DILI in order to assess the 
relevance of active miRNA release into the circulation as a method of cell-cell signalling.  
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Hypothesis 3 
Liver microRNAs are expressed zonally depending on their proximity to a portal or ventral 
vein, and these expression changes will be related to hepatocyte phenotype and function in 
these regions. Upon liver injury by paracetamol, we expect to observe changes in microRNA 
expression in the region surrounding the central vein, however we also hypothesise that 
expression changes may occur away from this region in order to adapt to the oncoming 
toxicity.  
Comment: Analysis of the global microRNA profiles of zone I and zone III of the liver 
suggests that miRNAs are indeed differentially expressed depending on the location across 
the port-central axis. Interestingly, the differentially expressed miRNAs can also be related 
back to the Wnt/Beta-Catenin pathway, the molecular driver of zonation, which suggests that 
miRNAs may play a role in the zonated phenotype of the liver. Further work involving the 
manipulation of these miRNAs will have to be performed in order to fully understand their 
role in zonation. 
Hypothesis 4 
Intrahepatic biliary epithelial cells, which undergo damage during cholestatic injury, will 
contain a unique microRNA profile, differing from the surrounding hepatocytes. This profile 
will allow the selection of specific markers of BEC which will provide use as biomarkers of 
damage to this cell type in cell models, pre-clinical animal models, and possibly within the 
clinic.  
Comment: A method was successfully established for the isolation of BEC from mouse liver, 
and global profiles of hepatocyte and BEC miRNAs were generated. However, all miRNAs 
identified only in BEC had also been implicated in other forms of tissue/cell injury in prior 
studies, suggesting that none would be a suitable marker of BEC-specific injury. Further work 
must be done to establish whether any of these miRNAs could offer use as an in vitro marker 
of BEC-injury.      
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Drug-induced liver injury (DILI) is a common form of adverse drug reaction seen within the
clinic. Sensitive, specific and non-invasive biomarkers of liver toxicity are required to help
diagnose hepatotoxicity and also to identify safety liabilities during drug development.
Limitations exist in the current gold standard DILI biomarkers: alanine aminotransferase is not
liver-specific and therefore gives rise to false-positive signals. Interest has grown in the
potential of microRNAs (miRNAs) as biomarkers of DILI. Some miRNAs display remarkable
organ specificity, can be measured sensitively and are stable in a wide range of biofluids.
However, little is currently known about the mechanisms through which miRNAs are released
from cells. Furthermore, a clinically suitable method to measure miRNAs has not yet been
developed. This review aims to highlight the current research surrounding these markers
and areas in which further work is required to establish these markers within clinical and
pre-clinical settings.
KEYWORDS: acetaminophen • DILI • exosome • hepatocyte • injury • liver • miR-122 • miRNA
Drug-induced liver injury
The liver is the main organ responsible for the
detoxification of xenobiotics and natural tox-
ins. Due to the biotransformational capacity of
the liver, it is prone to generating chemically
reactive metabolites, which makes the liver
particularly susceptible to drug-induced liver
injury (DILI) [1]. DILI is a complex disease
that can be classified into two subcategories,
type A and type B. Type A DILI occurs in a
predictable and dose-dependent manner, usu-
ally at supratherapeutic doses, such as in the
case of acetaminophen (APAP) overdose. In
contrast, type B DILI is idiosyncratic in nature
and usually occurs at a therapeutic dose. The
susceptibility of a patient to DILI can be
influenced by host factors including age, sex,
nutrition, poly-pharmacy (including alcohol),
co-morbidity and genetics. To date, over
1000 different drugs have been associated with
hepatotoxicty independent of drug class or
disease indication (National Institute of Health
Database of drugs and supplements associated
with liver toxicity [2,3]). DILI is a common
adverse drug reaction seen within the clinic in
Europe and the USA, representing a major
impediment to the generation and accessibility
of new medicines [1]. It is a major clinical con-
cern and led to 40,393 deaths in the USA
alone in 2010 [4]. Because of this, sensitive
biomarkers of DILI are required to facilitate in
its diagnosis, direct treatment strategy within
the clinic and also detect safety liabilities reli-
ably during drug development. A biomarker
by definition is ‘a characteristic that is objec-
tively measured and evaluated as an indicator
of normal biological processes, pathogenic pro-
cesses or pharmacological responses to a thera-
peutic intervention’. For a biomarker to be of
clinical use, it must have both biological and
bioanalytical sensitivity, tissue/organ specificity,
easy accessibility and it must display a change
early enough for a therapeutic intervention to
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be effective. Furthermore, a prognostic marker would direct in
patient management to help the physician provide appropriate
treatment (TABLE 1) (see review [5]).
Clinical & pre-clinical biomarkers of DILI
The current gold-standard biomarkers of liver injury are alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) [6]. These enzymes are involved in amino acid biosynthe-
sis and are released into the circulation following hepatocyte
cell membrane breakdown during necrosis. Despite these
markers being the gold standard, they suffer from a lack of
liver specificity; ALT exists in two isoforms (ALT1 and ALT2),
which are expressed in heart, kidney and muscle tissue to dif-
ferent degrees. Therefore, these enzymes may not only report
on liver injury. ALT1 has been demonstrated to be expressed
in high levels in human liver tissue, as well as being the most
abundant isoform detectable in human serum. Importantly
however, ALT1 is also detectable in high levels in kidney and
muscle tissue, which would hamper the use of an isoform-
specific assay [7]. As a product of this, ALT has previously been
demonstrated to be elevated in cases of muscle injury [8].
A variety of studies have also demonstrated that ALT levels
may become raised in humans undertaking extreme endurance
sports events [9]. Additionally, ALT can be raised by hyperali-
mentation [10] and basal expression can be induced by drugs [11].
ALT2 does not offer use as a biomarker of liver injury, as it is
expressed at negligible levels in the liver [7].
Due to the clear lack of an appropriate clinical biomarker
to detect DILI, the usual method of practice in clinics in the
UK is to establish a causal relationship between the drug in
question and the possible diagnosis of liver damage. To
establish this relationship, several qualitative scoring systems
have been developed, a commonly used example of which is
the Roussel Uclaf Causality Assessment Method/Council for
International Organizations of Medical Sciences scale, which
was developed by Danan and Beni-
chou [12]. The Roussel Uclaf Causality
Assessment Method/Council for Inter-
national Organizations of Medical Sci-
ences scale takes the type of liver injury
into account (hepatocellular, cholestatic
or mixed) and is a qualitative system
that scores on seven criteria: temporal
relationship, clinical course, risk factors,
concomitant drugs, non-drug etiologies,
likelihood of reaction based on pub-
lished research and response to re-
challenge [13]. The score developed from
this scale then allows clinicians to cate-
gorize patients based on their risk of
developing DILI. The limitations of this
system have now been highlighted in
several studies, which suggest that the
lack of a clear scoring method and non-
intuitive output have limited the reli-
ability of this system [14,15]. In the UK, the current method
of practice is to assess the risk of poor outcome (i.e., develop-
ment of liver failure) in cases of liver injury using the King’s
College Criteria, developed at the Liver Unit, King’s College
Hospital, London [16]. The King’s College Criteria is also
qualitative system, which takes into account blood pH, serum
creatitine, grade of encephalopathy and prothrombin time to
assess patient’s prognosis of outcome [16,17].
Outside of the clinic, in pre-clinical drug development, the
current FDA-endorsed approach in the USA is the combina-
tion of four markers, ALT, AST, alkaline phosphatase and total
bilirubin, which provides an integrated assessment of liver func-
tion. This approach is based on Hy’s law, which states that if a
drug causes ALT/AST levels to increase to >3! upper limit of
normal (ULN) and total bilirubin levels to increase above 2!
ULN and there is not an obvious indication of viral hepatitis
or other obvious cause, a drug is likely to cause hepatotoxicity.
Despite this approach, each of these markers is limited by the
possibility that they may also rise in other indications, aside
from liver injury [18]. AST, similar to ALT, is liable to rise in
muscle injury [6]; bilirubin detection can also be a by-product
of erythrocyte hemolysis through macrophage-mediated
recycling of the released hemoglobin into unconjugated
bilirubin and also several other non-DILI-related condi-
tions [19,20]. Serum alkaline phosphatase, a marker of cholestasis,
is also not liver-enriched and may rise in bone diseases and in
pregnancy [21].
Recently, interest has grown surrounding a class of small
non-coding RNAs, miRNA as potential blood-based bio-
markers. miRNAs are small (~22 nucleotides long), RNA-
based molecules, which are implicated in gene regulation at a
translational level [22]. Having been discovered in the early
1990s as key regulators of development [23–25], recent work
has suggested they may play a role in the pathology of a wide
range of diseases. miRNAs have also been found to be
Table 1. The ideal characteristics of a potential biomarker
of drug-induced liver injury.
Characteristic
Specificity The biomarker should be informative of the status of a specific
organ or pathology
Sensitivity The biomarker should be sensitive enough to detect liver injury
early and without false positive
Translatable The biomarker should be applicable to both humans and pre-clinical
species to aid the process of new drug development
Detectable The biomarker assay should be easy and quick to measure in the
clinic without the need for specialist equipment
Repeatable The biomarker assay should be robust and data should be
reproducible between laboratories
Non-invasive The biomarker must be present within accessible biofluids for
ease of access
Diagnostic The biomarker should be easy to interpret to allow clinicians to
design a treatment strategy
Review Hornby, Starkey Lewis, Dear, Goldring & Park
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present and highly stable in biofluids, such as blood and
urine, so can be easily accessed in a non-invasive manner.
The stability of miRNAs has been attributed to the various
forms in which they are released from cells, including in
vesicle-encapsulated forms [26] and protein-bound com-
plexes [26,27]. Some miRNAs demonstrate remarkable tissue
enrichment, such as miR-218 in the brain/muscle [28],
miR-1 in the heart [29] and miR-122 is present almost exclu-
sively in the liver, representing approximately 70% of the
total liver miRNA content [30].
miRNAs are usually encoded by intron sections of DNA
and are initially formed as pri-miRNAs (~thousands of nucleo-
tides in length), which are cleaved within the nucleus by Dro-
sha, a class 2 RNase III enzyme [31], to form pre-miRNAs
(~70 nucleotides). Pre-miRNAs are actively exported from the
nucleus to the cytosol through transporters such as exportin
5 [32]. Within the cytosol, pre-miRNAs form a RNA-induced
silencing complex (RISC) with proteins such as argonaute
2 (Ago2) [33], where they are then cleaved further by Dicer, an
endoribonuclease, to liberate mature single-stranded miRNAs
(reviewed extensively in [34]). Mature miRNA/RISC complexes
target specific mRNAs through antisense recognition via the
miRNA sequence and thereby regulate RNA translation
through a variety of mechanisms (FIGURE 1) [35,36]. miRNAs play
an important role in embryogenesis [37], cell differentiation [38],
tissue homeostasis [39], carcinogenesis [40], cardiotoxicity [41] and
viral infections [42]. Importantly, miRNAs can be also highly
conserved between species [43]. Because of this, they have great
potential as translational biomarkers in pre-clinical models, as
well as in the clinic.
This review aims to highlight the current knowledge sur-
rounding miRNAs as biomarkers of DILI and provides a pro-
spective outlook on the clinical impact that these markers may
have in the coming years.
Protein
Exosome
release
Protein
Guide strand
Dicer
Ago2
RISC
Gene regulation
miRNA/RISC
complex
Mature
miRNA
Pri-
miRNA
Pre-
miRNA
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Passenger strand
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D
Figure 1. Mechanisms of miRNA processing, function and release into the circulation. (A) miRNA transcription, processing and
function. (B) miRNA/protein complex formation and export from the cell through current unclear mechanisms. (C) miRNA packaging into
exosomes in the multivesicular body and subsequent release from the cell through exocytosis. (D) miRNA release in microparticles bud-
ding from the cell membrane.
Ago2: Argonaute 2; RISC: RNA-induced silencing complex.
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APAP-induced liver injury
Because of the unpredictable nature of idiosyncratic DILI, no
single experimental model or compound is currently available to
examine mechanisms of this indication. Therefore, other models
must be utilized to understand the mechanisms of this complex
indication and discover novel biomarkers of DILI. APAP, the
most commonly used analgesic and antipyretic in the world, is a
potent liver toxin in both humans and rodents when taken at
supratherapeutic doses, causing damage in a well-defined and
dose-dependent manner. This predictable nature explains why
much of the literature surrounding potential biomarkers of DILI
has focused on APAP as a ‘model-compound’ to examine mecha-
nisms of liver injury and also potential translational biomarkers
to diagnose DILI. Additionally, in 2012–13 there were approxi-
mately 46,000 documented cases of APAP overdose in English
emergency rooms (National Health Service Information
Centre – Hospital Episode Statistics for England). Similarly, in
the USA, 100,000 cases of APAP poisoning per year were docu-
mented, representing a major issue to public health and also to
the healthcare budget [44].
In the case of APAP overdose in the clinic, an increase in
serum ALT activity is not usually observed until at least 12 h
after APAP ingestion, therefore, ALT is not useful as an early
prognostic marker to determine an appropriate treatment regi-
men. Due to the lack of an early biological marker that can be
used prognostically, the current method to stratify patients who
are at risk of developing severe liver injury is to measure plasma
APAP concentration using the Rumack-Matthew nomo-
gram [45]. However, such a chemical readout has limitations
since it assumes equal risk among patients, which is clearly not
the case. Therefore, an early biological readout that could pro-
vide ‘patient-specific’ prognostic value would be hugely benefi-
cial to the clinical management of APAP-induced acute liver
injury (ALI). The limitation of the APAP nomogram was
highlighted in a recent letter to the editor in which a case-
report of a 25-year-old male who had consumed an APAP
overdose was documented. The male presented at the Royal
infirmary of Edinburgh 4.5 h after ingesting a single dose of
co-codamol (60–70 tablets, 30–35 g of APAP, 480–560 mg
codeine) and blood was taken to assess the APAP content. The
APAP content in the blood was shown to be 107 mg/l and
this was deemed low risk by the UK guidelines (Rumack-Mat-
thew nomogram; original high-risk cut-off was 200 mg/l [45])
at that time and because of this the patient was discharged.
The patient then re-presented at hospital 43 h later showing
signs of hepatotoxicity. Since then, the UK guidelines have
been lowered to classify 100 mg/l APAP as requiring treatment;
however, in countries such as North America, New Zealand
and Australia, which still classify 150 mg/l APAP as the cutoff,
this patient would still be sent home after first presentation [46].
miRNAs as potential biomarkers of DILI
Initially, many of the studies examining the potential of miR-
NAs to serve as biomarkers focused on the use of these mole-
cules to detect cancer [47]. However, recent studies have
demonstrated the utility of some liver-enriched miRNAs, in
particular miR-122, as possible markers of DILI and other
forms of liver injury. A growing body of evidence shows that
miR-122 plays an important role in the physiology of the
hepatocyte. Several web-based algorithms predict that miR-122
may target several thousand genes, but most of these are yet to
be experimentally verified (for experimentally verified miRNA
target prediction database, refer to [48]). Studies utilizing anti-
sense oligonucleotides in mice to inhibit miR-122 have
established its role in the regulation of lipid and cholesterol
metabolism [49]. It was observed that when miR-122 function
is abolished, the translation of important enzymes in these pro-
cesses becomes deregulated, such as cholesterol 7a-hydroxylase
[49]. Additionally, studies in human hepatocellular carcinoma
(HCC) cell lines have demonstrated that miR-122 has
been associated with hepatocyte differentiation through post-
transcriptional repression of CUTL1, a transcriptional repressor
of genes involved in cell differentiation [36].
In pathological states, it has been shown that miR-122 may
play a role in the development of cancerous tumors and in hepa-
titis C virus (HCV) infection ( [50]; reviewed by [51]). In a study
examining the replication of HCV, it was observed that HCV
was unable to replicate in cell lines that did not express
miR-122 (HepG2) when compared with cell lines that were
miR-122 positive (Huh 7). This was further explored utilizing
antisense strategies to knock-down miR-122 expression, which
consistently noted impaired HCV replication [50]. Interestingly,
miR-122 is now being investigated as a drug target for HCV in
Phase II studies [52]. In HCC, miR-122 is specifically downregu-
lated in both humans and rodents [53], and interestingly, has been
demonstrated to modulate cyclin G1 in HCC-derived cell lines.
Further studies in primary tumor cells lines have demonstrated
an inverse expression relationship between miR-122 and cyclin
G1, suggesting that downregulation of miR-122 in HCC may
affect the cell cycle [54]. Mice that are genetically deficient of
miR-122 are viable but develop spontaneous liver lesions and
HCCs early in life [55,56]. Therefore, it is clear that miR-122 plays
an important role in liver biology and defines the phenotype of
the mature hepatocyte (FIGURE 2).
Due to the large abundance and remarkable liver enrichment
of miR-122, several studies examined the use of this miRNA to
serve as a circulating biomarker of liver injury. In a study examin-
ing APAP-induced ALI in mice, the authors were able to demon-
strate that miR-122 as well as another liver-enriched miRNA,
miR-192, detected liver injury earlier and at lower toxic doses,
than ALT activity when measured in serum [57]. To test the trans-
lational potential of miR-122 and miR-192 as biomarkers of
DILI, a study examining these markers in 53 patients admitted
to hospital after taking an APAP overdose was performed. We
demonstrated that miR-122 and miR-192 were raised in serum
when compared with healthy controls. Another observation in
this study was that miR-122 levels return to baseline between
3 and 7 days after initial hospitalization, whereas serum ALT lev-
els remained elevated [58]. This suggests that miR-122 has a
shorter circulatory half-life, which may allow miR-122 to closely
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reflect the actual state of the liver more than a biomarker, which
remains in the circulation for a long period of time without deg-
radation. More recently, a study examining the utility of several
mechanistic biomarkers of DILI in patients who had ingested a
single toxic dose of APAP demonstrated that initial
miR-122 levels at hospital presentation were able to predict max-
imum ALT activity and peak international normalized ratio score
during the hospital stay of the patient, while initial ALT activity
could not. This highlighted for the first time that miR-122 is
raised very early during liver injury in man, and may provide
prognostic value to identify patients who develop liver injury [59].
Moreover, miR-122 was raised as early as 4 h after a toxic APAP
dose, almost 8 h before an increase in ALT levels is usually
detected in serum. The importance of this was highlighted in a
recent letter to the editor described in an earlier section of the
review [46]. Despite the patient being classified as ‘low-risk’ when
assessed using the Rumack-Matthew nomogram [45], on retro-
spective analysis of blood biomarkers taken upon first presenta-
tion at the hospital, miR-122 levels were measured to be
approximately 50! ULN, while ALT levels remained at baseline.
Importantly, in this case miR-122 would have directed clinicians
to administer N-acetylcysteine treatment, instead of sending the
patient home and allowing the progression of the toxicity [46].
Importantly, Starkey-Lewis et al. [58] demonstrated that
miR-122 may also be a sensitive marker of DILI caused by
other drugs, aside from APAP. In a single case of clarithromy-
cin-induced liver injury, serum miR-122 was demonstrated to
be elevated, correlating with serum ALT, similar to APAP-
induced DILI. Since this initial study, circulating miR-122 lev-
els have been demonstrated to report on other drugs associated
with DILI, such as heparin [60] and in several experimental
models associated with liver injury in rodents, including galac-
tosamine- and alcohol-induced liver injury [8]. In a study exam-
ining the effects of chronic subcutaneous heparin injections in
48 healthy male subjects, which the authors proposed caused
mild hepatocyte necrosis, miR-122 was demonstrated to rise in
the serum, peaking 7 days after the study began. These results
were said to be consistent with hepatocyte leakage in necrotic
Hepatitis virus
replication
Hepatocellular
carcinoma formation
Hepatocyte
differentiation
Cholesterol
metabolism
7-Hydroxycholesterol
Cholesterol
EndogenousPathological
Hepatocyte
regeneration
miR-122
HO
HO OH
Figure 2. The endogenous and pathological roles of miR-122. Under endogenous conditions, miR-122 is involved in the regulation
of 7a-hydroxylase translation, an enzyme that converts cholesterol into 7-hydroxycholesterol in cholesterol metabolism. miR-122 is also
involved in the regulation of hepatocyte differentiation and maintenance of hepatocyte phenotype in endogenous conditions. In patho-
logical conditions, miR-122 has been suggested to have a role in hepatocyte regeneration after injury, hepatitis virus replication and also
in the formation of hepatocellular carcinoma.
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conditions and importantly the dynamic range of miR-122
was higher than that of alternative protein biomarkers, such
as ALT (peak miR-122: 8–16! baseline; peak ALT: <1–12!
baseline) [60]. These data collectively suggest that miR-122
could be a liver-specific, early and sensitive marker of DILI
within the clinic, which may be able to predict the severity
of the pathology.
In addition to the utility of miR-122 as a biomarker of DILI,
it has also been demonstrated to be used as a marker of viral hep-
atitis. Zhang et al. was able to show that plasma miR-122 levels
change in a disease–severity relationship in patients infected with
hepatitis B virus, showing a strong correlation with plasma ALT
activity [8]. Additionally, miR-122 levels were raised earlier in the
plasma and correlated strongly with histological grading. The
strength of miR-122 as a biomarker (vs ALT) was tested using a
ROC analysis and a multivariate logistic regression analysis,
which suggested that miR-122 is a stronger biomarker of hepati-
tis B virus-associated liver injury than ALT [8]. In a different
study examining patients with chronic hepatitis C viral infection
(CHC), serum miR-122 levels were shown to strongly correlate
with serum ALT levels in patients undergoing necroinflamma-
tion associated with CHC [61]. However, miR-122 did not corre-
late with changes in liver function and also the fibrosis stage of
hepatitis, suggesting in CHC, miR-122 is a marker of cellular
damage and not overall liver function [61]. An additional study
testing the value of miRNAs as biomarkers to distinguish
between HCC and chronic viral hepatitis using a ROC analysis
was able to support miR-122 as a strong biomarker of cellular
damage. However, miR-122 was only able to distinguish patients
with chronic viral hepatitis from healthy controls and not from
patients with HCC, once again suggesting that miR-122 is a
marker of hepatocyte damage [62].
miRNA stability in circulation & forms of release
Despite the RNA-based structure of miRNAs, which can be
degraded quickly by cellular RNases, miRNAs are extremely sta-
ble in biofluids [47]. Stability is an ideal quality for a biomarker,
as clinical samples in their very nature are unlikely to be col-
lected, processed and stored in exactly the same way, especially
without an accepted universal protocol. Previous work has attrib-
uted this stability to the various forms in which miRNAs exist in
the circulation [26]. Previously, miRNAs have been detected in
the circulation within various biofluids, such as serum, plasma
and urine, enveloped within small vesicles [63,64]. The importance
of which in biomarker discovery has be discussed in detail in a
recent Toxicology letter published by a division of the FDA [65].
More recently, miRNAs have been detected circulating in a
vesicle-free form, in which miRNAs are in complex with a pro-
tein or lipoprotein complex [26,27,66].
Vesicle-based miRNAs
Exosomes
Exosomes are a class of phospholipid nanovesicle, around
30–150 nm in diameter, which are formed within endocytic
compartments called multivesicular bodies and are then released
into the circulation through exocytosis [67]. Exosomes were ini-
tially thought to be cellular debris and harbor no function.
However, now it is understood that exosomes play a distinct
role in cellular signaling, which allows them to play a role in
the development of malignancies [68] and in the spread of viral
infections [69]. Their full endogenous role still requires study
due to their relatively recent discovery [70]. Exosomes are
released from a myriad of cell types, including hepatocytes [67]
and inflammatory cells [71], and have been demonstrated to
contain cellular proteins, DNA, mitochondrial DNA [72], RNA,
lipids as well as miRNAs (ExoCarta provides an encyclopedia
of recorded exosome contents; [73]). miRNAs can associate with
multivesicular bodies at the pre-miRNA stage, controlled by
the presence of specific sequence motifs in the miRNAs [74]
and are then packaged into exosomes before release into the
circulation, which is controlled by a ceramide secretory sys-
tem [75]. Exosomes can be extracted from circulating biofluids
through a variety of methods including ultracentrifugation [76],
immunoprecipitation [77] and through use of specific exosome
isolation solutions (Exoquick, SBI, Cambridge Bioscience,
Cambdrige, UK/Life Technologies, Paisley, UK). The presence
of exosomes in solution can be accessed through monitoring
the presence of specific exosome markers such as CD63 [78] or
TSG101 [79], using molecular biology techniques such as west-
ern blotting or through visualization and measurement using
electron microscopy or nanoparticle tracking analysis [76,79,80].
Microparticles
Microparticles are a class of secretary vesicles, >100 nm in
diameter, which are formed through ‘blebbing’ of the plasma
membrane and are distinctly different from exosomes in their
qualitative/quantitative content [81]. This process is regulated by
intracellular calcium levels, cytoskeleton protein reorganization
and changes in membrane lipid asymmetry [82]. Microparticle
release has been documented to take place during cellular apo-
ptosis and is thought to be a cellular response to attempt to
reverse apoptosis [83]. Changes in the levels of plasma micropar-
ticles have been associated with many disease states, including
cardiovascular disease [83], metabolic syndrome [84] and diabetes
(Type 1 and 2) [85]. Similar to exosomes, microparticles have
been shown to be implicated in cell–cell signaling, showing
function in recipient cells [86]. Witek et al. demonstrated that
liver-derived microparticles can alter gene expression in recipi-
ent liver endothelial cells through Hedgehog signaling [87].
Microparticles, like exosomes, have been demonstrated to con-
tain protein, DNA, RNA and lipids. Interestingly, in a study
examining the content of microparticles secreted from mesen-
chymal stem cells, the RNA content of microparticles almost
exclusively consisted of miRNAs, demonstrating that packing
of these vesicles is a selective process, which does not necessarily
reflect the donor cell content [88]. Interestingly, this study
found that hsa-let-7b and hsa-let-7g are secreted in their imma-
ture pre-miRNA forms, which would allow them to form a
mature-miRNA/RISC complex in effector cells and elicit an
effect on RNA translation [88]. This role is yet to be understood
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fully and much work is still required before the role of
microparticle-packaged miRNA is understood. Previous studies
examining microparticles have focused on the use of ultracen-
trifugation techniques to separate these vesicles from other
vesicles such as exosomes and also from the microparticle-
depleted supernatant of biofluids. The success of this extraction
is usually then monitored through the presence of microparticle
markers, such as phosphatidyl serine and annexin V in both
the extracted microparticle solution and the supernatant [89].
Protein & lipid complexes
miRNAs have also been detected in the circulation of pro-
tein complexes. In a study examining the miRNA content of
the different fractions (microvesicles, exosomes and exosome-
depleted supernatant) of cell culture medium of several
human cell lines, including HepG2s, it was observed that a
striking amount of miRNAs were present in the vesicle-
depleted solution, suggesting that some miRNAs are present
in a vesicle-free form. The authors proposed that these miR-
NAs were bound in protein complexes and demonstrated
that a nucleophosmin 1 (NPM1), a protein which has previ-
ously been shown to be involved in ribosomal export from
the cell, was able to protect synthetic miR-122 from degra-
dation by RNAses. This provides some evidence that NPM1
may provide the remarkable stability of vesicle-free miRNA
in the circulation [90]. Turchinovich et al. built on this work
in both cell lines and also in human blood plasma, demon-
strating that the majority of circulating miRNAs are present
in a vesicle-free form. However, through immunoprecipita-
tion studies they suggested that miRNAs existed in a com-
plex in the circulation with Ago2, a member of the RISC
complex, as opposed to NPM1. One viewpoint is that per-
haps circulating miRNAs on the most part are a by-product
of dead cells that are released into extracellular space bound
to intracellular proteins upon the breakdown of the cell
membrane and afforded protection from RNAses from the
protein complex [27]. Recent work examining the serum of
healthy human donors supported this initial paper suggesting
that miRNAs form complexes in the circulation with Ago2.
However, they were also able to demonstrate that the associ-
ation of miRNAs with either a protein complex or a vesicle
does not seem to be a random occurrence and that some
miRNAs associate exclusively either with protein complexes
or with extracellular vesicles, under normal conditions.
In this study, it was demonstrated through differential-
centrifugation and size-exclusion chromatography that differ-
ent miRNAs exist within vesicles or are associated with
protein-bound complexes [26]. In the serum of healthy volun-
teers, miR-122 was found predominantly in a protein-bound
form, whereas let-7a, another miRNA, was found almost
exclusively within exosomes/microparticles. However, the mech-
anism through which these protein complexes are released
remains poorly understood [26,27].
High-density lipoproteins have also been demonstrated to trans-
port miRNAs through a neutral sphingomyelinase-dependent
mechanism [66]. miRNA/high-density lipoprotein complexes
travel to recipient cells and undergo endocytosis through a
scavenger receptor type class 1-dependent mechanism. Notably
in this study, the delivered complexes were able to modify
RNA translation in hepatocyte model of atherosclerosis, sug-
gesting that these complexes are a form of cell–cell signaling
pathway [66]. However, studies will have to be undertaken to
assess whether these complexes play a role in DILI or in the
release of biomarkers, which will allow a deeper understanding
of the overall pathology.
miRNA packaging & function
A recent mouse study, examining drug-induced, alcoholic
and inflammatory liver injury, demonstrated that miR-122
was detected in different fractions of blood during the APAP
toxicity study. Early in the injury (3 h), miR-122 was ele-
vated in the ‘exosome-fraction’ of the serum over the
exosome-depleted supernatant. As the injury progressed to
6 h, the miR-122 levels of the exosome-depleted supernatant
became elevated over the exosome-fraction [91]. This might
suggest that miR-122 release in APAP injury is biphasic. For
example, early in APAP injury miR-122 may be released
through active mechanisms within the cell, which could pos-
sibly arise from the hepatocytes response to the toxic insult,
with an aim of promoting hepatocyte proliferation and liver
regeneration. But as APAP injury progresses and injury
switches from an early stressed state to hepatocellular necro-
sis, miR-122 may be released in a similar mechanism to that
of ALT, that is, when cell membrane integrity is lost. Indeed,
this hypothesis of early active ‘shedding’ is supported by stud-
ies demonstrating that loss of cellular miR-122 is associated
with hepatogenesis and cell proliferation [55,56]. This may
explain why miR-122 is elevated in APAP-induced DILI before
that of ALT and other markers. However, this hypothesis needs
to be urgently tested and further work is required to under-
stand both why and how miRNAs are released throughout the
course of liver injury.
Analytical techniques & clinical potential
Appropriate biofluids for miRNA use as biomarker
miRNAs are detectable in various biofluids, including blood,
urine, feces and breast milk, fulfilling the criteria of accessibility
of a biomarker, which raises the question, which is an appro-
priate fluid for biomarker measurement in both the clinic and
in pre-clinical testing. Clinically, measurement in a biofluid
that requires no processing would be favorable, such as whole
blood. Recently, in a study examining miRNA deregulation in
pancreatic cancer patients, the authors were able to measure
miR-122 in whole blood, which suggests that this would be a
suitable biofluid for detection [92]. Previously however, much of
the work examining miR-122 as a marker of DILI has focused
on blood serum as the source. One advantage of using serum
or plasma over whole blood is the removal of whole blood
cells, which if frozen would hemolyze and release their con-
tents, including blood cell-rich miRNAs [93]. In a study aiming
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to test serum and plasma appropriate biofluids for miRNA
measurement, given that much of the clinical specimens are
serum, Mitchell et al. demonstrated that the levels of four
miRNAs (miR-15b, -16, -19b and -24) correlated consistently
between serum and plasma [47]. However, recent work has sug-
gested that plasma is a favorable biofluid over serum due to the
inhibition of coagulation in plasma collection tubes.
Wang et al. compared the miRNA content of serum and
plasma samples taken at identical times from healthy human
donors, demonstrating more miRNA content in the serum
samples compared with the plasma samples. Interestingly, the
concentrations of blood cell-rich and platelet-rich miRNAs,
such as miR-16 and miR-126, respectively, were identical
between serum and plasma samples, suggesting the difference
in miRNA content is not due to blood cell hemolysis.
A suggested cause of the increased miRNA content in serum
was that the coagulation process triggered miRNA release from
cells contained within the sample, through a trafficking sys-
tem [93]. This suggests that plasma would be a favorable bio-
fluid over serum due to reduced changes in miRNA content in
the sample preparation process. However, one counterargument
to this suggestion is highlighted by work conducted by
Arroyo et al., in which it was demonstrated that miRNAs are
in fact not resistant to plasma RNases as previously thought.
This suggests that miRNAs in plasma samples are likely to
degrade faster than in serum, which would support the use of
serum samples for sample longevity [26].
In addition to circulating sources of biomarkers, a recent
study has explored the possibility of the use of urinary miRNAs
as possible biomarkers of DILI in rats administered with
APAP [94]. This study examined the levels of 44 miRNAs in
the urine, miR-291a-5p was found to correlate strongly with
the histopathology of the liver. Furthermore, miR-291a-5p was
able to distinguish between a non-toxic and toxic dose of
APAP, suggesting it may also be a marker of the severity of
liver injury [94]. This together suggests that urine may also be a
possible source of biomarkers of DILI; however, rigorous test-
ing in larger subject groups and different population demo-
graphics will have to be carried out before these markers can
have a use within the clinic. It will also be important to under-
stand whether these urine biomarkers offer a similar level of
liver-specificity to similar blood-based biomarkers.
Inter-individual variation
Inter-individual variation will also have to be considered, if
miRNAs are to be served as clinical biomarkers. This was first
documented in a study using significance analysis of miRNAs,
in which four miRNAs were identified that were 63–95%
higher in females, compared with males [95]. In another study,
Wang et al. demonstrated differences in miRNA content of
male serum samples, specifically miR-130b and miR-18b were
slightly higher in males compared with females [93]. The signifi-
cance of this in DILI is still unknown and will require further
study. However, this highlights the need for studies that assess
baseline levels across different population groups and patient
groups for individual miRNAs. This information would then
allow clinicians to set an ULN for each of these biomarkers
across a population.
Data normalization for reverse transcription-quantitative
PCR
The current techniques used to quantify circulating miRNA
levels, in particular, reverse transcription-quantitative PCR
(RT-qPCR), are liable to systematic bias in the data they pro-
duce because variation exists within the assay (e.g., variation in
RNA isolation). In addition to bioanalytical variation, samples
Table 2. Normalizing methods for current techniques to detect and quantify miRNAs.
Type Function Name Type Biofluid Ref.
Exogenous Used to remove bioanalytical
bias during sample processing
Cel-miR-39 miRNA Serum
Plasma
[26,47,105]
Cel-miR-54 miRNA Plasma [47]
Cel-miR-238 miRNA Plasma [47]
Endogenous Used to remove biological
and sample variance
U6 (RNU-6B) snRNA Plasma
whole blood
[8,106]
Let-7d miRNA Serum [96,107]
miR-16 miRNA Serum [108]
miR-24 miRNA CSF [98]
RNU-48 snRNA Urine [109]
miR-193 miRNA Urine [94]
miR-323 miRNA Urine
miR-675 miRNA Urine
None N/A N/A N/A Serum [61]
N/A: Not applicable.
Review Hornby, Starkey Lewis, Dear, Goldring & Park
356 Expert Rev. Clin. Pharmacol. 7(3), (2014)
Ex
pe
rt 
Re
vie
w 
of 
Cl
ini
ca
l P
ha
rm
ac
olo
gy
 D
ow
nlo
ad
ed
 fr
om
 in
for
ma
he
alt
hc
are
.co
m 
by
 U
niv
ers
ity
 of
 L
ive
rpo
ol 
on
 04
/22
/14
Fo
r p
ers
on
al 
us
e o
nly
.
Bibliography 
	  
215	  
	  
	  
may also be biologically different, due to inter-individual varia-
tion and conditions during sample collection can also influence
sample quality (e.g., storage temperature, storage time). To
reduce sample variance, normalization techniques have to be
utilized to account for these differences (TABLE 2).
Normalization to total RNA level
Previously, a commonly used method of practice for assessing
miRNA level in a biofluid was to normalize RNA content in
samples, through spectrophotometric analysis. However, this is
not an appropriate method to reduce biological variation.
Wang et al. was able to demonstrate that total RNA content of
samples has no correlation with the miRNA content and there-
fore this cannot be used as a normalizer for miRNA levels [93].
Measuring a purified miRNA fraction is also not recommended
as the total RNA content is typically toward the lower limit of
detection of the spectrophotometer.
Relative quantification using ‘spike-in’ exogenous miRNA
Another common normalizing practice is to ‘spike-in’ a
known amount of exogenous miRNA, such as non-
mammalian cel-miR-39 and cel-lin-4, during the miRNA
extraction process. This method serves to correct for losses
in miRNA extraction and purification. However, this
method is not useful in eliminating biological variation and
sample variation, this procedure is analogous to using an
internal standard.
Relative quantification using endogenous normalizers
For clinical samples, use of an endogenous miRNA normalizer
to reduce biological sample variation is recommended, similar
to the almost universal use of GAPDH in gene expression stud-
ies. Use of an endogenous normalizer aims to correct for vari-
ance in RNA content in PCR assays, reducing both biological
variation and also technical variation. The use of a biological
normalizer in the development of a clinical assay for miRNAs
will be important due to the variable conditions, which inevita-
bly occur in a clinic during sample collection, processing, stor-
age and transport. Each of these stages can potentially impact
the biological quality of the sample. However, currently no
universal normalizer has been set for use throughout different
studies and labs. Studies have chosen a wide range of endoge-
nous normalizers such as U6 snRNA [58], let-7d [96], RNU48,
miR-16 [8,97] and miR-24 [98]; however, there have been several
issues regarding the use of these normalizers. Serum
U6 snRNA expression has been demonstrated to have a slight,
but significant change in patients undergoing severe APAP-
induced ALI, when compared with healthy individuals [58].
Additionally, Qi et al. demonstrated that U6 snRNA levels var-
ied significantly between young and aged subjects. In this
study, it was suggested that let-7d was a superior normalizer
showing less variation between patient groups (including young
and aging patients, autoimmune disease and malignant mela-
noma) [96]. However, similar to this, work in our lab was able
to demonstrate that even let-7d expression in serum was
changed in APAP-induced ALI patients, suggesting that the
severity of injury may affect global miRNA levels [96]. However,
to further reduce sample discrepancies, both an exogenous and
endogenous normalizer should be utilized together. Interest-
ingly however, one study examining miR-122 as a serum
marker of necro-inflammation in patients with chronic hepatitis
C infection chose to use no normalizing strategy. Bihrer et al.
demonstrated that even without normalization, miR-122 con-
tent was still elevated in patients undergoing necroinflammtion
when compared with healthy controls. This may be a possible
strategy in certain cases (e.g., APAP-induced ALI) for
miR-122 quantification because of its high liver specificity [61].
This approach would be attractive in a clinical setting due to
the requirement to only measure one target.
For absolute quantification of miRNA levels, a standard-
curve can be utilized; this technique utilizes a synthetic
form of the miRNA of interest of a known concentration,
from which a standard curve is created, which can be
assayed alongside clinical samples. This will then provide a
value for the number of miRNA of interest in each sample,
in a copies/l format, similar to ALT, which is measured in
units/l [99]. To further develop the potential of these
markers within the clinic, a robust, simple and relatively
cheap assay will be required to streamline the process of
quantifying these markers.
Assays to detect & quantify miRNA
Currently, the development of miRNAs as clinical bio-
markers has been hindered by the assays used to quantify
them in the circulation. The most common techniques for
miRNA quantification are PCR-based, such as RT-qPCR,
northern blotting, microarray or next-generation sequencing.
Despite RT-qPCR having a high level of bioanalytical sensi-
tivity, it is inappropriate for clinical use as it can take up to
8 h to perform the assay. In the case of APAP-induced ALI,
the onset of toxicity may be rapid and therefore this test
would be too slow to provide prognostic value. Additionally,
RT-qPCR is liable to bioanalytical bias through different
methods of miRNA extraction and user error due to the
highly technical nature of the assay. To facilitate the transi-
tion of miRNAs from a proof-of concept biomarker to a true
clinical bedside test, a fast, robust, simple and sensitive new
clinical assay must be developed for the rapid quantification
of miRNAs in accessible biofluids.
Several novel assays are currently in development for the
detection of miRNAs, which would be more suitable in a clini-
cal setting; however, none has yet undergone the rigorous test-
ing required for use. The scientists at the National University
of Singapore have developed a label-free method to quantify
miRNAs through the use of gold nanoparticle networks and
a duplex-specific nuclease, which allow miRNAs detection at
subfemtomolar levels, with almost no sample preparation
required [100]. Additionally, Cissell et al. have developed a
microtiter plate assay to quantify miRNAs, using Renilla-luciferase
labeled miRNA as a competitor to free miRNA for binding to
miRNAs as potential circulating biomarkers of DILI Review
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a complementary miRNA probe. This bioluminescence assay
takes a total of 1.5 h, requires no PCR amplification step and
is sensitive to a femtomolar level [101]. Apart from these exam-
ples, many other novel methods for miRNA detection and
quantification have emerged in the literature, such as label-free
detection of miRNAs with silicon nanowire biosensors [102], use
of universal tagged probes and time-resolved fluorescence tech-
nology [103] and solution-phase detection of miRNAs [104].
However, before these methods become applicable in the clinic,
robust testing must be done to assess the repeatability of these
assays (TABLE 3).
Expert commentary & five-year view
DILI is a major concern both within the clinic and in the
development of safer drugs. To aid in the diagnosis of DILI in
the clinic and also within the development of new drugs, sensi-
tive and specific biomarkers, which are detectable in accessible
biofluids are required. The current gold-standard biomarkers
are held back, either by non-specific tissue expression or that
they are not detectible early enough in the course of a disease
to be prognostic.
Recently, miRNAs have emerged as promising class of bio-
markers of various diseases and tissue injury. Specifically
miR-122, a liver-enriched miRNA has demonstrated its use
both in animal and human studies as a sensitive and specific
biomarker of DILI. Much of this initial work has focused on
APAP as an experimental model to examine DILI and so it
will be important in the future to identify additional DILI
scenarios to further test the wider applicability of these bio-
markers. Additionally, before miR-122 can find use within the
clinic, a more robust, less technical and importantly, a quicker
assay, will have to be developed for its quantification. Several
potential new assays have been developed, but none of these
has undergone the rigorous testing required for use within the
clinic. In the coming years, work will have to be done to estab-
lish the new gold-standard assay to detect miRNAs and studies
will have to be done to assess baseline values of these bio-
markers across varying population groups. However, these bio-
markers show qualities over and above the current markers, so
it is likely in the next 5 years a marker, such as
miR-122 should progress into clinical use. Additionally, it will
also be important to further our understanding of the release
mechanisms of miRNAs into the circulation. This knowledge
may aid us in understanding the current physiology of the cell
and how they react to injury, which could aid in the direction
of treatment and also in the development of safer medicines in
the future.
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Table 3. Current and emerging assays to detect and quantify miRNAs in biofluids.
Assay Detail Available or
under
development?
RT-qPCR Assay converts miRNA present within the fluid of interest into cDNA, then RNA is
amplified from cDNA through the PCR. miRNA is quantified through the use of a
user set copy cycle threshold. The more abundant the miRNA the quicker it will
be amplified and cross the threshold, therefore having a lower Ct value
Available (not in
clinical practice)
Microarray Assay allows quantification of a large number of miRNAs in a single reaction.
miRNAs are hybridized with fluorescent probes and the level of fluorescence
measured relates to the miRNA level
Available (not in
clinical practice)
Northern blotting miRNAs are separated through electrophoresis and then quantified through
hybridization with a fluorescent probe
Available (not in
clinical practice)
Bioluminescent
microtiter assay [101]
Competitive oligonucleotide hybridization assay using bioluminescent Renilla
luciferase probes to quantify miRNAs
Under
development
Gold nanoparticle network
and duplex-specific nuclease
assay [100]
Assay utilizes homogenous hybridization, the amplification power of a duplex-
specific nuclease and gold nanoparticle networks for signal amplification. This
allows quantification of miRNAs down to subfemtomolar levels without the need
for labeling
Under
development
Silicon nanowire
biosensors [102]
Assay allows ultra-sensitive detection of miRNAs through use of SiNWs. miRNAs
attach directly to peptide nucleic acids immobilized on the surface of the SiNWs.
Resistance changes before and after hybridization allow quantification of miRNA
Under
development
SiNWs: Silicon nanowire structures.
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Key issues
• Drug-induced liver injury (DILI) is a leading adverse drug reaction experienced in the clinic.
• Sensitive biomarkers of DILI are required in clinical diagnosis and in drug development.
• The current gold-standard biomarkers for DILI have well-recognized limitations. New specific, sensitive and robust markers of DILI must
be found to aid in clinical diagnosis and pre-clinical drug development.
• miRNAs, a class of small non-coding RNAs hold many of the properties required for potential biomarkers; certain miRNAs are tissue
specific, non-invasive, sensitive and easily quantifiable.
• miRNAs are released into the circulation in several forms, including vesicle-bound and protein-bound forms; however, the physiological
function of these mechanisms is still not understood in DILI.
• Current PCR-based assays are liable to bioanalytical, biological and sample variance. Therefore, both endogenous and exogenous miRNA
normalizers must be used to reduce variation in the current assays.
• The current assays for miRNA quantification are time-consuming and vary between laboratories; therefore, new robust assays must be
developed before these markers could be used in the clinic.
• Techniques using bioluminescence and label-free miRNA quantification are under development; however, robust testing will first be
required before they have application in the clinic.
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